0001193125-22-284524.txt : 20221114 0001193125-22-284524.hdr.sgml : 20221114 20221114160233 ACCESSION NUMBER: 0001193125-22-284524 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Healthcare Acquisition Corp. CENTRAL INDEX KEY: 0001839185 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40466 FILM NUMBER: 221384912 BUSINESS ADDRESS: STREET 1: UGLAND HOUSE, BOX 309 CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1104 BUSINESS PHONE: 212-446-4800 MAIL ADDRESS: STREET 1: UGLAND HOUSE, BOX 309 CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1104 10-Q 1 d412062d10q.htm FORM 10-Q Form 10-Q
false0001839185Q3--12-310 0001839185 2022-09-30 0001839185 2021-12-31 0001839185 2022-01-01 2022-09-30 0001839185 2021-01-01 2021-09-30 0001839185 2022-07-01 2022-09-30 0001839185 2021-07-01 2021-09-30 0001839185 2021-04-30 0001839185 2021-01-01 2021-12-31 0001839185 2022-01-01 2022-03-31 0001839185 2022-04-01 2022-06-30 0001839185 2021-01-01 2021-03-31 0001839185 2021-04-01 2021-06-30 0001839185 2022-07-07 2022-07-07 0001839185 2021-09-30 0001839185 2020-12-31 0001839185 2022-03-31 0001839185 2022-06-30 0001839185 2021-03-31 0001839185 2021-06-30 0001839185 us-gaap:CommonClassBMember 2022-09-30 0001839185 us-gaap:CommonClassAMember 2022-09-30 0001839185 us-gaap:IPOMember 2022-09-30 0001839185 smihu:SponsorMember smihu:FounderSharesMember us-gaap:CommonClassBMember 2022-09-30 0001839185 us-gaap:CommonClassBMember smihu:SponsorMember 2022-09-30 0001839185 smihu:SponsorMember smihu:PromissoryNoteMember 2022-09-30 0001839185 smihu:WorkingCapitalLoanMember 2022-09-30 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0001839185 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001839185 us-gaap:MeasurementInputRiskFreeInterestRateMember smihu:PublicAndPrivateWarrantsMember 2022-09-30 0001839185 smihu:PublicAndPrivateWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-09-30 0001839185 us-gaap:MeasurementInputExpectedTermMember smihu:PublicAndPrivateWarrantsMember 2022-09-30 0001839185 us-gaap:MeasurementInputSharePriceMember smihu:FpaLiabilityMember 2022-09-30 0001839185 us-gaap:MeasurementInputExpectedTermMember smihu:FpaLiabilityMember 2022-09-30 0001839185 smihu:MeasurementInputEstimatedTermToBusinessCombinationsMember smihu:FpaLiabilityMember 2022-09-30 0001839185 smihu:MeasurementInputProbabilityOfBusinessCombinationsMember smihu:FpaLiabilityMember 2022-09-30 0001839185 smihu:MeasurementOfPurchasePriceOfFpaUnitMember smihu:FpaLiabilityMember 2022-09-30 0001839185 smihu:FpaLiabilityMember us-gaap:MeasurementInputDiscountRateMember 2022-09-30 0001839185 smihu:FpaLiabilityMember 2022-09-30 0001839185 smihu:SponsorMember 2022-09-30 0001839185 smihu:SponsorMember us-gaap:CommonClassAMember 2022-09-30 0001839185 smihu:PublicWarrantsMember 2022-09-30 0001839185 smihu:PrivatePlacementWarrantsMember 2022-09-30 0001839185 smihu:PublicWarrantsMember us-gaap:CommonClassAMember smihu:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember 2022-09-30 0001839185 smihu:PublicWarrantsMember us-gaap:CommonClassAMember smihu:SharePriceEqualOrExceedsTenRupeesPerDollarMember 2022-09-30 0001839185 smihu:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember smihu:PublicWarrantsMember 2022-09-30 0001839185 smihu:SharePriceEqualOrExceedsTenRupeesPerDollarMember smihu:PublicWarrantsMember 2022-09-30 0001839185 us-gaap:CommonClassAMember smihu:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember smihu:PublicWarrantsMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel2Member smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember smihu:PrivateWarrantsMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember smihu:FpaLiabilityMember 2022-09-30 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 smihu:FpaLiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 smihu:FpaLiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:CommonClassBMember smihu:FounderSharesMember 2022-09-30 0001839185 smihu:YsBiopharmaMember 2022-09-30 0001839185 smihu:YsBiopharmaMember srt:MinimumMember 2022-09-30 0001839185 smihu:YsBiopharmaMember us-gaap:CommonStockMember srt:MaximumMember 2022-09-30 0001839185 us-gaap:CommonClassBMember 2021-12-31 0001839185 us-gaap:CommonClassAMember 2021-12-31 0001839185 smihu:FounderSharesMember smihu:SponsorMember us-gaap:CommonClassBMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001839185 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001839185 us-gaap:MeasurementInputRiskFreeInterestRateMember smihu:PublicAndPrivateWarrantsMember 2021-12-31 0001839185 us-gaap:MeasurementInputSharePriceMember smihu:PublicAndPrivateWarrantsMember 2021-12-31 0001839185 us-gaap:MeasurementInputExpectedTermMember smihu:PublicAndPrivateWarrantsMember 2021-12-31 0001839185 us-gaap:MeasurementInputSharePriceMember smihu:FpaLiabilityMember 2021-12-31 0001839185 us-gaap:MeasurementInputExpectedTermMember smihu:FpaLiabilityMember 2021-12-31 0001839185 smihu:MeasurementInputEstimatedTermToBusinessCombinationsMember smihu:FpaLiabilityMember 2021-12-31 0001839185 smihu:MeasurementInputProbabilityOfBusinessCombinationsMember smihu:FpaLiabilityMember 2021-12-31 0001839185 smihu:MeasurementOfPurchasePriceOfFpaUnitMember smihu:FpaLiabilityMember 2021-12-31 0001839185 smihu:FpaLiabilityMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001839185 smihu:FpaLiabilityMember 2021-12-31 0001839185 smihu:SponsorMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel1Member smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember smihu:PrivateWarrantsMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember smihu:FpaLiabilityMember 2021-12-31 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 smihu:FpaLiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 smihu:FpaLiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001839185 us-gaap:CommonClassAMember 2021-01-01 2021-09-30 0001839185 us-gaap:CommonClassBMember 2021-01-01 2021-09-30 0001839185 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-07-01 2021-09-30 0001839185 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001839185 smihu:AdministrativeServiceFeeMember 2021-07-01 2021-09-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2021-07-01 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2021-07-01 2021-09-30 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2021-07-01 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-07-01 2021-09-30 0001839185 us-gaap:CommonClassAMember 2021-07-01 2021-09-30 0001839185 us-gaap:CommonClassBMember 2021-07-01 2021-09-30 0001839185 smihu:SponsorMember smihu:PrivatePlacementWarrantsMember 2022-01-01 2022-09-30 0001839185 us-gaap:IPOMember 2022-01-01 2022-09-30 0001839185 smihu:SponsorMember 2022-01-01 2022-09-30 0001839185 smihu:FounderSharesMember us-gaap:CommonClassBMember smihu:SponsorMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassBMember smihu:SponsorMember 2022-01-01 2022-09-30 0001839185 smihu:PublicWarrantsAndPrivateWarrantsMember us-gaap:IPOMember 2022-01-01 2022-09-30 0001839185 smihu:PublicWarrantsMember 2022-01-01 2022-09-30 0001839185 smihu:PrivatePlacementWarrantsMember 2022-01-01 2022-09-30 0001839185 smihu:PublicAndPrivateWarrantsMember 2022-01-01 2022-09-30 0001839185 smihu:FpaLiabilityMember 2022-01-01 2022-09-30 0001839185 srt:MaximumMember smihu:PrivatePlacementWarrantsMember 2022-01-01 2022-09-30 0001839185 srt:MaximumMember us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001839185 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001839185 us-gaap:CapitalUnitsMember 2022-01-01 2022-09-30 0001839185 smihu:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember smihu:PublicWarrantsMember 2022-01-01 2022-09-30 0001839185 smihu:SharePriceEqualOrExceedsTenRupeesPerDollarMember smihu:PublicWarrantsMember 2022-01-01 2022-09-30 0001839185 smihu:PublicWarrantsMember smihu:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassAMember smihu:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassAMember smihu:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember 2022-01-01 2022-09-30 0001839185 smihu:AdministrativeServiceFeeMember 2022-01-01 2022-09-30 0001839185 smihu:CommonClassAClassBMember smihu:SponsorMember 2022-01-01 2022-09-30 0001839185 us-gaap:IPOMember smihu:SponsorMember 2022-01-01 2022-09-30 0001839185 smihu:UsGovernmentSecuritiesMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001839185 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001839185 smihu:DerivativeWarrantLiabilitiesMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001839185 smihu:YsBiopharmaMember 2022-01-01 2022-09-30 0001839185 smihu:AdministrativeServiceFeeMember 2022-07-01 2022-09-30 0001839185 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2022-07-01 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-07-01 2022-09-30 0001839185 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001839185 us-gaap:CommonClassBMember 2022-07-01 2022-09-30 0001839185 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-04-01 2022-06-30 0001839185 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001839185 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-01-01 2022-03-31 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-01-01 2022-03-31 0001839185 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001839185 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-06-11 2021-06-11 0001839185 us-gaap:IPOMember 2021-06-11 2021-06-11 0001839185 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-06-11 0001839185 us-gaap:IPOMember 2021-06-11 0001839185 srt:ScenarioForecastMember 2021-07-01 2023-06-30 0001839185 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2021-01-01 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2021-01-01 2021-06-30 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-01-01 2021-06-30 0001839185 us-gaap:IPOMember 2021-01-01 2021-12-31 0001839185 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember 2020-12-31 2020-12-31 0001839185 smihu:AnchorInvestorsMember us-gaap:CommonClassBMember 2021-04-30 2021-04-30 0001839185 smihu:SponsorMember smihu:FounderSharesMember 2021-04-30 2021-04-30 0001839185 srt:DirectorMember smihu:FounderSharesMember smihu:SponsorMember 2021-04-30 2021-04-30 0001839185 us-gaap:CommonClassAMember smihu:AnchorInvestorsMember 2021-04-30 2021-04-30 0001839185 smihu:RedeemableWarrantsMember smihu:AnchorInvestorsMember 2021-04-30 2021-04-30 0001839185 us-gaap:CommonClassBMember smihu:SponsorMember 2021-04-30 2021-04-30 0001839185 smihu:AnchorInvestorsMember us-gaap:CommonClassBMember smihu:FounderSharesMember 2021-04-30 2021-04-30 0001839185 us-gaap:CommonClassAMember smihu:SponsorMember 2021-04-30 2021-04-30 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember 2021-04-30 0001839185 smihu:SponsorMember 2021-07-23 2021-07-23 0001839185 smihu:AdministrativeServiceFeeMember 2021-12-31 2021-12-31 0001839185 smihu:PromissoryNoteMember smihu:SponsorMember us-gaap:CommonClassAMember 2022-09-29 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember 2022-09-29 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember us-gaap:CommonClassAMember 2022-09-29 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember 2022-10-12 2022-10-12 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember us-gaap:SubsequentEventMember 2022-10-12 2022-10-12 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember 2022-09-29 2022-09-29 0001839185 smihu:AdministrativeServiceFeeMember 2021-06-08 2021-09-30 0001839185 us-gaap:CommonClassAMember 2022-11-14 0001839185 us-gaap:CommonClassBMember 2022-11-14 0001839185 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-09-30 0001839185 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-09-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001839185 us-gaap:RetainedEarningsMember 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2021-09-30 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-09-30 0001839185 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-09-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001839185 us-gaap:RetainedEarningsMember 2022-09-30 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-09-30 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-09-30 0001839185 us-gaap:RetainedEarningsMember 2022-06-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001839185 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-06-30 0001839185 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-06-30 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-06-30 0001839185 us-gaap:RetainedEarningsMember 2021-06-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001839185 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-06-30 0001839185 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-06-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001839185 us-gaap:RetainedEarningsMember 2021-12-31 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001839185 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001839185 us-gaap:RetainedEarningsMember 2022-03-31 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-12-31 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-12-31 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-03-31 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-12-31 0001839185 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001839185 us-gaap:RetainedEarningsMember 2020-12-31 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-31 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-03-31 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001839185 us-gaap:RetainedEarningsMember 2021-03-31 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2020-12-31 0001839185 smihu:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001839185 smihu:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001839185 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-06-30 iso4217:USD xbrli:shares utr:Month utr:Day xbrli:pure iso4217:USD xbrli:shares smihu:Nominees utr:Year utr:Y
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 10-Q
 
 
 
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
    
    
    
    
to
    
    
    
    
.
 
 
SUMMIT HEALTHCARE ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
 
 
 
Cayman Islands
  
001-40466
  
98-1574360
(State or other jurisdiction of
incorporation or organization)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification Number)
Unit 1101, 11th Floor
1 Lyndhurst Tower
1 Lyndhurst Terrace
Central, Hong Kong
    
N/A
(Address of principal executive offices)
    
(
Zip
Code)
+852-2155-7212
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Class A ordinary shares, par value $0.0001 per share
  
SMIH
  
The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
  
SMIHW
  
The Nasdaq Stock Market LLC
Units, each consisting of one Class A ordinary
share and one-half of one redeemable warrant
  
SMIHU
  
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in
Rule 12b-2
of the Exchange Act). (Check one):
 
Large accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☒    Smaller reporting company   ☒
     Emerging growth company   ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes  ☒    No  ☐
As of November
14
, 2022, 20,000,000 Class A ordinary shares, par value $0.0001, and 5,750,000 Class B ordinary shares, par value $0.0001, were issued and outstanding.
 
 
 

SUMMIT HEALTHCARE ACQUISITION CORP.

Quarterly Report on Form

10-Q

TABLE OF CONTENTS

 

     Page  

Part I. Financial Information

      1  

Item 1. Financial Statements

      1  

Condensed Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021

      1  

Unaudited Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021

      2  

Unaudited Condensed Statements of Changes in Shareholders’ Deficit for the Three and Nine Months Ended September 30, 2022

      3  

Unaudited Condensed Statements of Changes in Shareholders’ Equity (Deficit) for the Three and Nine Months Ended September 30, 2021

      4  

Unaudited Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021

      5  

Notes to Unaudited Condensed Financial Statements

      6  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

      19  

Item 3. Quantitative and Qualitative Disclosures Regarding Market Risk

      22  

Item 4. Controls and Procedures

      22  

Part II. Other Information

      23  

Item 1. Legal Proceedings

      23  

Item 1A. Risk Factors

      23  

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

      23  

Item 3. Defaults Upon Senior Securities

      23  

Item 4. Mine Safety Disclosures

      24  

Item 5. Other Information

      24  

Item 6. Exhibits

      24  

Part III. Signatures

      25  

 

i

PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
SUMMIT HEALTHCARE ACQUISITION CORP.
CONDENSED BALANCE SHEETS

 
  
September 30,

2022
 
 
December 31,

2021
 
 
  
(unaudited)
 
 
 
 
Assets
                 
Current assets:
                 
Cash
    $ 70,097     $ 885,198  
Prepaid expenses
      218,545       141,677  
    
 
 
    
 
 
  
Total current assets
      288,642       1,026,875  
Investments held in Trust Account
      201,200,243       200,007,275  
    
 
 
    
 
 
  
Total Assets
    $ 201,488,885     $ 201,034,150  
    
 
 
    
 
 
  
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
                 
Current liabilities:
                 
Accrued expenses
    $ 599,956     $ 142,631  
Due to related party
      30,000       —    
    
 
 
    
 
 
  
Total current liabilities
      629,956       142,631  
FPA liability
      3,209,928       2,785,941  
Warrant liability
      2,414,882       10,423,429  
Deferred underwriting commissions
      —         7,000,000  
    
 
 
    
 
 
  
Total Liabilities
      6,254,766       20,352,001  
    
 
 
    
 
 
  
Commitments and Contingencies (Note 7)
                 
Class A ordinary shares subject to possible redemption, $0.0001 par value; 20,000,000 shares issued and outstanding at redemption value of $10.06 and $10.00 per share, as of September 30, 2022 and December 31, 2021, respectively
      201,200,243       200,000,000  
Shareholders’ Deficit
                 
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding
      —       —  
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 20,000,000 shares issued and outstanding as of September 30, 2022 and December 31,
2021, all of which are subject to possible redemption
      —       —    
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 5,750,000 shares issued and outstanding as of September 30, 2022 and December 31, 2021
      575       575  
Accumulated deficit
      (5,966,699 )      (19,318,426 ) 
    
 
 
    
 
 
  
Total shareholders’ Deficit
      (5,966,124 )      (19,317,851 ) 
    
 
 
    
 
 
  
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
    $ 201,488,885     $ 201,034,150  
    
 
 
    
 
 
  
The accompanying notes are an integral part of the condensed financial statements.
 
1
SUMMIT HEALTHCARE ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
 
 
  
Three Months Ended

September 30,
 
 
Nine Months Ended

September 30,
 
 
  
2022
 
 
2021
 
 
2022
 
 
2021
 
General and administrative expenses
    $ 581,189     $ 202,904     $ 1,225,560     $ 246,868  
    
 
 
    
 
 
    
 
 
    
 
 
  
Loss from operations
   
 
(581,189
) 
  
 
(202,904
) 
  
 
(1,225,560
) 
  
 
(246,868
) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Other income (expense):
                                 
Change in fair value of FPA
      (409,888 )      (561,983 )      (423,987 )      (2,807,021 ) 
Change in fair value of warrant liability
      (1,206,319 )      1,797,111       8,008,547       (88,010 ) 
Transaction costs allocable to warrants
     
—
       —        
—
       (507,417 ) 
Interest earned on investments held in Trust Account
      902,750       2,573       1,192,968       3,049  
Gain recognized on extinguishment of deferred underwriting commissions
      7,000,000      
—
       7,000,000      
—
  
    
 
 
    
 
 
    
 
 
    
 
 
  
Total other income (expense), net
      6,286,543       1,237,701       15,777,528       (3,399,399 ) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Net income (loss)
   
$
5,705,354
 
  
$
1,034,797
 
  
$
14,551,968
 
  
$
(3,646,267
) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted weighted average shares outstanding, Class A ordinary shares
      20,000,000       20,000,000       20,000,000       8,205,128  
    
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted net income (loss) per share, Class A ordinary shares subject to possible redemption
   
$
0.22
 
  
$
0.04
 
  
$
0.57
 
  
$
(0.26
) 
    
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted weighted average shares outstanding, Class B ordinary shares
      5,750,000       5,750,000       5,750,000       5,750,000  
    
 
 
    
 
 
    
 
 
    
 
 
  
Basic and diluted net income (loss) per share, Class B ordinary shares
   
$
0.22
 
  
$
0.04
 
  
$
0.57
 
  
$
(0.26
) 
    
 
 
    
 
 
    
 
 
    
 
 
  
The accompanying notes are an integral part
of
these unaudited condensed financial statements.
 
2
SUMMIT HEALTHCARE ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022
 
    
Class A
Ordinary Shares
     
Class B
Ordinary Shares
     
Additional
Paid-in

Capital
     
Accumulated
Deficit
    
Total
Shareholders’
Deficit
  
    
Shares
     
Amount
     
Shares
     
Amount
  
Balance as of December 31, 2021
   
 
—  
 
   
$
—  
 
   
 
5,750,000
 
   
$
575
 
   
$
—  
 
   
$
(19,318,426
) 
  
$
(19,317,851
) 
Net income
      —          —          —          —          —          7,126,838       7,126,838  
    
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of March 31, 2022
   
 
—  
 
   
 
—  
 
   
 
5,750,000
 
   
 
575
 
   
$
—  
 
   
 
(12,191,588
) 
  
 
(12,191,013
) 
Net income
      —          —          —          —          —          1,719,777       1,719,777  
Accretion of carrying value to redemption value-interest
      —          —          —          —          —          (297,492 )      (297,492 ) 
    
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of June 30, 2022
   
 
—  
 
   
 
—  
 
   
 
5,750,000
 
   
 
575
 
   
$
—  
 
   
 
(10,769,303
) 
  
 
(10,768,728
) 
Net income
   
 
—  
 
      —          —          —          —          5,705,354       5,705,354  
Accretion of carrying value to redemption value-interest
   
 
—  
 
      —          —          —          —          (902,750 )      (902,750 ) 
    
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
Balance as of September 30, 2022
            
$
 
 
   
 
5,750,000
 
   
$
575
 
   
$
—  
 
   
$
(5,966,699
) 
  
$
(5,966,124
) 
    
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
    
 
 
  
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
3
SUMMIT HEALTHCARE ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021
 
    
Class A
Ordinary Shares
     
Class B
Ordinary Shares
    
Additional
Paid-in

Capital
    
Accumulated
Deficit
    
Total
Shareholders’
Equity (Deficit)
  
    
Shares
     
Amount
     
Shares
    
Amount
  
Balance as of December 31, 2020
   
 
—  
 
   
$
—  
 
   
 
6,500,000
 
  
$
650
 
  
$
24,350
 
  
$
(3,636
) 
  
$
21,364
 
Net loss
      —          —          —         —         —         —         —    
    
 
 
     
 
 
     
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance as of March 31, 2021
   
 
—  
 
   
 
—  
 
   
 
6,500,000
 
  
 
650
 
  
 
24,350
 
  
 
(3,636
) 
  
 
21,364
 
Accretion of Class A ordinary shares to redemption value
   
 
—  
 
   
 
—  
 
   
 
—  
 
  
 
—  
 
     (24,350 )      (18,769,138 )      (18,793,488 ) 
Net loss
      —          —          —         —         —         (4,681,064 )      (4,681,064 ) 
    
 
 
     
 
 
     
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance as of June 30, 2021
   
 
—  
 
   
 
—  
 
   
 
6,500,000
 
  
 
650
 
  
 
—  
 
  
 
(23,453,838
) 
  
 
(23,453,188
) 
Forfeiture of founder shares
      —          —          (750,000 )      (75 )      —         75       —    
Net loss
      —          —          —         —         —         1,034,797       1,034,797  
    
 
 
     
 
 
     
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance as of September 30, 2021
   
 
—  
 
   
$
—  
 
   
 
5,750,000
 
  
$
575
 
  
$
—  
 
  
$
(22,418,966
) 
  
$
(22,418,391
) 
    
 
 
     
 
 
     
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
 
4
SUMMIT HEALTHCARE ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS
 
    
For the Nine
Months ended
September 30, 2022
    
For the Nine
Months ended
September 30, 2021
  
Cash Flows from Operating Activities:
                 
Net income (loss)
    $ 14,551,968     $ (3,646,267 ) 
Adjustments to reconcile net income (loss) to net cash used in operating activities:
                 
Interest earned on investments held in Trust Account
      (1,192,968 )      (3,049 ) 
Change in fair value of FPA liability
      423,987       2,807,021  
Change in fair value of warrant liability
      (8,008,547 )      88,010  
Transaction costs allocable to warrants
      —         507,417  
Gain recognized on extinguishment of deferred underwriting commissions
      (7,000,000 )      —    
Changes in operating assets and liabilities:
                 
Prepaid expenses
      (76,868 )      (221,704 ) 
Accrued offering costs and expenses
      457,327       7,619  
Due to related party
      30,000       37,667  
    
 
 
    
 
 
  
Net cash used in operating activities
   
 
(815,101
) 
  
 
(423,286
) 
    
 
 
    
 
 
  
Cash Flows from Investing Activities
                 
Investment of cash in Trust Account
      —         (200,000,000 ) 
    
 
 
    
 
 
  
Net cash used in investing activities
   
 
—  
 
  
 
(200,000,000
) 
    
 
 
    
 
 
  
Cash Flows from Financing Activities:
                 
Proceeds received from initial public offering, net of underwriters’ discount
      —         196,000,000  
Proceeds from private placement
      —         6,000,000  
Payment of offering costs
      —         (140,554 ) 
Repayment of note payable from related party
      —         (361,023 ) 
    
 
 
    
 
 
  
Net cash provided by financing activities
   
 
—  
 
  
 
201,498,423
 
    
 
 
    
 
 
  
Net change in cash
   
 
(815,101
) 
  
 
1,075,137
 
Cash, beginning of the period
      885,198          
    
 
 
    
 
 
  
Cash, end of the period
   
$
70,097
 
  
$
1,075,137
 
    
 
 
    
 
 
  
Supplemental disclosure of
non-cash
investing and financing activity
                 
Deferred offering costs paid by Sponsor under promissory note
    $ —       $ 135,544  
    
 
 
    
 
 
  
Deferred underwriting commissions charged to additional paid in capital
    $ —       $ 7,000,000  
    
 
 
    
 
 
  
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
5
SUMMIT HEALTHCARE ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Note 1—Organization, Business Operation, Liquidity and Capital Resources
Summit Healthcare Acquisition Corp. (the “Company”) is a blank check company incorporated on December 22, 2020 as a Cayman Islands exempted company. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any specific Business Combination target under consideration or contemplation and the Company has not, nor has anyone on its behalf, contacted any prospective target business or had any discussions, formal or otherwise, with respect to such a transaction. The Company’s efforts to identify a prospective target business will not be limited to a particular geographic region or industry, although it intends to focus on healthcare.
As of September 30, 2022, the Company had not commenced any operations. All activity for the period from December 22, 2020 (inception) through September 30, 2022 relates to the Company’s formation and the initial public offering (the “IPO”), searching for a Business Combination target. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates
non-operating
income in the form of interest income on investments from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.
The Company’s Sponsor is Summit Healthcare Acquisition Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”). The registration statement for the Company’s IPO was declared effective on June 8, 2021 (the “Effective Date”). On June 11, 2021, the Company consummated the IPO of 20,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”) $10.00 per Unit, generating gross proceeds of $200,000,000, which is discussed in Note 3.
Simultaneously with the consummation of the IPO and the issuance and sale of the Units, the Company consummated the private placement of 6,000,000 Private Placement Warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant, to the Sponsor, generating total proceeds of $6,000,000. Transaction costs amounted to $11,587,941 consisting of $4,000,000 of underwriting commissions, $7,000,000 of deferred underwriting commissions and $587,941 of other cash offering costs.
Following the closing of the IPO on June 11, 2021, $200,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a U.S.-based trust account (the “Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee, and was invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain
conditions under Rule 2a-7 under the
Investment Company Act. As of September 30, 2022, the assets held in the Trust Account were held in money market fund.
Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the Company’s amended and restated memorandum and articles of association and subject to the requirements of law and regulation, will provide that the proceeds from the IPO and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the Company’s public shareholders until the earliest of: (i) the completion of an initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association, and (iii) the redemption of the Company’s public shares if the Company has not consummated its Business Combination within 24 months from the closing of the IPO, subject to applicable law.
The ordinary shares subject to redemption are recorded at a $10.06 per share redemption value and classified as temporary equity, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”
The Company will have 24 months from the closing of the IPO to complete the initial Business Combination (the “Combination Period”) or during any Extension Period. However, if the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares,
at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable
la
w.
 
6
The Sponsor and the Company’s officers and directors agreed to (i) waive their redemption rights with respect to their Class B ordinary shares, par value $0.0001 (the “Founder Shares”) in connection with the completion of the initial Business Combination, (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association, (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to complete the initial Business Combination within the Combination Period or during any Extension Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete its initial Business Combination within the prescribed timeframe), and (iv) vote any Founder Shares and public shares held by them in favor of the initial Business Combination.
The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share or (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay the Company’s tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriter of the IPO against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked it Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
Business Combination
On September 29, 2022, the Company entered into a Business Combination Agreement (the “Business Combination Agreement”) with YishengBio Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands (to be renamed as YS Biopharma Co., Ltd, herein referred to as “YS Biopharma”), Oceanview Bioscience Acquisition Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub I”) and Hudson Biomedical Group Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub II,” and together with Merger Sub I, “Merger Subs”).
The Business Combination Agreement provides for (i) the merger of Merger Sub I with and into the Company (the “First Merger”), with the Company surviving the First Merger as the surviving entity (the “Surviving Entity”) and becoming a wholly-owned subsidiary of YS Biopharma, and (ii) the merger of the Surviving Entity with and into Merger Sub II (the “Second Merger,” and together with the First Merger, the “Mergers,” together with other transactions contemplated by the Business Combination Agreement, the “Transactions”), with Merger Sub II surviving the Second Merger as the surviving company (the “Surviving Company”) and remaining as the wholly-owned subsidiary of YS Biopharma.
Liquidity and Capital Resources; Going Concern
As of September 30, 2022, the Company had $70,097 of cash for working capital purposes and
a
working capital deficit of $341,314.
The Company’s liquidity needs prior to the IPO had been satisfied through a payment from the Sponsor of $25,000 (see Note 5) for the Founder Shares to cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of $300,000 (see Note 5).
The promissory note was repaid on June 11, 2021. In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans, as defined below (see Note 5). As of September 30, 2022 and December 31, 2021, there were no amounts outstanding under any Working Capital Loans.
The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. On September 29, 2022, the Company issued a Convertible Promissory Note (as described in Note 6) to the Sponsor, pursuant to which, the Company may borrow up to $1,500,000 from the Sponsor for working capital purpose
s
. On October 12, 2022, the Company had
drew
down $700,000 under the Convertible Promissory Note.
 
7
The C
ompa
ny has until June 11, 2023 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by such date. If a Business Combination is not consummated by the required date, the Company will commence an automatic winding up, dissolution and liquidation. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”)
2014-15,
“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the management has determined that the liquidity condition and
mandatory
liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 11, 2023. The management plans to continue efforts to close a Business Combination within the prescribed time frame.
Note 2—Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and pursuant to the rules and regulations of the Security and Exchange Commission (“SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of the unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the fun audited condensed financial statements and the reported amounts of expenses during the reporting period.
Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant estimates included in these financial statements is the determination of the fair value of the warrant liability and Forward Purchase Agreement (“FPA”) liability.
 
8
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have cash equivalents as of September 30, 2022 and December 31, 2021.
Investments Held in Trust Account
As of September 30, 2022 and December 31, 2021, the
assets held in the Trust Account were held in a money market fund. The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, investments in money market funds that invest in U.S. government securities, cash, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Interest earned on these securities is included in interest earned on Investments Held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2022 and December 31, 2021, the Company had $201,200,243 and $200,007,275 held in the Trust Account, respectively.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation limit of $250,000. As of September 30, 2022 and December 31, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Offering Costs Associated with IPO
The Company complies with the requirements of the
ASC340-10-S99-1
and SEC Staff Accounting Bulletin (“SAB”) Topic 5A “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged to ordinary shares subject to possible redemption or the statement of operations based on the relative value of the Public and Private Warrants to the proceeds received from the Units and Private Placement Warrants sold upon the completion of the IPO. Accordingly, offering costs totaling $11,587,941 (consisting of $4,000,000 of underwriting fees, $7,000,000 of deferred underwriting fees and $587,941 of other offering costs), of which $507,417 was allocated to the Public Warrants and Private Warrants and was charged to operations in accordance with ASC
825-10
and $11,080,524 was charged to ordinary shares subject to possible redemption.
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then
re-valued
at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liability and Forward Purchase Agreement
The Company accounts for the 16,000,000 warrants issued in connection with the IPO (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) and Forward Purchase Agreement (“FPA”) in accordance with the guidance contained in FASB ASC 815 “Derivatives and Hedging” whereby under that provision the warrants and FPA do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company will classify warrants and FPA as liabilities at their fair value. These liabilities are subject to
re-measurement
at each reporting period. With such
re-measurement,
the changes in fair value are recognized in the Statement of Operations in the period of change. Derivative warrant liabilities and FPA are classified as
non-current
liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Fair Value Measurements
The fair value of the Company’s assets and liabilities, excluding the warrant liability and FPA liability, which qualify as financial instruments under FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.
 
9
Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
 
  •  
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
  •  
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
  •  
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2022 and December 31, 2021, 20,000,000 and 20,000,000 Class A ordinary shares, respectively, subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity (deficit) section of the Company’s balance sheet.
The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period.
As of September 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following table:
 
Gross proceeds
    $ 200,000,000  
Less: Proceeds allocated to Public Warrants
      (8,511,409 ) 
Less: Class A ordinary shares issuance costs
      (11,080,524 ) 
Add: Accretion of carrying value to redemption value
      19,591,933  
    
 
 
  
Class A ordinary shares subject to possible redemption as of December 31, 2021
      200,000,000  
Add: Accretion of carrying value to redemption value
      1,200,243  
    
 
 
  
Class A ordinary shares subject to possible redemption as of September 30, 2022
    $ 201,200,243  
    
 
 
  
Net Income (Loss) Per Ordinary Share
The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 16,000,000 potential
ordinary
shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three and nine months ended
September 30, 2022 and 2021,
because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares:
 
10
    
For the Three Months Ended
September 30,
  
    
2022
     
2021
  
    
Class A
     
Class B
     
Class A
     
Class B
  
Basic and diluted net income per share:
                                    
Numerator:
                                    
Allocation of net income
    $ 4,431,344      $ 1,274,011      $ 803,726      $ 231,071  
Denominator:
                                    
Weighted-average shares outstanding
      20,000,000        5,750,000        20,000,000        5,750,000  
    
 
 
     
 
 
     
 
 
     
 
 
  
Basic and diluted net income per share
    $ 0.22      $ 0.22      $ 0.04      $ 0.04  
 
    
For the Nine Months Ended
September 30,
  
    
2022
     
2021
  
    
Class A
     
Class B
     
Class A
     
Class B
  
Basic and diluted net income (loss) per share:
                                    
Numerator:
                                    
Allocation of net income (loss)
    $ 11,302,500      $ 3,249,469      $ (2,143,878 )     $ (1,502,389 ) 
Denominator:
                                    
Weighted-average shares outstanding
      20,000,000        5,750,000        8,205,128        5,750,000  
    
 
 
     
 
 
     
 
 
     
 
 
  
Basic and diluted net income (loss) per share
    $ 0.57      $ 0.57      $ (0.26 )     $ (0.26 ) 
Income Taxes
ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position
must be more-likely-than-not to be
sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Recent Accounting Pronouncements
In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2020-06,
Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic
815-40)
(“ASU2020-06”)
to simplify accounting for certain financial instruments. ASU
2020-06
eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU
2020-06
amends the diluted earnings per share guidance, including the requirement to use the
if-converted
method for all convertible instruments. ASU
2020-06
is effective on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that
ASU 2020-06
would have on its financial position, results of operations or cash flows.
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.
Note 3—Initial Public Offering
On June 11, 2021, the Company consummated its IPO of 20,000,000 Units (the “Units”), at a price of $10.00 per unit, generating gross proceeds to the Company of $200,000,000. Each Unit consists of one Class A ordinary share and
one-half
of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from the closing of the IPO, and will expire five years after the completion of the initial Business Combination or earlier upon redemption or liquidation (see Note 8).
Note 4—Private Placement
Simultaneously with the closing of the IPO and the sale of the Units, the Company consummated the private placement (the “Private Placement”) of an aggregate 6,000,000 Private Placement Warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $6,000,000. If the Company does not complete an initial Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants
will be non-redeemable by the
Company and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.
 
11
If the Private Placement Warrants are held by
hold
ers other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the IPO.
Note 5—Related Party Transactions
Founder Shares
On December 31, 2020, the Company issued to the Sponsor 5,750,000 Founder Shares for $25,000 for certain expenses paid on behalf of the Company, or approximately $0.004 per share. On April 30, 2021, the Company effected a share capitalization, pursuant to which the Company’s initial shareholders held an aggregate of 6,500,000 Class B ordinary shares. The accompanying unaudited condensed financial statements have been retroactively adjusted to reflect the stock dividend in the share capitalization. On April 30, 2021, the Company entered into forward purchase agreements (see Note 6) with anchor investors, in connection with entering into the forward purchase agreements, the Sponsor transferred to the anchor investors an aggregate of 375,000 Class B ordinary shares for no cash. On April 30, 2021, the Sponsor transferred 25,000 Class B ordinary shares each to three independent director nominees. Up to 750,000 Founder Shares were subject to forfeiture by the Sponsor depending on the extent to which the underwriters’ over-allotment option is exercised. On July 23, 2021, the Sponsor surrendered 750,000 Founder Shares, with no return of capital or payment by the Sponsor, after the expiration of the unexercised underwriters’ over-allotment option. As a result of the foregoing, as of September 30, 2022 and December 31, 2021, the Sponsor owned 5,750,000 Class B ordinary shares.
The Sponsor, officers and directors have agreed not to transfer, assign or sell any of their Founder Shares until earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s public shareholders having the right to exchange their ordinary shares for cash, securities or other property
(the “Lock-up”).
Any permitted transferees would be subject to the same restrictions and other agreements of our Sponsor, officers and directors with respect to any Founder Shares.
Promissory Note—Related Party
The Sponsor has agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the IPO. These loans were
non-interest
bearing, unsecured and were due at the earlier of September 30, 2021 or the closing of the IPO. The loan was to be repaid upon completion of the IPO out of the $1,000,000 of offering proceeds that has been allocated to the payment of offering expenses. The Company had drawn down $140,068 under the promissory note which was repaid as of June 11, 2021. The note was terminated as of June 11, 2021.
Related Party Loans
In addition, in order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender. Such warrants would be identical to the Private Placement Warrants.
On September 29, 2022, the Company issued an unsecured, interest-free promissory note to the Sponsor pursuant to which the Company may borrow up to $1,500,000 from the Sponsor for costs and expenses reasonably related to the Company’s working capital needs prior to the consummation of the Business Combination (the “Convertible Promissory Note”). All unpaid principal under the Convertible Promissory Note will become due and payable in full on the date on which the Company consummates the Business Combination, unless earlier accelerated upon the occurrence of an event of default. The Sponsor will have the option, at any time on or prior to the maturity date, to convert any amounts outstanding under the Convertible Promissory Note, up to $1,500,000 in the aggregate, into warrants to purchase the Company’s Class A ordinary shares, at a conversion price of $1.00 per warrant, with each warrant entitling the holder to purchase one Company’s Class A ordinary share at a price of $11.50 per share, subject to the same adjustments applicable to the private placement warrants sold concurrently with the Company’s initial public offering. As of September 30, 2022, there were no outstanding amount under the Convertible Promissory Note. On October 12, 2022, the Company had drawn down $700,000 under the Convertible Promissory
Note. The Convertible Promissory Note will be valued using the fair value method at each reporting period.
 
12
Administrative Service Fee
Commencing on the Effective Date, the Company paid an affiliate of the Sponsor $10,000 per month for office space, utilities, administrative services and remote support services. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company accrued $30,000 and $90,000 for the administrative service fee for the three and nine months ended September 30, 2022, respectively.
The Company accrued $30,000 and $
37,667
 for the three months ended September 30, 2021 and for the period from June 8, 2021 (the Effective Date) through September 30, 2021. As of September 30, 2022 and December 31, 2021, there were $30,000 and $0 administrative service fee unpaid, which is included in due to related party on the accompanying condensed balance sheets. 
Note
6
—Recurring Fair Value Measurements
Warrant Liability and FPA Liability
As of September 30, 2022 and December 31, 2021, the fair value of Company’s Warrant liability was $2,414,882 and $10,423,429, respectively, and the fair value of FPA liability was $3,209,928 and $2,785,941, respectively. Under the guidance in ASC
815-40,
the Public and Private Warrants and the FPA do not meet the criteria for equity treatment. As such, the Public and Private Warrants and the FPA must be recorded on the balance sheet at fair value. This valuation is subject tore-measurement each balance sheet date. With each
re-measurement,
the valuations will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations.
Recurring Fair Value Measurements
The following table presents fair value information as of September 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company’s Warrant liability is based on a valuation models utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair values of the Private Warrant liability and FPA liability are classified within Level 3 of the fair value hierarchy. The investments held in Trust Account includes money market funds. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its level 1 investments.
The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of September 30, 2022, that were accounted for at fair value on a recurring basis:
 
     (Level 1)      (Level 2)      (Level 3)  
Assets
                           
Investments held in Trust Account
    $ 201,200,243      $ —        $ —    
    
 
 
     
 
 
     
 
 
  
Liabilities
                           
Public Warrants
    $ —      $ 1,500,000      $ —    
Private Warrants
    $ —        $ —        $ 914,882  
FPA liability
    $ —        $ —        $ 3,209,928  
    
 
 
     
 
 
     
 
 
  
Total Liabilities
   
$
1,500,000
 
   
$
—  
 
   
$
4,124,810
 
    
 
 
     
 
 
     
 
 
  
The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of December 31, 2021, that were accounted for at fair value on a recurring basis:
 
     (Level 1)      (Level 2)      (Level 3)  
Assets
                           
Investments held in Trust Account
    $ 200,007,275      $ —        $ —    
    
 
 
     
 
 
     
 
 
  
Liabilities
                           
Public Warrants
    $ 6,500,000      $ —        $ —    
Private Warrants
    $ —        $ —        $ 3,923,429  
FPA liability
    $ —        $ —        $ 2,785,941  
    
 
 
     
 
 
     
 
 
  
Total Liabilities
   
$
6,500,000
 
   
$
—  
 
   
$
6,709,370
 
    
 
 
     
 
 
     
 
 
  
 
13
Measurement of the Warrants
The Company established the initial fair value for the Warrants on June 11, 2021, the date of the consummation of the Company’s IPO. The Company used a Monte Carlo simulation model to value the Warrants. The Company allocated the proceeds received from (i) the sale of Units (which is inclusive of one Class A ordinary share and
one-half
of one Public Warrant), (ii) the sale of Private Warrants, and (iii) the issuance of Class B ordinary shares, first to the Warrants based on their fair values as determined at initial measurement, with the remaining proceeds allocated to Class A ordinary shares subject to possible redemption (temporary equity), and Class B ordinary shares (permanent equity) based on their relative fair values at the initial measurement date. The estimated fair value of the Public Warrants was transferred from a Level 3 measurement to a Level 1 measurement in August 2021 after detachment of the Public Warrants from the Units and were separately listed and traded. For the period ended September 30, 2022, the Public Warrants were reclassified from Level 1 to Level 2 due to the valuation based on quoted prices (unadjusted) with less volume and transaction frequency than active markets. As of September 30, 2022 and December 31, 2021, the Private Warrants were valued using a Monte Carlo simulation model.
The key inputs for the valuation of Private Warrants are as follows:
 
Input   
September 30,
2022
    
December 31,
2021
  
Risk Free Rate
      4.04 %      1.29 % 
Stock Price
    $ 9.82     $ 9.72  
Est. Term Remaining (Yrs)
      5.55       5.35  
The following table provides a reconciliation of changes in fair value of the Company’s derivative warrant liabilities classified as Level 3 for the nine months ended September 30, 2022 and 2021:
 
 
  
Public
Warrants
 
  
Private
Warrants
 
  
Warrants
Liability
 
Fair value at December 31, 2021
    $ —        $ 3,923,429      $ 3,923,429  
Change in fair value
      —          (2,713,773        (2,713,773 ) 
    
 
 
     
 
 
     
 
 
  
Fair Value at March 31, 2022
 
$
—  
 
 
$
1,209,656
 
 
$
1,209,656
 
Change in fair value
 
 
—  
 
 
 
(751,093
) 
 
 
(751,093
) 
Fair Value at June 30, 2022
 
$
—  
 
 
$
458,563
 
 
$
458,563
 
Change in fair value
 
 
—  
 
 
 
456,319
 
 
 
456,319
 
Fair Value at September 30, 2022
    $ —        $ 914,882      $ 914,882  
    
 
 
     
 
 
     
 
 
  
 
 
  
Public
Warrants
 
  
Private
Warrants
 
  
Warrants
Liability
 
Fair value at December 31, 2020
  
$
—  
  
  
$
—  
  
  
$
—  
  
Initial value of warrant liabilities at IPO
 (
June 11, 202
1
)
      8,511,409        5,201,555        13,712,964  
Change in fair value
 
 
1,212,798
 
 
 
672,323
 
 
 
1,885,121
 
Fair value at June 30, 2021
 
$
9,724,207
 
 
$
5,873,878
 
 
$
15,598,085
 
Change in fair value
      (1,123,207 )      (673,904 )       (1,797,111 )
Transfer of Public warrants from Level 3 to Level 1
      (8,601,000 )       —          (8,601,000 ) 
    
 
 
     
 
 
     
 
 
  
Fair Value at September 30, 2021
    $ —        $ 5,199,974      $ 5,199,974  
    
 
 
     
 
 
     
 
 
  
FPA
To arrive at the conclusion of Fair Value of the Forward Purchase Agreements, the Company analyzed the agreements and other documentation. The Company utilized the underlying shares and warrant values determined above and the following inputs in order to project the net asset or liability value of the FPA:
 
Input   
September 30,
2022
    
December 31,
2021
  
Stock Price
    $ 9.82     $ 9.72  
Warrant Price
    $ 0.150     $ 0.65  
Est. Term to Business Combination (Yrs)
      0.55       0.33  
Probability of Business Combination
      85 %      85 % 
Purchase price of FPA unit
    $ 10.00     $ 10.00  
Discount rate
      3.93 %      0.04 % 
 
14
The following table provides a reconciliation of changes in fair value of the Company’s FPA liability classified as Level 3 for the nine months ended September 30, 2022 and 2021:

 
 
  
FPA liability
 
Fair value at December 31, 2021
    $ 2,785,941  
Change in fair value
      (127,629 )
    
 
 
  
Fair Value at
March 31
, 2022
    $ 2,658,312  
Change in fair value
      141,728  
 
 
 
 
 
Fair Value at June 30, 2022
    $ 2,800,040  
Change in fair value
      409,888  
 
 
 
 
 
Fair Value at September 30, 2022
    $ 3,209,928  
    
 
 
  
 
 
  
FPA Liability
 
Fair value at December 31, 2020
    $ —    
Initial value of FPA liability at IPO
 (
June
11
, 2021
)
      2,322,741  
Change in fair value
      (77,703 )
    
 
 
  
Fair value at June 30, 2021
    $ 2,245,038  
Change in fair value
      561,983  
 
 
 
 
 
Fair value at September 30, 2021
    $ 2,807,021  
    
 
 
  
Transfers between levels of the fair value hierarchy are recognized at the end of the reporting period. There are no transfers to or from Level 3 for the
three and 
nine months ended September 30, 2022.
Note 7—Commitments & Contingencies
Risks and Uncertainties
Management continues to evaluate the impact
of the COVID-19 pandemic on
the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of this financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.
Registration Rights
The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the IPO. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
Lock-up
period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriters Agreement
The underwriters
had a 45-day option to
purchase up to an additional 3,000,000 units to cover over-allotments, if any. The over-allotment option expired unexercised on July 23, 2021.
The underwriters were paid a cash underwriting discount of two percent (2%) of the gross proceeds of the IPO, or $4,000,000. Additionally, the underwriters are entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the IPO upon the completion of the Company’s initial Business Combination. On July 7, 2022, a waiver letter was signed by the Company and BofA Securities, Inc. (“BofA”), pursuant to which BofA announced it waived its entitlement to the payment of any deferred underwriting discount to be paid under the terms of the underwriting agreement. The Company recognized $7,000,000
gain recognized on extinguishment of deferred underwriting commissions in the operations in connection with such waiver. 
 
15
Forward Purchase Agreements
On April 30, 2021, the Company entered into forward purchase agreements with the Sponsor, Snow Lake Capital (HK) Limited and Valliance Fund (the “anchor investors”), pursuant to which the anchor investors agreed to subscribe for an aggregate of 3,000,000 Class A ordinary shares plus 750,000 redeemable warrants for a purchase price of $10.00 multiplied by the number of Class A ordinary shares, or $30,000,000 in the aggregate, in a private placement to close concurrently with the closing of the initial business combination. The Company issued 750,000 additional Class B ordinary shares to the Sponsor, which represent the adjustment to the ratio applicable to the conversion of the Class B ordinary shares that the Sponsor would have been entitled to at the closing of the initial business combination as a result of the issuance of 3,000,000 additional Class A ordinary shares under the forward purchase agreements. As a result, the issuance of the Class A ordinary shares at the closing of the initial business combination will not trigger a further adjustment to this ratio. Further, prior to the IPO, the Sponsor transferred to the anchor investors an aggregate of 375,000 Founder Shares for no cash consideration. Subject to certain exceptions to forfeiture and transfer provisions, the Founder Shares transferred in connection with these agreements are subject to similar contractual conditions and restrictions as the Founder Shares issued to the Sponsor in connection with the IPO. The forward purchase warrants will have the same terms as the public warrants.
The forward purchase agreements provide that the anchor investors are entitled to registration rights with respect to the forward purchase securities and Class A ordinary shares underlying the forward purchase warrants and Founder Shares.
The proceeds from the sale of the forward purchase securities may be used as part of the consideration to the sellers in the initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post Business Combination company. These purchases will be required to be made regardless of whether any Class A ordinary shares are redeemed by the public shareholders and are intended to provide the Company with a minimum funding level for the initial Business Combination. The anchor investors will not have the ability to approve the initial Business Combination prior to the signing of a material definitive agreement and, if the Company seeks shareholder approval, have agreed to vote their Founder Shares and any public shares held by them in favor of the initial Business Combination. The forward purchase securities will be issued only in connection with the closing of the initial Business Combination.
Business Combination Agreement
On September 29, 2022, the Company entered into a Business Combination Agreement with YishengBio Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands (to be renamed as YS Biopharma Co., Ltd, herein referred to as “YS Biopharma”), Oceanview Bioscience Acquisition Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub I”) and Hudson Biomedical Group Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub II,” and together with Merger Sub I, “Merger Subs”). Capitalized terms in this Item 1.01 not otherwise defined shall have the meanings ascribed to them in the Business Combination Agreement.
The Business Combination Agreement provides for (i) the merger of Merger Sub I with and into Summit (the “First Merger”), with Summit surviving the First Merger as the surviving entity (the “Surviving Entity”) and becoming a wholly-owned subsidiary of YS Biopharma, and (ii) the merger of the Surviving Entity with and into Merger Sub II (the “Second Merger,” and together with the First Merger, the “Mergers,” together with other transactions contemplated by the Business Combination Agreement, the “Transactions”), with Merger Sub II surviving the Second Merger as the surviving company (the “Surviving Company”) and remaining as the wholly-owned subsidiary of YS Biopharma.
Subject to, and in accordance with the terms and conditions set forth in the Business Combination Agreement, immediately prior to the effective time of the First Merger (the “First Merger Effective Time”), (i) each preferred share of YS Biopharma with par value of US$0.000005 will be converted into one ordinary share of YS Biopharma with par value of US$0.000005; (ii) after the conversion of all preferred shares into ordinary shares, each four of the ordinary shares of YS Biopharma with par value of US$0.000005 will be consolidated into one ordinary share of YS Biopharma with par value of US$0.00002, and each four of the options to acquire ordinary shares of YS Biopharma will be consolidated into one option to acquire ordinary share of YS Biopharma, subject to rounding up to the nearest whole number of shares; and (iii) the second amended and restated memorandum and articles of association of YS Biopharma shall be adopted and become effective. Items (i) through (iii) are herein referred to as the “YS Biopharma Capital Restructuring.”
Concurrently with the execution of the Business Combination Agreement, YS Biopharma and Summit entered into a Shareholder Support Agreement and Deed with certain YS Biopharma shareholders and certain Summit shareholders with respect to the Transactions and post-Closing rights and obligations of shareholders of YS Biopharma.
 
16
Note 8—Warrant Liability
As of September 30, 2022 and December 31, 2021, 16,000,000 warrants (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) are outstanding. Each warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. The warrants will become exercisable on the later of 12 months from the closing of the IPO or 30 days after the completion of its initial Business Combination, and will expire five years after the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation
Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00.
Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):
 
  •  
in whole and not in part;
 
  •  
at a price of $0.01 per warrant;
 
  •  
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
 
  •  
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days with in
a 30-trading day
period ending three trading days before the Company sends the notice of redemption to the warrant holders.
If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00
Once the warrants become exercisable, the Company may redeem the outstanding warrants:
 
  •  
in whole and not in part;
 
  •  
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of the Class A ordinary shares;
 
  •  
if, and only if, the closing price of our Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days with in
the 30-trading day
period ending three trading days before the Company sends the notice of redemption to the warrant holders; and
 
  •  
if the closing price of the Class A ordinary shares for any 20 trading days with in
a 30-trading day
period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above.
In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and in the case of any such issuance to the Company’s Sponsors or its affiliate, without taking into account any Founder Shares held by the Company’s Sponsor or such affiliates, as applicable, prior to such issuance (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the completion of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
 
17
Note 9—Shareholders’ Deficit
Preference shares
The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2022 and December 31, 2021, there were no preference shares issued or outstanding.
Class A Ordinary Shares
The Company is authorized to issue 500,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2022 and December 31, 2021, there were 20,000,000 Class A ordinary shares issued and outstanding, including the 20,000,000 shares presented in ordinary shares subject to redemption.
Class B Ordinary Shares
The Company is authorized to issue 50,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2022 and December 31, 2021, there were 5,750,000 Class B ordinary shares issued and outstanding. Of the 6,500,000 Class B ordinary shares, an aggregate of up to 750,000 shares were subject to forfeiture to the Company for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding ordinary shares after the IPO. On July 23, 2021, the Sponsor surrendered 750,000 Founder Shares, with no return of capital or payment by the Sponsor, after the expiration of the unexercised underwriters’ over-allotment option.
Class A ordinary shareholders and Class B ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law. Prior to the initial Business Combination, only holders of the Founder Shares will have the right to vote on the election of directors. Holders of the public shares will not be entitled to vote on the appointment of directors during such time. In addition, prior to the completion of an initial Business Combination, holders of a majority of the Founder Shares may remove a member of the board of directors for any reason.
The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have redemption rights or be entitled to liquidating distributions from the Trust Account if the Company does not consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate,
on an as-converted basis, 20%
of the sum of (i) the total number of ordinary shares issued and outstanding upon the completion of the IPO, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued or to be issued to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, its affiliates or any member of our management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
Note 10—Subsequent Events
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued. Based on this review, other than the events described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

On October 12, 2022, the Company had drawn down $700,000 under the Convertible Promissory Note. The Convertible Promissory Note will be valued using the fair value method at each reporting period.
 
18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

References to the “Company,” “our,” “us” or “we” refer to Summit Healthcare Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this Form 10-Q. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings.

Overview

We are a blank check company incorporated on December 22, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. We intend to effectuate our initial business combination using cash from the proceeds of our initial public offering (“Initial Public Offering”) and the sale of the private placement warrants and forward purchase securities, the proceeds of the sale of our shares in connection with our initial business combination (pursuant to forward purchase agreements or backstop agreements we may enter into following the consummation of this offering or otherwise), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, or a combination of the foregoing or other sources.

The issuance of additional ordinary shares in a Business Combination:

 

  •  

may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions of the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares;

 

  •  

may subordinate the rights of holders of Class A ordinary shares if preferred shares are issued with rights senior to those afforded our Class A ordinary shares;

 

  •  

could cause a change of control if a substantial number of our ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;

 

  •  

may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and

 

  •  

may adversely affect prevailing market prices for our Class A ordinary shares and/or warrants.

Similarly, if we issue debt securities, it could result in:

 

  •  

default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations;

 

  •  

acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;

 

  •  

our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand;

 

  •  

our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;

 

  •  

our inability to pay dividends on our Class A ordinary shares;

 

  •  

using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary shares if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;

 

19

  •  

limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;

 

  •  

increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and

 

  •  

limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception through September 30, 2022 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our initial Business Combination. We generate non-operating income in the form of interest income on marketable securities. We are incurring expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with completing a Business Combination.

For the three months ended September 30, 2022, we had net income of $5,705,354, which consists of interest income on investments held in the Trust Account of $902,750 and gain recognized on extinguishment of deferred underwriting commissions of $7,000,000, offset by a change in fair value of warrant liabilities of $1,206,319, a change in fair value of FPA of $409,888 and general and administrative expenses of $581,189.

For the nine months ended September 30, 2022, we had net income of $14,551,968, which consists of interest income on investments held in the Trust Account of $1,192,968, a change in fair value of warrant liabilities of $8,008,547 and gain recognized on extinguishment of deferred underwriting commissions of $7,000,000, offset by a change in fair value of FPA of $423,987 and general and administrative expenses of $1,225,560.

For the three months ended September 30, 2021, we had net income of $1,034,797, which consists of a change in fair value of warrant liabilities of $1,797,111 and interest income on investments held in the Trust Account of $2,573, offset by the general and administrative expenses of $202,904 and change in fair value of FPA of $561,983.

For the nine months ended September 30, 2021, we had net loss of $3,646,267, which consists of general and administrative expenses of $246,868, a change in fair value of warrant liabilities of $88,010, a change in fair value of FPA of $2,807,021 and transaction costs allocable to warrants $507,417, offset by interest income on investments held in the Trust Account of $3,049.

Liquidity and Capital Resources; Going concern

On June 11, 2021, we consummated our Initial Public Offering of 20,000,000 Units, at a price of $10.00 per Unit, generating gross proceeds of $200,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 6,000,000 Private Placement Warrants to our sponsor at a price of $1.00 per warrant, generating gross proceeds of $6,000,000.

Following our Initial Public Offering and the sale of the Private Placement Warrants, a total of $200,000,000 was placed in the Trust Account. We incurred $11,587,941 in transaction costs, including $4,000,000 of underwriting fees, $7,000,000 of deferred underwriting fees (which was waived in full in July 2022 and resulted in $7,000,000 gain recognized on extinguishment of deferred underwriting commissions) and $587,941 of other cash offering costs.

For the nine months ended September 30, 2022, cash used in operating activities was $815,101. Net income of $14,551,968 consists of an unrealized loss on change in fair value of FPA liability of $423,987, an unrealized gain on change in fair value of warrant liabilities of $8,008,547, interest earned on investments held in the Trust Account of $1,192,968, gain recognized on extinguishment of deferred underwriting commissions of $7,000,000 and changes in operating assets and liabilities, which provided $410,459 of cash from operating activities.

For the nine months ended September 30, 2021, cash used in operating activities was $423,286. Net loss of $3,646,267 consists of an unrealized loss on change on fair value of warrants and FPA warrants of $2,895,031, transaction costs allocable to warrants of $507,417, offset by interest earned on investments held in the Trust Account of $3,049, and changes in operating assets and liabilities, which used $176,418 of cash from operating activities.

As of September 30, 2022, we had investments held in the Trust Account of $201,200,243. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (which interest shall be net of taxes payable and excluding deferred underwriting commissions) to complete our Business Combination. To the extent that our share capital is used, in whole or in part, as consideration to complete a Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

 

20

As of September 30, 2022, we had cash of $70,097 held outside of trust account. We intend to use the funds for working capital purpose primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a Business Combination.

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we would repay such loaned amounts. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into warrants, at a price of $1.00 per warrant unit at the option of the lender. The warrants would be identical to the Private Placement Warrants. On September 29, 2022, we issued a Convertible Promissory Note (as described in Note 6 of the financial statement) to the Sponsor, pursuant to which, we may borrow up to $1,500,000 from the Sponsor for working capital purpose. On October 12, 2022, we had drawn down $700,000 under the Convertible Promissory Note.

If our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our initial Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our Public Shares upon completion of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination.

If we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. We cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.

We have until June 11, 2023 to consummate a business combination. It is uncertain that we will be able to consummate a business combination by such date. If a business combination is not consummated by the required date, we will commence an automatic winding up, dissolution and liquidation. In connection with our assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the management has determined that the liquidity condition and automatic liquidation, should a business combination not occur, and potential subsequent dissolution raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after June 11, 2023.

Off-balance sheet financing arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2022. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay our sponsor a monthly fee of up to $10,000 for office space, and administrative and support services, provided to us. We began incurring these fees on June 8, 2021 and will continue to incur these fees monthly until the earlier of the completion of a Business Combination and our liquidation.

Critical Accounting Policies

The preparation of condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

Derivative Financial Instruments

We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

 

21

Warrant Liability and Forward Purchase Agreement

We account for the 16,000,000 warrants issued in connection with the IPO (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) and Forward Purchase Agreement (“FPA”) in accordance with the guidance contained in FASB ASC 815 “Derivatives and Hedging” whereby under that provision the warrants and FPA do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we will classify warrants and FPA as liabilities at their fair value. These liabilities are subject to re-measurement at each reporting period. With such re-measurement, the changes in fair value are recognized in the Statement of Operations in the period of change. Derivative warrant liabilities and FPA are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Class A Ordinary Shares Subject to Possible Redemption

We account for our Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. Our Class A ordinary shares feature certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2022 and December 31, 2021, 20,000,000 and 20,000,000 Class A ordinary shares, respectively, subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity (deficit) section of our balance sheet.

Net Income (Loss) Per Ordinary Share

We have two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 16,000,000 potential Class A ordinary shares for outstanding warrants to purchase our Class A ordinary shares were excluded from diluted earnings per share for the three months and nine months ended September 30, 2022 because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods.

Recent Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective on January 1, 2024 for smaller reporting companies and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Our management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on our financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and President, to allow timely decisions regarding required disclosure.

 

22

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our management carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures under the supervision of our Chief Executive Officer and our Principal Financial Officer and concluded that our disclosure controls and procedures are effective as of September 30, 2022.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the period from July 1, 2022 through September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors.

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities

Unregistered Sales

On December 31, 2020, our Sponsor paid $25,000, or approximately $0.004 per share, to cover certain expenses on our behalf in consideration of 5,750,000 Founder Shares. Following a share capitalization on April 30, 2021, our Sponsor held an aggregate of 6,500,000 Founder Shares and then, in connection with entering into the forward purchase agreements, transferred to the anchor investors an aggregate of 375,000 Founder Shares for no cash consideration. These 375,000 Founder Shares are not subject to forfeiture in the event the underwriters’ over-allotment option is not exercised. On April 30, 2021, our Sponsor transferred 25,000 Founder Shares to each of our independent directors. These 75,000 Founder Shares are not subject to forfeiture in the event the underwriter’s over-allotment option is not exercised. On July 23, 2021, our Sponsor surrendered 750,000 Founder Shares, with no return of capital or payment by the Sponsor, after the expiration of the unexercised underwriters’ over-allotment option. As of November 14, 2022, the Sponsor held 5,300,000 Founder Shares with an effective purchase price of approximately $0.004 per share, the anchor investors held 375,000 Founder Shares and the independent directors held 75,000 Founder Shares, respectively.

We have not sold any equity securities during the quarter ended September 30, 2022. During the quarter ended September 30, 2022, we did not repurchase any shares of our equity securities.

Item 3. Defaults Upon Senior Securities

None.

 

23

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits.

 

Exhibit
Number		   

Description

  31.1*    Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  31.2*    Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  32.1**    Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  32.2**    Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*    Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*    Inline XBRL Taxonomy Extension Schema Document
101.CAL*    Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*    Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*    Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*    Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*

Filed herewith.

**

Furnished.

 

24

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 14th day of November 2022.

 

SUMMIT HEALTHCARE ACQUISITION CORP.
By:   /s/ Bo Tan
  Name:   Bo Tan
  Title:   Chief Executive Officer, Co-Chief Investment Officer and Director (Principal Executive Officer and Principal Financial and Accounting Officer)

 

25

EX-31.1 2 d412062dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a)

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bo Tan, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Summit Healthcare Acquisition Corp. (the “Company”);

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4.

The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c.

Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5.

The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: November 14, 2022

 

/s/ Bo Tan
Bo Tan

Chief Executive Officer and Co-Chief Investment Officer

(Principal Executive Officer)

 

1

EX-31.2 3 d412062dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AND RULE 15d-14(a)

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bo Tan, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Summit Healthcare Acquisition Corp. (the “Company”);

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4.

The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c.

Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5.

The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: November 14, 2022

 

/s/ Bo Tan
Bo Tan

Chief Executive Officer and Co-Chief Investment Officer

(Principal Financial Officer)

 

1

EX-32.1 4 d412062dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Bo Tan, Chief Executive Officer of Summit Healthcare Acquisition Corp. (the “Company”), certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1.

The Quarterly Report of the Company on Form 10-Q for the fiscal quarter ended September 30, 2022 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2022

 

/s/ Bo Tan
Bo Tan
Chief Executive Officer and Co-Chief Investment Officer (Principal Executive Officer)

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.

 

 EX-32.2 5 d412062dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Bo Tan, Chief Executive Officer and Co-Chief Investment Officer (Principal Financial Officer) of Summit Healthcare Acquisition Corp. (the “Company”), certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1.

The Quarterly Report of the Company on Form 10-Q for the fiscal quarter ended September 30, 2022 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2022

 

/s/ Bo Tan
Bo Tan

Chief Executive Officer and Co-Chief Investment Officer

(Principal Financial Officer)

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.

EX-101.SCH 6 smihu-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Unaudited Condensed Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Unaudited Condensed Statements of Changes in Shareholders' Deficit link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Unaudited Condensed Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - Organization, Business Operation, Liquidity and Capital Resources link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Initial Public Offering link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Private Placement link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Recurring Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Commitments & Contingencies link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Warrant Liability link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Shareholders' Deficit link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Recurring Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Organization, Business Operation, Liquidity and Capital Resources - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Significant Accounting Policies - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Significant Accounting Policies - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Significant Accounting Policies - Summary of Class A ordinary shares subject to possible redemption (Detail) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Initial Public Offering - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Private Placement - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Recurring Fair Value Measurements - Summary of Fair Value Hierarchy the Company's Assets and Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants (Detail) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants of FPA (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Recurring Fair Value Measurements - Summary of reconciliation of changes in fair value of derivative warrant liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Recurring Fair Value Measurements - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Commitments & Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Warrant Liability - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Shareholders' Deficit - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Subsequent Events - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 smihu-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 smihu-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 smihu-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 smihu-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Nov. 14, 2022
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Entity Registrant Name SUMMIT HEALTHCARE ACQUISITION CORP.  
Entity Central Index Key 0001839185  
Document Period End Date Sep. 30, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
Entity Incorporation, State or Country Code E9  
Entity File Number 001-40466  
Entity Tax Identification Number 98-1574360  
Entity Address, Address Line One Unit 1101  
Entity Address, Address Line Two 11th Floor  
Entity Address, Address Line Three 1 Lyndhurst Tower 1 Lyndhurst Terrace  
Entity Address, City or Town Central  
Entity Address, Country HK  
Entity Address, Postal Zip Code 0  
City Area Code 852  
Local Phone Number 2155-7212  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Common Class A    
Document Information [Line Items]    
Title of 12(b) Security Class A ordinary shares, par value $0.0001 per share  
Trading Symbol SMIH  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   20,000,000
Common Class B    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   5,750,000
Warrant    
Document Information [Line Items]    
Title of 12(b) Security Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50  
Trading Symbol SMIHW  
Security Exchange Name NASDAQ  
Capital Units    
Document Information [Line Items]    
Title of 12(b) Security Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant  
Trading Symbol SMIHU  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash $ 70,097 $ 885,198
Prepaid expenses 218,545 141,677
Total current assets 288,642 1,026,875
Investments held in Trust Account 201,200,243 200,007,275
Total Assets 201,488,885 201,034,150
Current liabilities:    
Accrued expenses 599,956 142,631
Due to related party 30,000 0
Total current liabilities 629,956 142,631
FPA liability 3,209,928 2,785,941
Warrant liability 2,414,882 10,423,429
Deferred underwriting commissions 0 7,000,000
Total Liabilities 6,254,766 20,352,001
Commitments and Contingencies (Note 7)
Class A ordinary shares subject to possible redemption, $0.0001 par value; 20,000,000 shares issued and outstanding at redemption value of $10.06 and $10.00 per share, as of September 30, 2022 and December 31, 2021, respectively 201,200,243 200,000,000
Shareholders' Deficit    
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding
Accumulated deficit (5,966,699) (19,318,426)
Total shareholders' Deficit (5,966,124) (19,317,851)
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit 201,488,885 201,034,150
Common Class A    
Current liabilities:    
Class A ordinary shares subject to possible redemption, $0.0001 par value; 20,000,000 shares issued and outstanding at redemption value of $10.06 and $10.00 per share, as of September 30, 2022 and December 31, 2021, respectively 201,200,243 200,000,000
Shareholders' Deficit    
Common Stock   0
Common Class B    
Shareholders' Deficit    
Common Stock $ 575 $ 575
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Temporary Equity, Redemption Price Per Share $ 10.06  
Preferred stock par or stated value per share $ 0.0001 $ 0.0001
Preferred stock shares authorized 5,000,000 5,000,000
Preferred stock shares issued 0 0
Preferred stock shares outstanding 0 0
Common Class A    
Temporary Equity, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Temporary Equity, Shares Issued 20,000,000 20,000,000
Temporary Equity, Shares Outstanding 20,000,000 20,000,000
Temporary Equity, Redemption Price Per Share $ 10.06 $ 10
Common stock par or stated value per share $ 0.0001 $ 0.0001
Common stock shares authorized 500,000,000 500,000,000
Common stock shares issued 20,000,000 20,000,000
Common stock shares outstanding 20,000,000 20,000,000
Common Class B    
Common stock par or stated value per share $ 0.0001 $ 0.0001
Common stock shares authorized 50,000,000 50,000,000
Common stock shares issued 5,750,000 5,750,000
Common stock shares outstanding 5,750,000 5,750,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
General and administrative expenses $ 581,189 $ 202,904 $ 1,225,560 $ 246,868
Loss from operations (581,189) (202,904) (1,225,560) (246,868)
Other income (expense):        
Change in fair value of FPA (409,888) (561,983) (423,987) (2,807,021)
Change in fair value of warrant liability (1,206,319) 1,797,111 8,008,547 (88,010)
Transaction costs allocable to warrants   0 0 (507,417)
Interest earned on investments held in Trust Account 902,750 2,573 1,192,968 3,049
Gain recognized on extinguishment of deferred underwriting commissions 7,000,000   7,000,000 0
Total other income (expense), net 6,286,543 1,237,701 15,777,528 (3,399,399)
Net income (loss) $ 5,705,354 $ 1,034,797 $ 14,551,968 $ (3,646,267)
Common Class A        
Other income (expense):        
Basic weighted average shares outstanding 20,000,000 20,000,000 20,000,000 8,205,128
Diluted weighted average shares outstanding 20,000,000 20,000,000 20,000,000 8,205,128
Basic net income (loss) per ordinary share $ 0.22 $ 0.04 $ 0.57 $ (0.26)
Diluted net income (loss) per ordinary share $ 0.22 $ 0.04 $ 0.57 $ (0.26)
Common Class B        
Other income (expense):        
Basic weighted average shares outstanding 5,750,000 5,750,000 5,750,000 5,750,000
Diluted weighted average shares outstanding 5,750,000 5,750,000 5,750,000 5,750,000
Basic net income (loss) per ordinary share $ 0.22 $ 0.04 $ 0.57 $ (0.26)
Diluted net income (loss) per ordinary share $ 0.22 $ 0.04 $ 0.57 $ (0.26)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Statements of Changes in Shareholders' Deficit - USD ($)
Total
Additional Paid-in Capital
Accumulated Deficit
Common Class A
Common Class A
Ordinary Shares
Common Class B
Ordinary Shares
Balances at beginning at Dec. 31, 2020 $ 21,364 $ 24,350 $ (3,636)   $ 0 $ 650
Balances at beginning, Shares at Dec. 31, 2020         0 6,500,000
Net income (loss) 0   0      
Balances at end at Mar. 31, 2021 21,364 24,350 (3,636)   $ 0 $ 650
Balances at end, Shares at Mar. 31, 2021         0 6,500,000
Balances at beginning at Dec. 31, 2020 21,364 24,350 (3,636)   $ 0 $ 650
Balances at beginning, Shares at Dec. 31, 2020         0 6,500,000
Net income (loss) (3,646,267)       $ (2,143,878) $ (1,502,389)
Balances at end at Sep. 30, 2021 (22,418,391) 0 (22,418,966)   $ 0 $ 575
Balances at end, Shares at Sep. 30, 2021         0 5,750,000
Balances at beginning at Dec. 31, 2020 21,364 24,350 (3,636)   $ 0 $ 650
Balances at beginning, Shares at Dec. 31, 2020         0 6,500,000
Accretion of Class A ordinary shares to redemption value       $ (19,591,933)    
Balances at end at Dec. 31, 2021 (19,317,851) 0 (19,318,426)   $ 0 $ 575
Balances at end, Shares at Dec. 31, 2021         0 5,750,000
Balances at beginning at Mar. 31, 2021 21,364 24,350 (3,636)   $ 0 $ 650
Balances at beginning, Shares at Mar. 31, 2021         0 6,500,000
Net income (loss) (4,681,064)   (4,681,064)      
Accretion of Class A ordinary shares to redemption value (18,793,488) (24,350) (18,769,138)      
Balances at end at Jun. 30, 2021 (23,453,188) 0 (23,453,838)   $ 0 $ 650
Balances at end, Shares at Jun. 30, 2021         0 6,500,000
Forfeiture of founder shares     75     $ (75)
Forfeiture of founder shares, Shares           (750,000)
Net income (loss) 1,034,797   1,034,797   $ 803,726 $ 231,071
Balances at end at Sep. 30, 2021 (22,418,391) 0 (22,418,966)   $ 0 $ 575
Balances at end, Shares at Sep. 30, 2021         0 5,750,000
Balances at beginning at Dec. 31, 2021 (19,317,851) 0 (19,318,426)   $ 0 $ 575
Balances at beginning, Shares at Dec. 31, 2021         0 5,750,000
Net income (loss) 7,126,838   7,126,838      
Balances at end at Mar. 31, 2022 (12,191,013) 0 (12,191,588)   $ 0 $ 575
Balances at end, Shares at Mar. 31, 2022         0 5,750,000
Balances at beginning at Dec. 31, 2021 (19,317,851) 0 (19,318,426)   $ 0 $ 575
Balances at beginning, Shares at Dec. 31, 2021         0 5,750,000
Accretion of Class A ordinary shares to redemption value       $ (1,200,243)    
Balances at end at Jun. 30, 2022 (10,768,728) 0 (10,769,303)   $ 0 $ 575
Balances at end, Shares at Jun. 30, 2022         0 5,750,000
Balances at beginning at Dec. 31, 2021 (19,317,851) 0 (19,318,426)   $ 0 $ 575
Balances at beginning, Shares at Dec. 31, 2021         0 5,750,000
Net income (loss) 14,551,968       $ 11,302,500 $ 3,249,469
Balances at end at Sep. 30, 2022 (5,966,124) 0 (5,966,699)     $ 575
Balances at end, Shares at Sep. 30, 2022           5,750,000
Balances at beginning at Mar. 31, 2022 (12,191,013) 0 (12,191,588)   $ 0 $ 575
Balances at beginning, Shares at Mar. 31, 2022         0 5,750,000
Net income (loss) 1,719,777   1,719,777      
Accretion of carrying value to redemption value-interest (297,492)   (297,492)      
Balances at end at Jun. 30, 2022 (10,768,728) 0 (10,769,303)   $ 0 $ 575
Balances at end, Shares at Jun. 30, 2022         0 5,750,000
Net income (loss) 5,705,354   5,705,354   $ 4,431,344 $ 1,274,011
Accretion of carrying value to redemption value-interest (902,750)   (902,750)      
Balances at end at Sep. 30, 2022 $ (5,966,124) $ 0 $ (5,966,699)     $ 575
Balances at end, Shares at Sep. 30, 2022           5,750,000
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Cash Flows from Operating Activities:        
Net income (loss) $ 5,705,354 $ 1,034,797 $ 14,551,968 $ (3,646,267)
Adjustments to reconcile net income (loss) to net cash used in operating activities:        
Interest earned on investments held in Trust Account     (1,192,968) (3,049)
Change in fair value of FPA liability 409,888 561,983 423,987 2,807,021
Change in fair value of warrant liability 1,206,319 (1,797,111) (8,008,547) 88,010
Transaction costs allocable to warrants   0 0 507,417
Gain recognized on extinguishment of deferred underwriting commissions (7,000,000)   (7,000,000) 0
Changes in operating assets and liabilities:        
Prepaid expenses     (76,868) (221,704)
Accrued offering costs and expenses     457,327 7,619
Due to related party     30,000 37,667
Net cash used in operating activities     (815,101) (423,286)
Cash Flows from Investing Activities        
Investment of cash in Trust Account     0 (200,000,000)
Net cash used in investing activities     0 (200,000,000)
Cash Flows from Financing Activities:        
Proceeds received from initial public offering, net of underwriters' discount     0 196,000,000
Proceeds from private placement     0 6,000,000
Payment of offering costs     0 (140,554)
Repayment of note payable from related party     0 (361,023)
Net cash provided by financing activities     0 201,498,423
Net change in cash     (815,101) 1,075,137
Cash, beginning of the period     885,198  
Cash, end of the period $ 70,097 $ 1,075,137 70,097 1,075,137
Supplemental disclosure of non-cash investing and financing activity        
Deferred offering costs paid by Sponsor under promissory note     0 135,544
Deferred underwriting commissions charged to additional paid in capital     $ 0 $ 7,000,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization, Business Operation, Liquidity and Capital Resources
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Business Operation, Liquidity and Capital Resources
Note 1—Organization, Business Operation, Liquidity and Capital Resources
Summit Healthcare Acquisition Corp. (the “Company”) is a blank check company incorporated on December 22, 2020 as a Cayman Islands exempted company. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any specific Business Combination target under consideration or contemplation and the Company has not, nor has anyone on its behalf, contacted any prospective target business or had any discussions, formal or otherwise, with respect to such a transaction. The Company’s efforts to identify a prospective target business will not be limited to a particular geographic region or industry, although it intends to focus on healthcare.
As of September 30, 2022, the Company had not commenced any operations. All activity for the period from December 22, 2020 (inception) through September 30, 2022 relates to the Company’s formation and the initial public offering (the “IPO”), searching for a Business Combination target. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates
non-operating
income in the form of interest income on investments from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.
The Company’s Sponsor is Summit Healthcare Acquisition Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”). The registration statement for the Company’s IPO was declared effective on June 8, 2021 (the “Effective Date”). On June 11, 2021, the Company consummated the IPO of 20,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”) $10.00 per Unit, generating gross proceeds of $200,000,000, which is discussed in Note 3.
Simultaneously with the consummation of the IPO and the issuance and sale of the Units, the Company consummated the private placement of 6,000,000 Private Placement Warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant, to the Sponsor, generating total proceeds of $6,000,000. Transaction costs amounted to $11,587,941 consisting of $4,000,000 of underwriting commissions, $7,000,000 of deferred underwriting commissions and $587,941 of other cash offering costs.
Following the closing of the IPO on June 11, 2021, $200,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a U.S.-based trust account (the “Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee, and was invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain
conditions under Rule 2a-7 under the
Investment Company Act. As of September 30, 2022, the assets held in the Trust Account were held in money market fund.
Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the Company’s amended and restated memorandum and articles of association and subject to the requirements of law and regulation, will provide that the proceeds from the IPO and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the Company’s public shareholders until the earliest of: (i) the completion of an initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association, and (iii) the redemption of the Company’s public shares if the Company has not consummated its Business Combination within 24 months from the closing of the IPO, subject to applicable law.
The ordinary shares subject to redemption are recorded at a $10.06 per share redemption value and classified as temporary equity, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”
The Company will have 24 months from the closing of the IPO to complete the initial Business Combination (the “Combination Period”) or during any Extension Period. However, if the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares,
at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable
la
w.
 
The Sponsor and the Company’s officers and directors agreed to (i) waive their redemption rights with respect to their Class B ordinary shares, par value $0.0001 (the “Founder Shares”) in connection with the completion of the initial Business Combination, (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association, (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to complete the initial Business Combination within the Combination Period or during any Extension Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete its initial Business Combination within the prescribed timeframe), and (iv) vote any Founder Shares and public shares held by them in favor of the initial Business Combination.
The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share or (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay the Company’s tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriter of the IPO against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked it Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
Business Combination
On September 29, 2022, the Company entered into a Business Combination Agreement (the “Business Combination Agreement”) with YishengBio Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands (to be renamed as YS Biopharma Co., Ltd, herein referred to as “YS Biopharma”), Oceanview Bioscience Acquisition Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub I”) and Hudson Biomedical Group Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub II,” and together with Merger Sub I, “Merger Subs”).
The Business Combination Agreement provides for (i) the merger of Merger Sub I with and into the Company (the “First Merger”), with the Company surviving the First Merger as the surviving entity (the “Surviving Entity”) and becoming a wholly-owned subsidiary of YS Biopharma, and (ii) the merger of the Surviving Entity with and into Merger Sub II (the “Second Merger,” and together with the First Merger, the “Mergers,” together with other transactions contemplated by the Business Combination Agreement, the “Transactions”), with Merger Sub II surviving the Second Merger as the surviving company (the “Surviving Company”) and remaining as the wholly-owned subsidiary of YS Biopharma.
Liquidity and Capital Resources; Going Concern
As of September 30, 2022, the Company had $70,097 of cash for working capital purposes and
a
working capital deficit of $341,314.
The Company’s liquidity needs prior to the IPO had been satisfied through a payment from the Sponsor of $25,000 (see Note 5) for the Founder Shares to cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of $300,000 (see Note 5).
The promissory note was repaid on June 11, 2021. In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans, as defined below (see Note 5). As of September 30, 2022 and December 31, 2021, there were no amounts outstanding under any Working Capital Loans.
The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. On September 29, 2022, the Company issued a Convertible Promissory Note (as described in Note 6) to the Sponsor, pursuant to which, the Company may borrow up to $1,500,000 from the Sponsor for working capital purpose
s
. On October 12, 2022, the Company had
drew
down $700,000 under the Convertible Promissory Note.
The C
ompa
ny has until June 11, 2023 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by such date. If a Business Combination is not consummated by the required date, the Company will commence an automatic winding up, dissolution and liquidation. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”)
2014-15,
“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the management has determined that the liquidity condition and
mandatory
liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 11, 2023. The management plans to continue efforts to close a Business Combination within the prescribed time frame.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Significant Accounting Policies
Note 2—Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and pursuant to the rules and regulations of the Security and Exchange Commission (“SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of the unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the fun audited condensed financial statements and the reported amounts of expenses during the reporting period.
Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant estimates included in these financial statements is the determination of the fair value of the warrant liability and Forward Purchase Agreement (“FPA”) liability.
 
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have cash equivalents as of September 30, 2022 and December 31, 2021.
Investments Held in Trust Account
As of September 30, 2022 and December 31, 2021, the
assets held in the Trust Account were held in a money market fund. The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, investments in money market funds that invest in U.S. government securities, cash, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Interest earned on these securities is included in interest earned on Investments Held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2022 and December 31, 2021, the Company had $201,200,243 and $200,007,275 held in the Trust Account, respectively.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation limit of $250,000. As of September 30, 2022 and December 31, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Offering Costs Associated with IPO
The Company complies with the requirements of the
ASC340-10-S99-1
and SEC Staff Accounting Bulletin (“SAB”) Topic 5A “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged to ordinary shares subject to possible redemption or the statement of operations based on the relative value of the Public and Private Warrants to the proceeds received from the Units and Private Placement Warrants sold upon the completion of the IPO. Accordingly, offering costs totaling $11,587,941 (consisting of $4,000,000 of underwriting fees, $7,000,000 of deferred underwriting fees and $587,941 of other offering costs), of which $507,417 was allocated to the Public Warrants and Private Warrants and was charged to operations in accordance with ASC
825-10
and $11,080,524 was charged to ordinary shares subject to possible redemption.
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then
re-valued
at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liability and Forward Purchase Agreement
The Company accounts for the 16,000,000 warrants issued in connection with the IPO (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) and Forward Purchase Agreement (“FPA”) in accordance with the guidance contained in FASB ASC 815 “Derivatives and Hedging” whereby under that provision the warrants and FPA do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company will classify warrants and FPA as liabilities at their fair value. These liabilities are subject to
re-measurement
at each reporting period. With such
re-measurement,
the changes in fair value are recognized in the Statement of Operations in the period of change. Derivative warrant liabilities and FPA are classified as
non-current
liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Fair Value Measurements
The fair value of the Company’s assets and liabilities, excluding the warrant liability and FPA liability, which qualify as financial instruments under FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.
 
Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
 
  •  
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
  •  
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
  •  
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2022 and December 31, 2021, 20,000,000 and 20,000,000 Class A ordinary shares, respectively, subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity (deficit) section of the Company’s balance sheet.
The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period.
As of September 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following table:
 
Gross proceeds
    $ 200,000,000  
Less: Proceeds allocated to Public Warrants
      (8,511,409 ) 
Less: Class A ordinary shares issuance costs
      (11,080,524 ) 
Add: Accretion of carrying value to redemption value
      19,591,933  
    
 
 
  
Class A ordinary shares subject to possible redemption as of December 31, 2021
      200,000,000  
Add: Accretion of carrying value to redemption value
      1,200,243  
    
 
 
  
Class A ordinary shares subject to possible redemption as of September 30, 2022
    $ 201,200,243  
    
 
 
  
Net Income (Loss) Per Ordinary Share
The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 16,000,000 potential
ordinary
shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three and nine months ended
September 30, 2022 and 2021,
because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares:
    
For the Three Months Ended
September 30,
  
    
2022
     
2021
  
    
Class A
     
Class B
     
Class A
     
Class B
  
Basic and diluted net income per share:
                                    
Numerator:
                                    
Allocation of net income
    $ 4,431,344      $ 1,274,011      $ 803,726      $ 231,071  
Denominator:
                                    
Weighted-average shares outstanding
      20,000,000        5,750,000        20,000,000        5,750,000  
    
 
 
     
 
 
     
 
 
     
 
 
  
Basic and diluted net income per share
    $ 0.22      $ 0.22      $ 0.04      $ 0.04  
 
    
For the Nine Months Ended
September 30,
  
    
2022
     
2021
  
    
Class A
     
Class B
     
Class A
     
Class B
  
Basic and diluted net income (loss) per share:
                                    
Numerator:
                                    
Allocation of net income (loss)
    $ 11,302,500      $ 3,249,469      $ (2,143,878 )     $ (1,502,389 ) 
Denominator:
                                    
Weighted-average shares outstanding
      20,000,000        5,750,000        8,205,128        5,750,000  
    
 
 
     
 
 
     
 
 
     
 
 
  
Basic and diluted net income (loss) per share
    $ 0.57      $ 0.57      $ (0.26 )     $ (0.26 ) 
Income Taxes
ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position
must be more-likely-than-not to be
sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Recent Accounting Pronouncements
In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2020-06,
Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic
815-40)
(“ASU2020-06”)
to simplify accounting for certain financial instruments. ASU
2020-06
eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU
2020-06
amends the diluted earnings per share guidance, including the requirement to use the
if-converted
method for all convertible instruments. ASU
2020-06
is effective on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that
ASU 2020-06
would have on its financial position, results of operations or cash flows.
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Initial Public Offering
 9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Initial Public Offering
Note 3—Initial Public Offering
On June 11, 2021, the Company consummated its IPO of 20,000,000 Units (the “Units”), at a price of $10.00 per unit, generating gross proceeds to the Company of $200,000,000. Each Unit consists of one Class A ordinary share and
one-half
of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from the closing of the IPO, and will expire five years after the completion of the initial Business Combination or earlier upon redemption or liquidation (see Note 8).
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Private Placement
 9 Months Ended
Sep. 30, 2022
Private Placement Warrants [Abstract]  
Private Placement
Note 4—Private Placement
Simultaneously with the closing of the IPO and the sale of the Units, the Company consummated the private placement (the “Private Placement”) of an aggregate 6,000,000 Private Placement Warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $6,000,000. If the Company does not complete an initial Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants
will be non-redeemable by the
Company and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.
 
If the Private Placement Warrants are held by
hold
ers other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the IPO.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
 9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions
Note 5—Related Party Transactions
Founder Shares
On December 31, 2020, the Company issued to the Sponsor 5,750,000 Founder Shares for $25,000 for certain expenses paid on behalf of the Company, or approximately $0.004 per share. On April 30, 2021, the Company effected a share capitalization, pursuant to which the Company’s initial shareholders held an aggregate of 6,500,000 Class B ordinary shares. The accompanying unaudited condensed financial statements have been retroactively adjusted to reflect the stock dividend in the share capitalization. On April 30, 2021, the Company entered into forward purchase agreements (see Note 6) with anchor investors, in connection with entering into the forward purchase agreements, the Sponsor transferred to the anchor investors an aggregate of 375,000 Class B ordinary shares for no cash. On April 30, 2021, the Sponsor transferred 25,000 Class B ordinary shares each to three independent director nominees. Up to 750,000 Founder Shares were subject to forfeiture by the Sponsor depending on the extent to which the underwriters’ over-allotment option is exercised. On July 23, 2021, the Sponsor surrendered 750,000 Founder Shares, with no return of capital or payment by the Sponsor, after the expiration of the unexercised underwriters’ over-allotment option. As a result of the foregoing, as of September 30, 2022 and December 31, 2021, the Sponsor owned 5,750,000 Class B ordinary shares.
The Sponsor, officers and directors have agreed not to transfer, assign or sell any of their Founder Shares until earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s public shareholders having the right to exchange their ordinary shares for cash, securities or other property
(the “Lock-up”).
Any permitted transferees would be subject to the same restrictions and other agreements of our Sponsor, officers and directors with respect to any Founder Shares.
Promissory Note—Related Party
The Sponsor has agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the IPO. These loans were
non-interest
bearing, unsecured and were due at the earlier of September 30, 2021 or the closing of the IPO. The loan was to be repaid upon completion of the IPO out of the $1,000,000 of offering proceeds that has been allocated to the payment of offering expenses. The Company had drawn down $140,068 under the promissory note which was repaid as of June 11, 2021. The note was terminated as of June 11, 2021.
Related Party Loans
In addition, in order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender. Such warrants would be identical to the Private Placement Warrants.
On September 29, 2022, the Company issued an unsecured, interest-free promissory note to the Sponsor pursuant to which the Company may borrow up to $1,500,000 from the Sponsor for costs and expenses reasonably related to the Company’s working capital needs prior to the consummation of the Business Combination (the “Convertible Promissory Note”). All unpaid principal under the Convertible Promissory Note will become due and payable in full on the date on which the Company consummates the Business Combination, unless earlier accelerated upon the occurrence of an event of default. The Sponsor will have the option, at any time on or prior to the maturity date, to convert any amounts outstanding under the Convertible Promissory Note, up to $1,500,000 in the aggregate, into warrants to purchase the Company’s Class A ordinary shares, at a conversion price of $1.00 per warrant, with each warrant entitling the holder to purchase one Company’s Class A ordinary share at a price of $11.50 per share, subject to the same adjustments applicable to the private placement warrants sold concurrently with the Company’s initial public offering. As of September 30, 2022, there were no outstanding amount under the Convertible Promissory Note. On October 12, 2022, the Company had drawn down $700,000 under the Convertible Promissory
Note. The Convertible Promissory Note will be valued using the fair value method at each reporting period.
 
Administrative Service Fee
Commencing on the Effective Date, the Company paid an affiliate of the Sponsor $10,000 per month for office space, utilities, administrative services and remote support services. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company accrued $30,000 and $90,000 for the administrative service fee for the three and nine months ended September 30, 2022, respectively.
The Company accrued $30,000 and $
37,667
 for the three months ended September 30, 2021 and for the period from June 8, 2021 (the Effective Date) through September 30, 2021. As of September 30, 2022 and December 31, 2021, there were $30,000 and $0 administrative service fee unpaid, which is included in due to related party on the accompanying condensed balance sheets. 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Recurring Fair Value Measurements
Note
6
—Recurring Fair Value Measurements
Warrant Liability and FPA Liability
As of September 30, 2022 and December 31, 2021, the fair value of Company’s Warrant liability was $2,414,882 and $10,423,429, respectively, and the fair value of FPA liability was $3,209,928 and $2,785,941, respectively. Under the guidance in ASC
815-40,
the Public and Private Warrants and the FPA do not meet the criteria for equity treatment. As such, the Public and Private Warrants and the FPA must be recorded on the balance sheet at fair value. This valuation is subject tore-measurement each balance sheet date. With each
re-measurement,
the valuations will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations.
Recurring Fair Value Measurements
The following table presents fair value information as of September 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company’s Warrant liability is based on a valuation models utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair values of the Private Warrant liability and FPA liability are classified within Level 3 of the fair value hierarchy. The investments held in Trust Account includes money market funds. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its level 1 investments.
The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of September 30, 2022, that were accounted for at fair value on a recurring basis:
 
     (Level 1)      (Level 2)      (Level 3)  
Assets
                           
Investments held in Trust Account
    $ 201,200,243      $ —        $ —    
    
 
 
     
 
 
     
 
 
  
Liabilities
                           
Public Warrants
    $ —      $ 1,500,000      $ —    
Private Warrants
    $ —        $ —        $ 914,882  
FPA liability
    $ —        $ —        $ 3,209,928  
    
 
 
     
 
 
     
 
 
  
Total Liabilities
   
$
1,500,000
 
   
$
—  
 
   
$
4,124,810
 
    
 
 
     
 
 
     
 
 
  
The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of December 31, 2021, that were accounted for at fair value on a recurring basis:
 
     (Level 1)      (Level 2)      (Level 3)  
Assets
                           
Investments held in Trust Account
    $ 200,007,275      $ —        $ —    
    
 
 
     
 
 
     
 
 
  
Liabilities
                           
Public Warrants
    $ 6,500,000      $ —        $ —    
Private Warrants
    $ —        $ —        $ 3,923,429  
FPA liability
    $ —        $ —        $ 2,785,941  
    
 
 
     
 
 
     
 
 
  
Total Liabilities
   
$
6,500,000
 
   
$
—  
 
   
$
6,709,370
 
    
 
 
     
 
 
     
 
 
  
 
Measurement of the Warrants
The Company established the initial fair value for the Warrants on June 11, 2021, the date of the consummation of the Company’s IPO. The Company used a Monte Carlo simulation model to value the Warrants. The Company allocated the proceeds received from (i) the sale of Units (which is inclusive of one Class A ordinary share and
one-half
of one Public Warrant), (ii) the sale of Private Warrants, and (iii) the issuance of Class B ordinary shares, first to the Warrants based on their fair values as determined at initial measurement, with the remaining proceeds allocated to Class A ordinary shares subject to possible redemption (temporary equity), and Class B ordinary shares (permanent equity) based on their relative fair values at the initial measurement date. The estimated fair value of the Public Warrants was transferred from a Level 3 measurement to a Level 1 measurement in August 2021 after detachment of the Public Warrants from the Units and were separately listed and traded. For the period ended September 30, 2022, the Public Warrants were reclassified from Level 1 to Level 2 due to the valuation based on quoted prices (unadjusted) with less volume and transaction frequency than active markets. As of September 30, 2022 and December 31, 2021, the Private Warrants were valued using a Monte Carlo simulation model.
The key inputs for the valuation of Private Warrants are as follows:
 
Input   
September 30,
2022
    
December 31,
2021
  
Risk Free Rate
      4.04 %      1.29 % 
Stock Price
    $ 9.82     $ 9.72  
Est. Term Remaining (Yrs)
      5.55       5.35  
The following table provides a reconciliation of changes in fair value of the Company’s derivative warrant liabilities classified as Level 3 for the nine months ended September 30, 2022 and 2021:
 
 
  
Public
Warrants
 
  
Private
Warrants
 
  
Warrants
Liability
 
Fair value at December 31, 2021
    $ —        $ 3,923,429      $ 3,923,429  
Change in fair value
      —          (2,713,773        (2,713,773 ) 
    
 
 
     
 
 
     
 
 
  
Fair Value at March 31, 2022
 
$
—  
 
 
$
1,209,656
 
 
$
1,209,656
 
Change in fair value
 
 
—  
 
 
 
(751,093
) 
 
 
(751,093
) 
Fair Value at June 30, 2022
 
$
—  
 
 
$
458,563
 
 
$
458,563
 
Change in fair value
 
 
—  
 
 
 
456,319
 
 
 
456,319
 
Fair Value at September 30, 2022
    $ —        $ 914,882      $ 914,882  
    
 
 
     
 
 
     
 
 
  
 
 
  
Public
Warrants
 
  
Private
Warrants
 
  
Warrants
Liability
 
Fair value at December 31, 2020
  
$
—  
  
  
$
—  
  
  
$
—  
  
Initial value of warrant liabilities at IPO
 (
June 11, 202
1
)
      8,511,409        5,201,555        13,712,964  
Change in fair value
 
 
1,212,798
 
 
 
672,323
 
 
 
1,885,121
 
Fair value at June 30, 2021
 
$
9,724,207
 
 
$
5,873,878
 
 
$
15,598,085
 
Change in fair value
      (1,123,207 )      (673,904 )       (1,797,111 )
Transfer of Public warrants from Level 3 to Level 1
      (8,601,000 )       —          (8,601,000 ) 
    
 
 
     
 
 
     
 
 
  
Fair Value at September 30, 2021
    $ —        $ 5,199,974      $ 5,199,974  
    
 
 
     
 
 
     
 
 
  
FPA
To arrive at the conclusion of Fair Value of the Forward Purchase Agreements, the Company analyzed the agreements and other documentation. The Company utilized the underlying shares and warrant values determined above and the following inputs in order to project the net asset or liability value of the FPA:
 
Input   
September 30,
2022
    
December 31,
2021
  
Stock Price
    $ 9.82     $ 9.72  
Warrant Price
    $ 0.150     $ 0.65  
Est. Term to Business Combination (Yrs)
      0.55       0.33  
Probability of Business Combination
      85 %      85 % 
Purchase price of FPA unit
    $ 10.00     $ 10.00  
Discount rate
      3.93 %      0.04 % 
The following table provides a reconciliation of changes in fair value of the Company’s FPA liability classified as Level 3 for the nine months ended September 30, 2022 and 2021:

 
 
  
FPA liability
 
Fair value at December 31, 2021
    $ 2,785,941  
Change in fair value
      (127,629 )
    
 
 
  
Fair Value at
March 31
, 2022
    $ 2,658,312  
Change in fair value
      141,728  
 
 
 
 
 
Fair Value at June 30, 2022
    $ 2,800,040  
Change in fair value
      409,888  
 
 
 
 
 
Fair Value at September 30, 2022
    $ 3,209,928  
    
 
 
  
 
 
  
FPA Liability
 
Fair value at December 31, 2020
    $ —    
Initial value of FPA liability at IPO
 (
June
11
, 2021
)
      2,322,741  
Change in fair value
      (77,703 )
    
 
 
  
Fair value at June 30, 2021
    $ 2,245,038  
Change in fair value
      561,983  
 
 
 
 
 
Fair value at September 30, 2021
    $ 2,807,021  
    
 
 
  
Transfers between levels of the fair value hierarchy are recognized at the end of the reporting period. There are no transfers to or from Level 3 for the
three and 
nine months ended September 30, 2022.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments & Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments & Contingencies
Note 7—Commitments & Contingencies
Risks and Uncertainties
Management continues to evaluate the impact
of the COVID-19 pandemic on
the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of this financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.
Registration Rights
The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the IPO. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
Lock-up
period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriters Agreement
The underwriters
had a 45-day option to
purchase up to an additional 3,000,000 units to cover over-allotments, if any. The over-allotment option expired unexercised on July 23, 2021.
The underwriters were paid a cash underwriting discount of two percent (2%) of the gross proceeds of the IPO, or $4,000,000. Additionally, the underwriters are entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the IPO upon the completion of the Company’s initial Business Combination. On July 7, 2022, a waiver letter was signed by the Company and BofA Securities, Inc. (“BofA”), pursuant to which BofA announced it waived its entitlement to the payment of any deferred underwriting discount to be paid under the terms of the underwriting agreement. The Company recognized $7,000,000
gain recognized on extinguishment of deferred underwriting commissions in the operations in connection with such waiver. 
Forward Purchase Agreements
On April 30, 2021, the Company entered into forward purchase agreements with the Sponsor, Snow Lake Capital (HK) Limited and Valliance Fund (the “anchor investors”), pursuant to which the anchor investors agreed to subscribe for an aggregate of 3,000,000 Class A ordinary shares plus 750,000 redeemable warrants for a purchase price of $10.00 multiplied by the number of Class A ordinary shares, or $30,000,000 in the aggregate, in a private placement to close concurrently with the closing of the initial business combination. The Company issued 750,000 additional Class B ordinary shares to the Sponsor, which represent the adjustment to the ratio applicable to the conversion of the Class B ordinary shares that the Sponsor would have been entitled to at the closing of the initial business combination as a result of the issuance of 3,000,000 additional Class A ordinary shares under the forward purchase agreements. As a result, the issuance of the Class A ordinary shares at the closing of the initial business combination will not trigger a further adjustment to this ratio. Further, prior to the IPO, the Sponsor transferred to the anchor investors an aggregate of 375,000 Founder Shares for no cash consideration. Subject to certain exceptions to forfeiture and transfer provisions, the Founder Shares transferred in connection with these agreements are subject to similar contractual conditions and restrictions as the Founder Shares issued to the Sponsor in connection with the IPO. The forward purchase warrants will have the same terms as the public warrants.
The forward purchase agreements provide that the anchor investors are entitled to registration rights with respect to the forward purchase securities and Class A ordinary shares underlying the forward purchase warrants and Founder Shares.
The proceeds from the sale of the forward purchase securities may be used as part of the consideration to the sellers in the initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post Business Combination company. These purchases will be required to be made regardless of whether any Class A ordinary shares are redeemed by the public shareholders and are intended to provide the Company with a minimum funding level for the initial Business Combination. The anchor investors will not have the ability to approve the initial Business Combination prior to the signing of a material definitive agreement and, if the Company seeks shareholder approval, have agreed to vote their Founder Shares and any public shares held by them in favor of the initial Business Combination. The forward purchase securities will be issued only in connection with the closing of the initial Business Combination.
Business Combination Agreement
On September 29, 2022, the Company entered into a Business Combination Agreement with YishengBio Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands (to be renamed as YS Biopharma Co., Ltd, herein referred to as “YS Biopharma”), Oceanview Bioscience Acquisition Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub I”) and Hudson Biomedical Group Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub II,” and together with Merger Sub I, “Merger Subs”). Capitalized terms in this Item 1.01 not otherwise defined shall have the meanings ascribed to them in the Business Combination Agreement.
The Business Combination Agreement provides for (i) the merger of Merger Sub I with and into Summit (the “First Merger”), with Summit surviving the First Merger as the surviving entity (the “Surviving Entity”) and becoming a wholly-owned subsidiary of YS Biopharma, and (ii) the merger of the Surviving Entity with and into Merger Sub II (the “Second Merger,” and together with the First Merger, the “Mergers,” together with other transactions contemplated by the Business Combination Agreement, the “Transactions”), with Merger Sub II surviving the Second Merger as the surviving company (the “Surviving Company”) and remaining as the wholly-owned subsidiary of YS Biopharma.
Subject to, and in accordance with the terms and conditions set forth in the Business Combination Agreement, immediately prior to the effective time of the First Merger (the “First Merger Effective Time”), (i) each preferred share of YS Biopharma with par value of US$0.000005 will be converted into one ordinary share of YS Biopharma with par value of US$0.000005; (ii) after the conversion of all preferred shares into ordinary shares, each four of the ordinary shares of YS Biopharma with par value of US$0.000005 will be consolidated into one ordinary share of YS Biopharma with par value of US$0.00002, and each four of the options to acquire ordinary shares of YS Biopharma will be consolidated into one option to acquire ordinary share of YS Biopharma, subject to rounding up to the nearest whole number of shares; and (iii) the second amended and restated memorandum and articles of association of YS Biopharma shall be adopted and become effective. Items (i) through (iii) are herein referred to as the “YS Biopharma Capital Restructuring.”
Concurrently with the execution of the Business Combination Agreement, YS Biopharma and Summit entered into a Shareholder Support Agreement and Deed with certain YS Biopharma shareholders and certain Summit shareholders with respect to the Transactions and post-Closing rights and obligations of shareholders of YS Biopharma.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrant Liability
 9 Months Ended
Sep. 30, 2022
Warrant Liability [Abstract]  
Warrant Liability
Note 8—Warrant Liability
As of September 30, 2022 and December 31, 2021, 16,000,000 warrants (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) are outstanding. Each warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. The warrants will become exercisable on the later of 12 months from the closing of the IPO or 30 days after the completion of its initial Business Combination, and will expire five years after the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation
Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00.
Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):
 
  •  
in whole and not in part;
 
  •  
at a price of $0.01 per warrant;
 
  •  
upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and
 
  •  
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days with in
a 30-trading day
period ending three trading days before the Company sends the notice of redemption to the warrant holders.
If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00
Once the warrants become exercisable, the Company may redeem the outstanding warrants:
 
  •  
in whole and not in part;
 
  •  
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of the Class A ordinary shares;
 
  •  
if, and only if, the closing price of our Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days with in
the 30-trading day
period ending three trading days before the Company sends the notice of redemption to the warrant holders; and
 
  •  
if the closing price of the Class A ordinary shares for any 20 trading days with in
a 30-trading day
period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above.
In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and in the case of any such issuance to the Company’s Sponsors or its affiliate, without taking into account any Founder Shares held by the Company’s Sponsor or such affiliates, as applicable, prior to such issuance (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the completion of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders' Deficit
 9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Shareholders' Deficit
Note 9—Shareholders’ Deficit
Preference shares
The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2022 and December 31, 2021, there were no preference shares issued or outstanding.
Class A Ordinary Shares
The Company is authorized to issue 500,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2022 and December 31, 2021, there were 20,000,000 Class A ordinary shares issued and outstanding, including the 20,000,000 shares presented in ordinary shares subject to redemption.
Class B Ordinary Shares
The Company is authorized to issue 50,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2022 and December 31, 2021, there were 5,750,000 Class B ordinary shares issued and outstanding. Of the 6,500,000 Class B ordinary shares, an aggregate of up to 750,000 shares were subject to forfeiture to the Company for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding ordinary shares after the IPO. On July 23, 2021, the Sponsor surrendered 750,000 Founder Shares, with no return of capital or payment by the Sponsor, after the expiration of the unexercised underwriters’ over-allotment option.
Class A ordinary shareholders and Class B ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law. Prior to the initial Business Combination, only holders of the Founder Shares will have the right to vote on the election of directors. Holders of the public shares will not be entitled to vote on the appointment of directors during such time. In addition, prior to the completion of an initial Business Combination, holders of a majority of the Founder Shares may remove a member of the board of directors for any reason.
The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have redemption rights or be entitled to liquidating distributions from the Trust Account if the Company does not consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate,
on an as-converted basis, 20%
of the sum of (i) the total number of ordinary shares issued and outstanding upon the completion of the IPO, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued or to be issued to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, its affiliates or any member of our management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
 9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events
Note 10—Subsequent Events
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued. Based on this review, other than the events described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

On October 12, 2022, the Company had drawn down $700,000 under the Convertible Promissory Note. The Convertible Promissory Note will be valued using the fair value method at each reporting period.
 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q
and pursuant to the rules and regulations of the Security and Exchange Commission (“SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.
Emerging Growth Company Status
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
Use of Estimates
The preparation of the unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the fun audited condensed financial statements and the reported amounts of expenses during the reporting period.
Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant estimates included in these financial statements is the determination of the fair value of the warrant liability and Forward Purchase Agreement (“FPA”) liability.
 
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have cash equivalents as of September 30, 2022 and December 31, 2021.
Investments Held in Trust Account
Investments Held in Trust Account
As of September 30, 2022 and December 31, 2021, the
assets held in the Trust Account were held in a money market fund. The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, investments in money market funds that invest in U.S. government securities, cash, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Interest earned on these securities is included in interest earned on Investments Held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2022 and December 31, 2021, the Company had $201,200,243 and $200,007,275 held in the Trust Account, respectively.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation limit of $250,000. As of September 30, 2022 and December 31, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Offering Costs Associated with IPO
Offering Costs Associated with IPO
The Company complies with the requirements of the
ASC340-10-S99-1
and SEC Staff Accounting Bulletin (“SAB”) Topic 5A “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged to ordinary shares subject to possible redemption or the statement of operations based on the relative value of the Public and Private Warrants to the proceeds received from the Units and Private Placement Warrants sold upon the completion of the IPO. Accordingly, offering costs totaling $11,587,941 (consisting of $4,000,000 of underwriting fees, $7,000,000 of deferred underwriting fees and $587,941 of other offering costs), of which $507,417 was allocated to the Public Warrants and Private Warrants and was charged to operations in accordance with ASC
825-10
and $11,080,524 was charged to ordinary shares subject to possible redemption.
Derivative Financial Instruments
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then
re-valued
at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or
non-current
based on whether or not
net-cash
settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Warrant Liability and Forward Purchase Agreement
Warrant Liability and Forward Purchase Agreement
The Company accounts for the 16,000,000 warrants issued in connection with the IPO (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) and Forward Purchase Agreement (“FPA”) in accordance with the guidance contained in FASB ASC 815 “Derivatives and Hedging” whereby under that provision the warrants and FPA do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company will classify warrants and FPA as liabilities at their fair value. These liabilities are subject to
re-measurement
at each reporting period. With such
re-measurement,
the changes in fair value are recognized in the Statement of Operations in the period of change. Derivative warrant liabilities and FPA are classified as
non-current
liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Fair Value Measurements
Fair Value Measurements
The fair value of the Company’s assets and liabilities, excluding the warrant liability and FPA liability, which qualify as financial instruments under FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.
Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
 
  •  
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
  •  
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
  •  
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Class A Ordinary Shares Subject to Possible Redemption
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2022 and December 31, 2021, 20,000,000 and 20,000,000 Class A ordinary shares, respectively, subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity (deficit) section of the Company’s balance sheet.
The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period.
As of September 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following table:
 
Gross proceeds
    $ 200,000,000  
Less: Proceeds allocated to Public Warrants
      (8,511,409 ) 
Less: Class A ordinary shares issuance costs
      (11,080,524 ) 
Add: Accretion of carrying value to redemption value
      19,591,933  
    
 
 
  
Class A ordinary shares subject to possible redemption as of December 31, 2021
      200,000,000  
Add: Accretion of carrying value to redemption value
      1,200,243  
    
 
 
  
Class A ordinary shares subject to possible redemption as of September 30, 2022
    $ 201,200,243  
    
 
 
  
Net Income (Loss) Per Ordinary Share
Net Income (Loss) Per Ordinary Share
The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 16,000,000 potential
ordinary
shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three and nine months ended
September 30, 2022 and 2021,
because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares:
    
For the Three Months Ended
September 30,
  
    
2022
     
2021
  
    
Class A
     
Class B
     
Class A
     
Class B
  
Basic and diluted net income per share:
                                    
Numerator:
                                    
Allocation of net income
    $ 4,431,344      $ 1,274,011      $ 803,726      $ 231,071  
Denominator:
                                    
Weighted-average shares outstanding
      20,000,000        5,750,000        20,000,000        5,750,000  
    
 
 
     
 
 
     
 
 
     
 
 
  
Basic and diluted net income per share
    $ 0.22      $ 0.22      $ 0.04      $ 0.04  
 
    
For the Nine Months Ended
September 30,
  
    
2022
     
2021
  
    
Class A
     
Class B
     
Class A
     
Class B
  
Basic and diluted net income (loss) per share:
                                    
Numerator:
                                    
Allocation of net income (loss)
    $ 11,302,500      $ 3,249,469      $ (2,143,878 )     $ (1,502,389 ) 
Denominator:
                                    
Weighted-average shares outstanding
      20,000,000        5,750,000        8,205,128        5,750,000  
    
 
 
     
 
 
     
 
 
     
 
 
  
Basic and diluted net income (loss) per share
    $ 0.57      $ 0.57      $ (0.26 )     $ (0.26 ) 
Income Taxes
Income Taxes
ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position
must be more-likely-than-not to be
sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2020-06,
Debt—Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic
815-40)
(“ASU2020-06”)
to simplify accounting for certain financial instruments. ASU
2020-06
eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU
2020-06
amends the diluted earnings per share guidance, including the requirement to use the
if-converted
method for all convertible instruments. ASU
2020-06
is effective on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that
ASU 2020-06
would have on its financial position, results of operations or cash flows.
Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of basic and diluted net income (loss) per common share The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares:
    
For the Three Months Ended
September 30,
  
    
2022
     
2021
  
    
Class A
     
Class B
     
Class A
     
Class B
  
Basic and diluted net income per share:
                                    
Numerator:
                                    
Allocation of net income
    $ 4,431,344      $ 1,274,011      $ 803,726      $ 231,071  
Denominator:
                                    
Weighted-average shares outstanding
      20,000,000        5,750,000        20,000,000        5,750,000  
    
 
 
     
 
 
     
 
 
     
 
 
  
Basic and diluted net income per share
    $ 0.22      $ 0.22      $ 0.04      $ 0.04  
 
    
For the Nine Months Ended
September 30,
  
    
2022
     
2021
  
    
Class A
     
Class B
     
Class A
     
Class B
  
Basic and diluted net income (loss) per share:
                                    
Numerator:
                                    
Allocation of net income (loss)
    $ 11,302,500      $ 3,249,469      $ (2,143,878 )     $ (1,502,389 ) 
Denominator:
                                    
Weighted-average shares outstanding
      20,000,000        5,750,000        8,205,128        5,750,000  
    
 
 
     
 
 
     
 
 
     
 
 
  
Basic and diluted net income (loss) per share
    $ 0.57      $ 0.57      $ (0.26 )     $ (0.26 ) 
Summary of Class A ordinary shares subject to possible redemption
As of September 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following table:
 
Gross proceeds
    $ 200,000,000  
Less: Proceeds allocated to Public Warrants
      (8,511,409 ) 
Less: Class A ordinary shares issuance costs
      (11,080,524 ) 
Add: Accretion of carrying value to redemption value
      19,591,933  
    
 
 
  
Class A ordinary shares subject to possible redemption as of December 31, 2021
      200,000,000  
Add: Accretion of carrying value to redemption value
      1,200,243  
    
 
 
  
Class A ordinary shares subject to possible redemption as of September 30, 2022
    $ 201,200,243  
    
 
 
  
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2022
Summary of Fair Value Hierarchy the Company's Assets and Liabilities
The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of September 30, 2022, that were accounted for at fair value on a recurring basis:
 
     (Level 1)      (Level 2)      (Level 3)  
Assets
                           
Investments held in Trust Account
    $ 201,200,243      $ —        $ —    
    
 
 
     
 
 
     
 
 
  
Liabilities
                           
Public Warrants
    $ —      $ 1,500,000      $ —    
Private Warrants
    $ —        $ —        $ 914,882  
FPA liability
    $ —        $ —        $ 3,209,928  
    
 
 
     
 
 
     
 
 
  
Total Liabilities
   
$
1,500,000
 
   
$
—  
 
   
$
4,124,810
 
    
 
 
     
 
 
     
 
 
  
The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of December 31, 2021, that were accounted for at fair value on a recurring basis:
 
     (Level 1)      (Level 2)      (Level 3)  
Assets
                           
Investments held in Trust Account
    $ 200,007,275      $ —        $ —    
    
 
 
     
 
 
     
 
 
  
Liabilities
                           
Public Warrants
    $ 6,500,000      $ —        $ —    
Private Warrants
    $ —        $ —        $ 3,923,429  
FPA liability
    $ —        $ —        $ 2,785,941  
    
 
 
     
 
 
     
 
 
  
Total Liabilities
   
$
6,500,000
 
   
$
—  
 
   
$
6,709,370
 
    
 
 
     
 
 
     
 
 
  
Public and Private Warrants  
Summary of Valuation of Public and Private Warrants
The key inputs for the valuation of Private Warrants are as follows:
 
Input   
September 30,
2022
    
December 31,
2021
  
Risk Free Rate
      4.04 %      1.29 % 
Stock Price
    $ 9.82     $ 9.72  
Est. Term Remaining (Yrs)
      5.55       5.35  
FPA liability  
Summary of Valuation of Public and Private Warrants The Company utilized the underlying shares and warrant values determined above and the following inputs in order to project the net asset or liability value of the FPA:
 
Input   
September 30,
2022
    
December 31,
2021
  
Stock Price
    $ 9.82     $ 9.72  
Warrant Price
    $ 0.150     $ 0.65  
Est. Term to Business Combination (Yrs)
      0.55       0.33  
Probability of Business Combination
      85 %      85 % 
Purchase price of FPA unit
    $ 10.00     $ 10.00  
Discount rate
      3.93 %      0.04 % 
Summary of reconciliation of changes in fair value of derivative warrant liabilities
The following table provides a reconciliation of changes in fair value of the Company’s FPA liability classified as Level 3 for the nine months ended September 30, 2022 and 2021:

 
 
  
FPA liability
 
Fair value at December 31, 2021
    $ 2,785,941  
Change in fair value
      (127,629 )
    
 
 
  
Fair Value at
March 31
, 2022
    $ 2,658,312  
Change in fair value
      141,728  
 
 
 
 
 
Fair Value at June 30, 2022
    $ 2,800,040  
Change in fair value
      409,888  
 
 
 
 
 
Fair Value at September 30, 2022
    $ 3,209,928  
    
 
 
  
 
 
  
FPA Liability
 
Fair value at December 31, 2020
    $ —    
Initial value of FPA liability at IPO
 (
June
11
, 2021
)
      2,322,741  
Change in fair value
      (77,703 )
    
 
 
  
Fair value at June 30, 2021
    $ 2,245,038  
Change in fair value
      561,983  
 
 
 
 
 
Fair value at September 30, 2021
    $ 2,807,021  
    
 
 
  
Derivative Warrant Liabilities [Member]  
Summary of reconciliation of changes in fair value of derivative warrant liabilities
The following table provides a reconciliation of changes in fair value of the Company’s derivative warrant liabilities classified as Level 3 for the nine months ended September 30, 2022 and 2021:
 
 
  
Public
Warrants
 
  
Private
Warrants
 
  
Warrants
Liability
 
Fair value at December 31, 2021
    $ —        $ 3,923,429      $ 3,923,429  
Change in fair value
      —          (2,713,773        (2,713,773 ) 
    
 
 
     
 
 
     
 
 
  
Fair Value at March 31, 2022
 
$
—  
 
 
$
1,209,656
 
 
$
1,209,656
 
Change in fair value
 
 
—  
 
 
 
(751,093
) 
 
 
(751,093
) 
Fair Value at June 30, 2022
 
$
—  
 
 
$
458,563
 
 
$
458,563
 
Change in fair value
 
 
—  
 
 
 
456,319
 
 
 
456,319
 
Fair Value at September 30, 2022
    $ —        $ 914,882      $ 914,882  
    
 
 
     
 
 
     
 
 
  
 
 
  
Public
Warrants
 
  
Private
Warrants
 
  
Warrants
Liability
 
Fair value at December 31, 2020
  
$
—  
  
  
$
—  
  
  
$
—  
  
Initial value of warrant liabilities at IPO
 (
June 11, 202
1
)
      8,511,409        5,201,555        13,712,964  
Change in fair value
 
 
1,212,798
 
 
 
672,323
 
 
 
1,885,121
 
Fair value at June 30, 2021
 
$
9,724,207
 
 
$
5,873,878
 
 
$
15,598,085
 
Change in fair value
      (1,123,207 )      (673,904 )       (1,797,111 )
Transfer of Public warrants from Level 3 to Level 1
      (8,601,000 )       —          (8,601,000 ) 
    
 
 
     
 
 
     
 
 
  
Fair Value at September 30, 2021
    $ —        $ 5,199,974      $ 5,199,974  
    
 
 
     
 
 
     
 
 
  
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization, Business Operation, Liquidity and Capital Resources - Additional information (Detail) - USD ($)
 9 Months Ended 12 Months Ended 24 Months Ended
Oct. 12, 2022
Jun. 11, 2021
Apr. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Jun. 30, 2023
Sep. 29, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Shares issued, price per share       $ 10        
Proceeds from issuance initial public offering       $ 0 $ 196,000,000      
Class of warrants and rights issued during the period       16,000,000        
Proceeds from issuance of private placement       $ 0 $ 6,000,000      
Deferred underwriting commissions noncurrent       0   $ 7,000,000    
Cash       70,097   885,198    
Working capital (deficit)       341,314        
Proceeds from unsecured notes payable       300,000        
Working capital loans       $ 0   0    
Temporary Equity, Redemption Price Per Share       $ 10.06        
Forecast                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Dissolution expense             $ 100,000  
Private Placement Warrants                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Class of warrants and rights issued during the period       6,000,000        
Sponsor                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Proceeds from issuance of common stock       $ 25,000        
Sponsor | Convertible promissory note                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Line of credit facility maximum borrowing capacity               $ 1,500,000
Proceeds from convertible debt $ 700,000              
Sponsor | Private Placement Warrants                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Class of warrants and rights issued during the period       6,000,000        
Class of warrants and rights issued, price per warrant       $ 1        
Proceeds from issuance of private placement       $ 6,000,000        
IPO                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Shares issued, price per share   $ 10            
Proceeds from issuance initial public offering   $ 200,000,000       $ 200,000,000    
Payments for underwriting expense       4,000,000        
Deferred underwriting commissions noncurrent       7,000,000        
Other offering costs       587,941        
Stock issuance costs       $ 11,587,941        
Common Class A                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Temporary Equity, Redemption Price Per Share       $ 10.06   $ 10    
Common stock par or stated value per share       0.0001   0.0001    
Common Class A | Sponsor                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Proceeds from issuance of common stock     $ 30,000,000          
Common stock par or stated value per share       0.0001        
Common Class A | IPO                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Stock issued during period, shares, new issues   20,000,000            
Shares issued, price per share   $ 10            
Proceeds from issuance initial public offering   $ 200,000,000            
Common Class B                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Common stock par or stated value per share       0.0001   $ 0.0001    
Common Class B | Founder shares                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Common stock par or stated value per share       0.0001        
Common Class B | Sponsor                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Common stock par or stated value per share       $ 0.0001        
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Additional information (Detail) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Cash Equivalents $ 0 $ 0
FDIC insured amount 250,000 250,000
Deferred underwriting commissions 0 7,000,000
Offering costs charged to the shareholders' equity $ 11,080,524  
Class of warrants and rights issued during the period 16,000,000  
Asset held in trust account $ 201,200,243 200,007,275
Warrant    
Antidilutive securities excluded from computation of earnings per share, Amount 16,000,000  
US Government Securities [Member]    
Restricted Investments Term 185 days  
IPO    
Stock issuance costs $ 11,587,941  
Payments for underwriting expense 4,000,000  
Deferred underwriting commissions 7,000,000  
Other offering costs 587,941  
Public Warrants And Private Warrants | IPO    
Other offering costs $ 507,417  
Private Placement Warrants    
Class of warrants and rights issued during the period 6,000,000  
Public Warrants    
Class of warrants and rights issued during the period 10,000,000  
Common Class A    
Offering costs charged to the shareholders' equity   $ 11,080,524
Temporary equity, shares outstanding 20,000,000 20,000,000
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Class of Stock [Line Items]                
Allocation of net income (loss) $ 5,705,354 $ 1,719,777 $ 7,126,838 $ 1,034,797 $ (4,681,064) $ 0 $ 14,551,968 $ (3,646,267)
Common Class A                
Class of Stock [Line Items]                
Basic weighted average shares outstanding 20,000,000     20,000,000     20,000,000 8,205,128
Diluted weighted average shares outstanding 20,000,000     20,000,000     20,000,000 8,205,128
Basic net income (loss) per ordinary share $ 0.22     $ 0.04     $ 0.57 $ (0.26)
Diluted net income (loss) per ordinary share $ 0.22     $ 0.04     $ 0.57 $ (0.26)
Common Class A | Common Stock [Member]                
Class of Stock [Line Items]                
Allocation of net income (loss) $ 4,431,344     $ 803,726     $ 11,302,500 $ (2,143,878)
Basic weighted average shares outstanding 20,000,000     20,000,000     20,000,000 8,205,128
Diluted weighted average shares outstanding 20,000,000     20,000,000     20,000,000 8,205,128
Basic net income (loss) per ordinary share $ 0.22     $ 0.04     $ 0.57 $ (0.26)
Diluted net income (loss) per ordinary share $ 0.22     $ 0.04     $ 0.57 $ (0.26)
Common Class B                
Class of Stock [Line Items]                
Basic weighted average shares outstanding 5,750,000     5,750,000     5,750,000 5,750,000
Diluted weighted average shares outstanding 5,750,000     5,750,000     5,750,000 5,750,000
Basic net income (loss) per ordinary share $ 0.22     $ 0.04     $ 0.57 $ (0.26)
Diluted net income (loss) per ordinary share $ 0.22     $ 0.04     $ 0.57 $ (0.26)
Common Class B | Common Stock [Member]                
Class of Stock [Line Items]                
Allocation of net income (loss) $ 1,274,011     $ 231,071     $ 3,249,469 $ (1,502,389)
Basic weighted average shares outstanding 5,750,000     5,750,000     5,750,000 5,750,000
Diluted weighted average shares outstanding 5,750,000     5,750,000     5,750,000 5,750,000
Basic net income (loss) per ordinary share $ 0.22     $ 0.04     $ 0.57 $ (0.26)
Diluted net income (loss) per ordinary share $ 0.22     $ 0.04     $ 0.57 $ (0.26)
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies - Summary of Class A ordinary shares subject to possible redemption (Detail) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 11, 2021
Jun. 30, 2021
Jun. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Temporary Equity [Line Items]            
Gross proceeds       $ 0 $ 196,000,000  
Less: Class A ordinary shares issuance costs       (11,080,524)    
Add: Accretion of carrying value to redemption value   $ 18,793,488        
Class A ordinary shares subject to possible redemption       201,200,243   $ 200,000,000
Common Class A [Member]            
Temporary Equity [Line Items]            
Less: Class A ordinary shares issuance costs           (11,080,524)
Add: Accretion of carrying value to redemption value     $ 1,200,243     19,591,933
Class A ordinary shares subject to possible redemption       $ 201,200,243   200,000,000
IPO [Member]            
Temporary Equity [Line Items]            
Gross proceeds $ 200,000,000         200,000,000
Less: Proceeds allocated to Public Warrants           $ (8,511,409)
IPO [Member] | Common Class A [Member]            
Temporary Equity [Line Items]            
Gross proceeds $ 200,000,000          
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Initial Public Offering - Additional Information (Detail) - USD ($)
 9 Months Ended 12 Months Ended
Jun. 11, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Shares issued, price per share   $ 10    
Proceeds from issuance initial public offering   $ 0 $ 196,000,000  
Class of warrant or right, threshold period for exercise from date of closing public offering   12 months    
Class of warrant or right redemption threshold consecutive trading days   30 days    
IPO        
Shares issued, price per share $ 10      
Proceeds from issuance initial public offering $ 200,000,000     $ 200,000,000
Common Class A | IPO        
Stock shares issued during the period shares 20,000,000      
Shares issued, price per share $ 10      
Proceeds from issuance initial public offering $ 200,000,000      
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Private Placement - Additional Information (Detail) - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Private Placement [Line Items]    
Class of warrants and rights issued during the period 16,000,000  
Proceeds from private placement $ 0 $ 6,000,000
Private Placement Warrants    
Private Placement [Line Items]    
Class of warrants and rights issued during the period 6,000,000  
Sponsor | Private Placement Warrants    
Private Placement [Line Items]    
Class of warrants and rights issued during the period 6,000,000  
Class of warrants and rights issued, price per warrant $ 1  
Proceeds from private placement $ 6,000,000  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions - Additional Information (Detail)
 3 Months Ended 4 Months Ended 9 Months Ended 12 Months Ended
Oct. 12, 2022
USD ($)
Sep. 29, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
shares
Jul. 23, 2021
shares
Apr. 30, 2021
USD ($)
Nominees
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
shares
Related Party Transaction [Line Items]                      
Offering proceeds allocated to payment of offering expenses                   $ 1,000,000  
Proceeds from issuance of debt                   140,068  
Due to related parties     $ 0       $ 30,000     30,000 $ 0
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party                   $ 30,000 $ 0
Class of warrant or right, exercise price of warrants or rights | $ / shares         $ 10   $ 11.5     $ 11.5  
Working Capital Loan                      
Related Party Transaction [Line Items]                      
Warrants issued price per warrant | $ / shares             $ 1     $ 1  
Working capital loans convertible into warrants             $ 1,500,000     $ 1,500,000  
Administrative Service Fee                      
Related Party Transaction [Line Items]                      
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party             30,000 $ 30,000 $ 37,667 90,000  
Expenses from transactions with related party     $ 10,000                
Sponsor                      
Related Party Transaction [Line Items]                      
Proceeds from issuance of common stock                   25,000  
Number of shares forfeited during the period | shares       750,000              
Sponsor | Convertible Promissory Note [Member]                      
Related Party Transaction [Line Items]                      
Due to related parties             0     0  
Line of credit facility maximum borrowing capacity   $ 1,500,000                  
Debt conversion, converted instrument, amount   $ 1,500,000                  
Proceeds from convertible debt $ 700,000                    
Sponsor | Convertible Promissory Note [Member] | Subsequent Event [Member]                      
Related Party Transaction [Line Items]                      
Proceeds from convertible debt $ 700,000                    
Sponsor | Promissory Note                      
Related Party Transaction [Line Items]                      
Debt instrument, face amount             $ 300,000     $ 300,000  
Sponsor | Founder shares                      
Related Party Transaction [Line Items]                      
Class B ordinary share issued to initial shareholders, shares | shares         25,000            
Sponsor | Founder shares | Director                      
Related Party Transaction [Line Items]                      
Number of independent director nominees | Nominees         3            
Common Class A                      
Related Party Transaction [Line Items]                      
Common stock shares outstanding | shares     20,000,000       20,000,000     20,000,000 20,000,000
Common Class A | Sponsor                      
Related Party Transaction [Line Items]                      
Proceeds from issuance of common stock         $ 30,000,000            
Common Class A | Sponsor | Convertible Promissory Note [Member]                      
Related Party Transaction [Line Items]                      
Class of warrant or right, exercise price of warrants or rights | $ / shares   $ 11.5                  
Common Class A | Sponsor | Promissory Note                      
Related Party Transaction [Line Items]                      
Warrants issued price per warrant | $ / shares   $ 1                  
Common Class A | Anchor investors                      
Related Party Transaction [Line Items]                      
Class B ordinary share issued to initial shareholders, shares | shares         3,000,000            
Common Class B                      
Related Party Transaction [Line Items]                      
Common stock shares outstanding | shares     5,750,000       5,750,000     5,750,000 5,750,000
Common Class B | Sponsor                      
Related Party Transaction [Line Items]                      
Stock issued during period, value, issued for services           $ 25,000          
Proceeds from sponsor to cover certain offering costs per share value | $ / shares           $ 0.004          
Common stock shares outstanding | shares         6,500,000   5,750,000     5,750,000  
Class B ordinary share issued to initial shareholders, shares | shares         750,000 5,750,000          
Share price | $ / shares             $ 12     $ 12  
Number of trading days for determining the share price                   20 days  
Number of consecutive trading days for determining the share price                   30 days  
Waiting period after which the share trading days are considered                   150 days  
Common Class B | Sponsor | Founder shares                      
Related Party Transaction [Line Items]                      
Common stock shares outstanding | shares     5,750,000       5,750,000     5,750,000 5,750,000
Common stock shares subject to forfeiture | shares                   750,000  
Common Class B | Anchor investors                      
Related Party Transaction [Line Items]                      
Class B ordinary share issued to initial shareholders, shares | shares         375,000            
Proceeds from issuance of common stock         $ 0            
Common Class B | Anchor investors | Founder shares                      
Related Party Transaction [Line Items]                      
Class B ordinary share issued to initial shareholders, shares | shares         375,000            
Proceeds from issuance of common stock         $ 0            
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements - Summary of Fair Value Hierarchy the Company's Assets and Liabilities (Detail) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability $ 2,414,882 $ 10,423,429
FPA liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability 3,209,928 2,785,941
Fair Value, Recurring | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments held in Trust Account 201,200,243 200,007,275
Warrant Liability 1,500,000 6,500,000
Fair Value, Recurring | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments held in Trust Account
Warrant Liability
Fair Value, Recurring | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments held in Trust Account
Warrant Liability 4,124,810 6,709,370
Fair Value, Recurring | Public Warrants | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability 6,500,000
Fair Value, Recurring | Public Warrants | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability 1,500,000
Fair Value, Recurring | Public Warrants | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability 0
Fair Value, Recurring | Private Warrants | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability
Fair Value, Recurring | Private Warrants | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability
Fair Value, Recurring | Private Warrants | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability 914,882 3,923,429
Fair Value, Recurring | FPA liability | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability
Fair Value, Recurring | FPA liability | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability
Fair Value, Recurring | FPA liability | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant Liability $ 3,209,928 $ 2,785,941
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants (Detail) - Public and Private Warrants
Sep. 30, 2022
yr
$ / shares
Dec. 31, 2021
yr
$ / shares
Risk Free Rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input 4.04 1.29
Stock Price    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input | $ / shares 9.82 9.72
Est. Term Remaining (Yrs)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input | yr 5.55 5.35
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants of FPA (Detail) - FPA liability
Sep. 30, 2022
$ / shares
yr
Dec. 31, 2021
yr
$ / shares
Stock Price    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input 9.82 9.72
Warrant Price    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input 0.15 0.65
Est. Term to Business Combination (Yrs)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input | yr 0.55 0.33
Probability of Business Combination    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input 85 85
Purchase price of FPA unit    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input 10 10
Discount rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants and rights outstanding, measurement input 3.93 0.04
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements - Summary of reconciliation of changes in fair value of derivative warrant liabilities (Detail) - Fair Value, Inputs, Level 3 [Member] - USD ($)
 3 Months Ended 6 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
FPA Liability [Member]          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance $ 2,800,040 $ 2,658,312 $ 2,785,941 $ 2,245,038 $ 0
Initial value at IPO date         2,322,741
Change in fair value 409,888 141,728 (127,629) 561,983 (77,703)
Ending balance 3,209,928 2,800,040 2,658,312 2,807,021 2,245,038
Warrant [Member]          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance 458,563 1,209,656 3,923,429 15,598,085 0
Initial value at IPO date         13,712,964
Change in fair value 456,319 (751,093) (2,713,773) (1,797,111) 1,885,121
Transfer of Public warrants from Level 3 to Level 1       (8,601,000)  
Ending balance 914,882 458,563 1,209,656 5,199,974 15,598,085
Public Warrants [Member]          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance 0 0 9,724,207 0
Initial value at IPO date         8,511,409
Change in fair value 0 0 (1,123,207) 1,212,798
Transfer of Public warrants from Level 3 to Level 1       (8,601,000)  
Ending balance 0 0 0 9,724,207
Private Warrants [Member]          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance 458,563 1,209,656 3,923,429 5,873,878 0
Initial value at IPO date         5,201,555
Change in fair value 456,319 (751,093) (2,713,773) (673,904) 672,323
Transfer of Public warrants from Level 3 to Level 1       0  
Ending balance $ 914,882 $ 458,563 $ 1,209,656 $ 5,199,974 $ 5,873,878
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recurring Fair Value Measurements - Additional information (Detail) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Warrant liability $ 2,414,882 $ 10,423,429
FPA liability    
Warrant liability $ 3,209,928 $ 2,785,941
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments & Contingencies - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Jul. 07, 2022
Jun. 11, 2021
Apr. 30, 2021
Dec. 31, 2020
Sep. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Loss Contingencies [Line Items]                
Overallotment option vesting period           45 days    
Underwriting discount           (2.00%)    
Deferred underwriting fee percent on gross proceeds of the IPO           3.50%    
Class of warrant or right, exercise price of warrants or rights     $ 10   $ 11.5 $ 11.5    
Gain recognized on the debt forgiveness $ 7,000,000       $ 7,000,000 $ 7,000,000 $ 0  
Preferred stock par or stated value per share         $ 0.0001 $ 0.0001   $ 0.0001
YS Biopharma [Member]                
Loss Contingencies [Line Items]                
Preferred stock par or stated value per share         0.000005 $ 0.000005    
Common stock conversion basis           one    
Common stock par or stated value per share         0.000005 $ 0.000005    
Sponsor                
Loss Contingencies [Line Items]                
Proceeds from issuance of common stock           $ 25,000    
Preferred stock par or stated value per share         0.0001 $ 0.0001    
Sponsor | Founder Shares [Member]                
Loss Contingencies [Line Items]                
Stock issued during period, shares, issued for services     25,000          
IPO                
Loss Contingencies [Line Items]                
Cash underwriting discount of the IPO paid to underwriters           $ 4,000,000    
Common Class A                
Loss Contingencies [Line Items]                
Common stock par or stated value per share         0.0001 $ 0.0001   0.0001
Common Class A | Anchor investors                
Loss Contingencies [Line Items]                
Stock issued during period, shares, issued for services     3,000,000          
Common Class A | Sponsor                
Loss Contingencies [Line Items]                
Proceeds from issuance of common stock     $ 30,000,000          
Common stock shares issued with effect of conversion     3,000,000          
Common stock par or stated value per share         0.0001 0.0001    
Common Class A | IPO                
Loss Contingencies [Line Items]                
Stock shares issued during the period shares   20,000,000            
Common Class B                
Loss Contingencies [Line Items]                
Common stock par or stated value per share         0.0001 0.0001   $ 0.0001
Common Class B | Founder Shares [Member]                
Loss Contingencies [Line Items]                
Common stock par or stated value per share         0.0001 0.0001    
Common Class B | Anchor investors                
Loss Contingencies [Line Items]                
Stock issued during period, shares, issued for services     375,000          
Proceeds from issuance of common stock     $ 0          
Common Class B | Anchor investors | Founder Shares [Member]                
Loss Contingencies [Line Items]                
Stock issued during period, shares, issued for services     375,000          
Proceeds from issuance of common stock     $ 0          
Common Class B | Sponsor                
Loss Contingencies [Line Items]                
Stock issued during period, shares, issued for services     750,000 5,750,000        
Common stock par or stated value per share         0.0001 0.0001    
Redeemable Warrants | Anchor investors                
Loss Contingencies [Line Items]                
Stock issued during period, shares, issued for services     750,000          
Maximum | Common Stock [Member] | YS Biopharma [Member]                
Loss Contingencies [Line Items]                
Common stock par or stated value per share         0.00002 $ 0.00002    
Maximum | Common Class A | Over-Allotment Option                
Loss Contingencies [Line Items]                
Stock shares issued during the period shares           3,000,000    
Maximum | Private Placement Warrants                
Loss Contingencies [Line Items]                
Minimum lock in period required for warrant exercise from the date of business combination           30 days    
Minimum | YS Biopharma [Member]                
Loss Contingencies [Line Items]                
Common stock par or stated value per share         $ 0.000005 $ 0.000005    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrant Liability - Additional Information (Detail) - $ / shares
 9 Months Ended
Sep. 30, 2022
Apr. 30, 2021
Disclosure of Warrant Liability [Line Items]    
Class of warrant or right, outstanding 16,000,000  
Class of warrant or right, exercise price of warrants or rights $ 11.5 $ 10
Class of warrant or right, threshold period for exercise from date of closing public offering 12 months  
Class of warrant or right redemption threshold consecutive trading days 30 days  
Common Class A | Share Price Equal or Exceeds Eighteen Rupees Per Dollar    
Disclosure of Warrant Liability [Line Items]    
Class of warrant or right, exercise price adjustment percentage higher of market value 180.00%  
Common Class A | Share Price Equal or Less Nine Point Two Rupees Per Dollar    
Disclosure of Warrant Liability [Line Items]    
Share redemption trigger price $ 9.2  
Minimum percentage gross proceeds required from issuance of equity 60.00%  
Class of warrant or right, exercise price adjustment percentage higher of market value 115.00%  
Public Warrants    
Disclosure of Warrant Liability [Line Items]    
Class of warrant or right, outstanding 10,000,000  
Public Warrants | Share Price Equal or Exceeds Eighteen Rupees Per Dollar    
Disclosure of Warrant Liability [Line Items]    
Class of warrants redemption price per unit $ 0.01  
Number of days of notice to be given for redemption of warrants 30 days  
Number of consecutive trading days for determining share price 20 days  
Number of trading days for determining the share price 30 days  
Public Warrants | Share Price Equal or Exceeds Ten Rupees Per Dollar    
Disclosure of Warrant Liability [Line Items]    
Class of warrants redemption price per unit $ 0.1  
Number of days of notice to be given for redemption of warrants 30 days  
Number of consecutive trading days for determining share price 20 days  
Number of trading days for determining the share price 30 days  
Public Warrants | Share Price Equal or Less Nine Point Two Rupees Per Dollar    
Disclosure of Warrant Liability [Line Items]    
Number of consecutive trading days for determining share price 20 days  
Public Warrants | Common Class A | Share Price Equal or Exceeds Eighteen Rupees Per Dollar    
Disclosure of Warrant Liability [Line Items]    
Share price $ 18  
Public Warrants | Common Class A | Share Price Equal or Exceeds Ten Rupees Per Dollar    
Disclosure of Warrant Liability [Line Items]    
Share price $ 10  
Private Placement Warrants    
Disclosure of Warrant Liability [Line Items]    
Class of warrant or right, outstanding 6,000,000  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders' Deficit - Additional Information (Detail) - $ / shares
 9 Months Ended
Jul. 23, 2021
Sep. 30, 2022
Dec. 31, 2021
Apr. 30, 2021
Stock Holders Equity Note [Line Items]        
Preferred stock shares authorized   5,000,000 5,000,000  
Preferred stock par or stated value per share   $ 0.0001 $ 0.0001  
Preferred stock shares issued   0 0  
Preferred stock shares outstanding   0 0  
Sponsor        
Stock Holders Equity Note [Line Items]        
Preferred stock shares authorized   5,000,000    
Preferred stock par or stated value per share   $ 0.0001    
Preferred stock shares issued   0 0  
Preferred stock shares outstanding   0 0  
Number of shares forfeited during the period 750,000      
IPO | Sponsor        
Stock Holders Equity Note [Line Items]        
Percentage of number of shares of common stock outstanding   20.00%    
Common Class A        
Stock Holders Equity Note [Line Items]        
Common stock shares authorized   500,000,000 500,000,000  
Common stock par or stated value per share   $ 0.0001 $ 0.0001  
Common stock shares issued   20,000,000 20,000,000  
Common stock shares outstanding   20,000,000 20,000,000  
Temporary equity, shares outstanding   20,000,000 20,000,000  
Temporary Equity, Shares Issued   20,000,000 20,000,000  
Common Class A | Sponsor        
Stock Holders Equity Note [Line Items]        
Common stock shares authorized   500,000,000    
Common stock par or stated value per share   $ 0.0001    
Common Class B        
Stock Holders Equity Note [Line Items]        
Common stock shares authorized   50,000,000 50,000,000  
Common stock par or stated value per share   $ 0.0001 $ 0.0001  
Common stock shares issued   5,750,000 5,750,000  
Common stock shares outstanding   5,750,000 5,750,000  
Common Class B | Sponsor        
Stock Holders Equity Note [Line Items]        
Common stock shares authorized   50,000,000    
Common stock par or stated value per share   $ 0.0001    
Common stock shares issued   6,500,000    
Common stock shares outstanding   5,750,000   6,500,000
Common stock shares issued subject to forfeiture   750,000    
Common Class A and Class B | Sponsor        
Stock Holders Equity Note [Line Items]        
Common stock, Conversion basis   one-to-one    
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events - Additional information (Detail)
Oct. 12, 2022
USD ($)
Sponsor | Convertible Promissory Note [Member]  
Subsequent Event [Line Items]  
Proceeds from Convertible Debt $ 700,000
XML 46 d412062d10q_htm.xml IDEA: XBRL DOCUMENT 0001839185 2022-09-30 0001839185 2021-12-31 0001839185 2022-01-01 2022-09-30 0001839185 2021-01-01 2021-09-30 0001839185 2022-07-01 2022-09-30 0001839185 2021-07-01 2021-09-30 0001839185 2021-04-30 0001839185 2021-01-01 2021-12-31 0001839185 2022-01-01 2022-03-31 0001839185 2022-04-01 2022-06-30 0001839185 2021-01-01 2021-03-31 0001839185 2021-04-01 2021-06-30 0001839185 2022-07-07 2022-07-07 0001839185 2021-09-30 0001839185 2020-12-31 0001839185 2022-03-31 0001839185 2022-06-30 0001839185 2021-03-31 0001839185 2021-06-30 0001839185 us-gaap:CommonClassBMember 2022-09-30 0001839185 us-gaap:CommonClassAMember 2022-09-30 0001839185 us-gaap:IPOMember 2022-09-30 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember smihu:FounderSharesMember 2022-09-30 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember 2022-09-30 0001839185 smihu:PromissoryNoteMember smihu:SponsorMember 2022-09-30 0001839185 smihu:WorkingCapitalLoanMember 2022-09-30 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 smihu:PublicAndPrivateWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001839185 smihu:PublicAndPrivateWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-09-30 0001839185 smihu:PublicAndPrivateWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001839185 smihu:FpaLiabilityMember us-gaap:MeasurementInputSharePriceMember 2022-09-30 0001839185 smihu:FpaLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001839185 smihu:FpaLiabilityMember smihu:MeasurementInputEstimatedTermToBusinessCombinationsMember 2022-09-30 0001839185 smihu:FpaLiabilityMember smihu:MeasurementInputProbabilityOfBusinessCombinationsMember 2022-09-30 0001839185 smihu:FpaLiabilityMember smihu:MeasurementOfPurchasePriceOfFpaUnitMember 2022-09-30 0001839185 smihu:FpaLiabilityMember us-gaap:MeasurementInputDiscountRateMember 2022-09-30 0001839185 smihu:FpaLiabilityMember 2022-09-30 0001839185 smihu:SponsorMember 2022-09-30 0001839185 smihu:SponsorMember us-gaap:CommonClassAMember 2022-09-30 0001839185 smihu:PublicWarrantsMember 2022-09-30 0001839185 smihu:PrivatePlacementWarrantsMember 2022-09-30 0001839185 smihu:PublicWarrantsMember us-gaap:CommonClassAMember smihu:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember 2022-09-30 0001839185 smihu:PublicWarrantsMember us-gaap:CommonClassAMember smihu:SharePriceEqualOrExceedsTenRupeesPerDollarMember 2022-09-30 0001839185 smihu:PublicWarrantsMember smihu:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember 2022-09-30 0001839185 smihu:PublicWarrantsMember smihu:SharePriceEqualOrExceedsTenRupeesPerDollarMember 2022-09-30 0001839185 us-gaap:CommonClassAMember smihu:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel1Member smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel2Member smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel1Member smihu:PrivateWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel2Member smihu:PrivateWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel1Member smihu:FpaLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel2Member smihu:FpaLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001839185 us-gaap:CommonClassBMember smihu:FounderSharesMember 2022-09-30 0001839185 smihu:YsBiopharmaMember 2022-09-30 0001839185 smihu:YsBiopharmaMember srt:MinimumMember 2022-09-30 0001839185 smihu:YsBiopharmaMember srt:MaximumMember us-gaap:CommonStockMember 2022-09-30 0001839185 us-gaap:CommonClassBMember 2021-12-31 0001839185 us-gaap:CommonClassAMember 2021-12-31 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember smihu:FounderSharesMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 smihu:PublicAndPrivateWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001839185 smihu:PublicAndPrivateWarrantsMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001839185 smihu:PublicAndPrivateWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001839185 smihu:FpaLiabilityMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001839185 smihu:FpaLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001839185 smihu:FpaLiabilityMember smihu:MeasurementInputEstimatedTermToBusinessCombinationsMember 2021-12-31 0001839185 smihu:FpaLiabilityMember smihu:MeasurementInputProbabilityOfBusinessCombinationsMember 2021-12-31 0001839185 smihu:FpaLiabilityMember smihu:MeasurementOfPurchasePriceOfFpaUnitMember 2021-12-31 0001839185 smihu:FpaLiabilityMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001839185 smihu:FpaLiabilityMember 2021-12-31 0001839185 smihu:SponsorMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel1Member smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel2Member smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel1Member smihu:PrivateWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel2Member smihu:PrivateWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel1Member smihu:FpaLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel2Member smihu:FpaLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001839185 us-gaap:CommonClassAMember 2021-01-01 2021-09-30 0001839185 us-gaap:CommonClassBMember 2021-01-01 2021-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001839185 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001839185 smihu:AdministrativeServiceFeeMember 2021-07-01 2021-09-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2021-07-01 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2021-07-01 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-07-01 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-07-01 2021-09-30 0001839185 us-gaap:CommonClassAMember 2021-07-01 2021-09-30 0001839185 us-gaap:CommonClassBMember 2021-07-01 2021-09-30 0001839185 smihu:PrivatePlacementWarrantsMember smihu:SponsorMember 2022-01-01 2022-09-30 0001839185 us-gaap:IPOMember 2022-01-01 2022-09-30 0001839185 smihu:SponsorMember 2022-01-01 2022-09-30 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember smihu:FounderSharesMember 2022-01-01 2022-09-30 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001839185 smihu:PublicWarrantsAndPrivateWarrantsMember us-gaap:IPOMember 2022-01-01 2022-09-30 0001839185 smihu:PublicWarrantsMember 2022-01-01 2022-09-30 0001839185 smihu:PrivatePlacementWarrantsMember 2022-01-01 2022-09-30 0001839185 smihu:PublicAndPrivateWarrantsMember 2022-01-01 2022-09-30 0001839185 smihu:FpaLiabilityMember 2022-01-01 2022-09-30 0001839185 srt:MaximumMember smihu:PrivatePlacementWarrantsMember 2022-01-01 2022-09-30 0001839185 srt:MaximumMember us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001839185 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001839185 us-gaap:CapitalUnitsMember 2022-01-01 2022-09-30 0001839185 smihu:PublicWarrantsMember smihu:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember 2022-01-01 2022-09-30 0001839185 smihu:PublicWarrantsMember smihu:SharePriceEqualOrExceedsTenRupeesPerDollarMember 2022-01-01 2022-09-30 0001839185 smihu:PublicWarrantsMember smihu:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassAMember smihu:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassAMember smihu:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember 2022-01-01 2022-09-30 0001839185 smihu:AdministrativeServiceFeeMember 2022-01-01 2022-09-30 0001839185 smihu:SponsorMember smihu:CommonClassAClassBMember 2022-01-01 2022-09-30 0001839185 smihu:SponsorMember us-gaap:IPOMember 2022-01-01 2022-09-30 0001839185 smihu:UsGovernmentSecuritiesMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001839185 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001839185 smihu:DerivativeWarrantLiabilitiesMember 2022-01-01 2022-09-30 0001839185 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001839185 smihu:YsBiopharmaMember 2022-01-01 2022-09-30 0001839185 smihu:AdministrativeServiceFeeMember 2022-07-01 2022-09-30 0001839185 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2022-07-01 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2022-07-01 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-07-01 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-07-01 2022-09-30 0001839185 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001839185 us-gaap:CommonClassBMember 2022-07-01 2022-09-30 0001839185 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2022-04-01 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2022-04-01 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-04-01 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-04-01 2022-06-30 0001839185 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001839185 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2022-01-01 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-01-01 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2022-01-01 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-01-01 2022-03-31 0001839185 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001839185 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-06-11 2021-06-11 0001839185 us-gaap:IPOMember 2021-06-11 2021-06-11 0001839185 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-06-11 0001839185 us-gaap:IPOMember 2021-06-11 0001839185 srt:ScenarioForecastMember 2021-07-01 2023-06-30 0001839185 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2021-01-01 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2021-01-01 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-01-01 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-01-01 2021-06-30 0001839185 us-gaap:IPOMember 2021-01-01 2021-12-31 0001839185 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember 2020-12-31 2020-12-31 0001839185 smihu:AnchorInvestorsMember us-gaap:CommonClassBMember 2021-04-30 2021-04-30 0001839185 smihu:SponsorMember smihu:FounderSharesMember 2021-04-30 2021-04-30 0001839185 srt:DirectorMember smihu:SponsorMember smihu:FounderSharesMember 2021-04-30 2021-04-30 0001839185 smihu:AnchorInvestorsMember us-gaap:CommonClassAMember 2021-04-30 2021-04-30 0001839185 smihu:AnchorInvestorsMember smihu:RedeemableWarrantsMember 2021-04-30 2021-04-30 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember 2021-04-30 2021-04-30 0001839185 smihu:AnchorInvestorsMember us-gaap:CommonClassBMember smihu:FounderSharesMember 2021-04-30 2021-04-30 0001839185 smihu:SponsorMember us-gaap:CommonClassAMember 2021-04-30 2021-04-30 0001839185 smihu:SponsorMember us-gaap:CommonClassBMember 2021-04-30 0001839185 smihu:SponsorMember 2021-07-23 2021-07-23 0001839185 smihu:AdministrativeServiceFeeMember 2021-12-31 2021-12-31 0001839185 smihu:PromissoryNoteMember smihu:SponsorMember us-gaap:CommonClassAMember 2022-09-29 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember 2022-09-29 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember us-gaap:CommonClassAMember 2022-09-29 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember 2022-10-12 2022-10-12 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember us-gaap:SubsequentEventMember 2022-10-12 2022-10-12 0001839185 smihu:ConvertiblePromissoryNoteMember smihu:SponsorMember 2022-09-29 2022-09-29 0001839185 smihu:AdministrativeServiceFeeMember 2021-06-08 2021-09-30 0001839185 us-gaap:CommonClassAMember 2022-11-14 0001839185 us-gaap:CommonClassBMember 2022-11-14 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-09-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001839185 us-gaap:RetainedEarningsMember 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-09-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001839185 us-gaap:RetainedEarningsMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2022-09-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-09-30 0001839185 us-gaap:RetainedEarningsMember 2022-06-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-06-30 0001839185 us-gaap:RetainedEarningsMember 2021-06-30 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-06-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-30 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001839185 us-gaap:RetainedEarningsMember 2021-12-31 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001839185 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001839185 us-gaap:RetainedEarningsMember 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2022-03-31 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-12-31 0001839185 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001839185 us-gaap:RetainedEarningsMember 2020-12-31 0001839185 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-31 0001839185 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-03-31 0001839185 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001839185 us-gaap:RetainedEarningsMember 2021-03-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2020-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2020-12-31 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2020-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2020-12-31 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PublicWarrantsMember 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:PrivateWarrantsMember 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-06-30 0001839185 us-gaap:FairValueInputsLevel3Member smihu:FpaLiabilityMember 2021-06-30 iso4217:USD shares utr:Month utr:Day pure iso4217:USD shares smihu:Nominees utr:Year utr:Y false 0001839185 Q3 --12-31 0 10-Q true 2022-09-30 2022 false SUMMIT HEALTHCARE ACQUISITION CORP. E9 001-40466 98-1574360 Unit 1101 11th Floor 1 Lyndhurst Tower 1 Lyndhurst Terrace Central HK 852 2155-7212 Class A ordinary shares, par value $0.0001 per share SMIH NASDAQ Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 SMIHW NASDAQ Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant SMIHU NASDAQ Yes Yes Non-accelerated Filer true true false true 20000000 5750000 70097 885198 218545 141677 288642 1026875 201200243 200007275 201488885 201034150 599956 142631 30000 0 629956 142631 3209928 2785941 2414882 10423429 0 7000000 6254766 20352001 0.0001 0.0001 20000000 20000000 20000000 20000000 10.06 10 201200243 200000000 0.0001 0.0001 5000000 5000000 0 0 0 0 0.0001 0.0001 500000000 500000000 20000000 20000000 20000000 20000000 0 0.0001 0.0001 50000000 50000000 5750000 5750000 5750000 5750000 575 575 -5966699 -19318426 -5966124 -19317851 201488885 201034150 581189 202904 1225560 246868 -581189 -202904 -1225560 -246868 409888 561983 423987 2807021 1206319 -1797111 -8008547 88010 0 507417 902750 2573 1192968 3049 7000000 7000000 6286543 1237701 15777528 -3399399 5705354 1034797 14551968 -3646267 20000000 20000000 20000000 20000000 20000000 20000000 8205128 8205128 0.22 0.22 0.04 0.04 0.57 0.57 -0.26 -0.26 5750000 5750000 5750000 5750000 5750000 5750000 5750000 5750000 0.22 0.22 0.04 0.04 0.57 0.57 -0.26 -0.26 0 0 5750000 575 0 -19318426 -19317851 7126838 7126838 0 0 5750000 575 0 -12191588 -12191013 1719777 1719777 297492 297492 0 0 5750000 575 0 -10769303 -10768728 5705354 5705354 902750 902750 5750000 575 0 -5966699 -5966124 0 0 6500000 650 24350 -3636 21364 0 0 0 0 6500000 650 24350 -3636 21364 24350 18769138 18793488 -4681064 -4681064 0 0 6500000 650 0 -23453838 -23453188 750000 75 -75 1034797 1034797 0 0 5750000 575 0 -22418966 -22418391 14551968 -3646267 1192968 3049 423987 2807021 -8008547 88010 0 507417 7000000 0 76868 221704 457327 7619 30000 37667 -815101 -423286 0 200000000 0 -200000000 0 196000000 0 6000000 0 140554 0 361023 0 201498423 -815101 1075137 885198 70097 1075137 0 135544 0 7000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1—Organization, Business Operation, Liquidity and Capital Resources </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summit Healthcare Acquisition Corp. (the “Company”) is a blank check company incorporated on December 22, 2020 as a Cayman Islands exempted company. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any specific Business Combination target under consideration or contemplation and the Company has not, nor has anyone on its behalf, contacted any prospective target business or had any discussions, formal or otherwise, with respect to such a transaction. The Company’s efforts to identify a prospective target business will not be limited to a particular geographic region or industry, although it intends to focus on healthcare. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">As of September 30, 2022, the Company had not commenced any operations. All activity for the period from December 22, 2020 (inception) through September 30, 2022 relates to the Company’s formation and the initial public offering (the “IPO”), searching for a Business Combination target. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income on investments from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s Sponsor is Summit Healthcare Acquisition Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”). The registration statement for the Company’s IPO was declared effective on June 8, 2021 (the “Effective Date”). On June 11, 2021, the Company consummated the IPO of 20,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”) $10.00 per Unit, generating gross proceeds of $200,000,000, which is discussed in Note 3. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the consummation of the IPO and the issuance and sale of the Units, the Company consummated the private placement of 6,000,000 Private Placement Warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant, to the Sponsor, generating total proceeds of $6,000,000. Transaction costs amounted to $11,587,941 consisting of $4,000,000 of underwriting commissions, $7,000,000 of deferred underwriting commissions and $587,941 of other cash offering costs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the IPO on June 11, 2021, $200,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a U.S.-based trust account (the “Trust Account”) with Continental Stock Transfer &amp; Trust Company acting as trustee, and was invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">conditions under Rule 2a-7 under the</div> Investment Company Act. As of September 30, 2022, the assets held in the Trust Account were held in money market fund. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the Company’s amended and restated memorandum and articles of association and subject to the requirements of law and regulation, will provide that the proceeds from the IPO and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the Company’s public shareholders until the earliest of: (i) the completion of an initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association, and (iii) the redemption of the Company’s public shares if the Company has not consummated its Business Combination within 24 months from the closing of the IPO, subject to applicable law. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ordinary shares subject to redemption are recorded at a $10.06 per share redemption value and classified as temporary equity, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will have 24 months from the closing of the IPO to complete the initial Business Combination (the “Combination Period”) or during any Extension Period. However, if the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at a per-share price, payable</div> in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable <div style="letter-spacing: 0px; top: 0px;;display:inline;">la</div>w. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and the Company’s officers and directors agreed to (i) waive their redemption rights with respect to their Class B ordinary shares, par value $0.0001 (the “Founder Shares”) in connection with the completion of the initial Business Combination, (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association, (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to complete the initial Business Combination within the Combination Period or during any Extension Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete its initial Business Combination within the prescribed timeframe), and (iv) vote any Founder Shares and public shares held by them in favor of the initial Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share or (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay the Company’s tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriter of the IPO against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked it Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combination </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September 29, 2022, the Company entered into a Business Combination Agreement (the “Business Combination Agreement”) with YishengBio Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands (to be renamed as YS Biopharma Co., Ltd, herein referred to as “YS Biopharma”), Oceanview Bioscience Acquisition Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub I”) and Hudson Biomedical Group Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub II,” and together with Merger Sub I, “Merger Subs”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination Agreement provides for (i) the merger of Merger Sub I with and into the Company (the “First Merger”), with the Company surviving the First Merger as the surviving entity (the “Surviving Entity”) and becoming a wholly-owned subsidiary of YS Biopharma, and (ii) the merger of the Surviving Entity with and into Merger Sub II (the “Second Merger,” and together with the First Merger, the “Mergers,” together with other transactions contemplated by the Business Combination Agreement, the “Transactions”), with Merger Sub II surviving the Second Merger as the surviving company (the “Surviving Company”) and remaining as the wholly-owned subsidiary of YS Biopharma. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources; Going Concern </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022, the Company had $70,097 of cash for working capital purposes and <div style="display:inline;">a </div>working capital deficit of $341,314. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s liquidity needs prior to the IPO had been satisfied through a payment from the Sponsor of $25,000 (see Note 5) for the Founder Shares to cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of $300,000 (see Note 5). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The promissory note was repaid on June 11, 2021. In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans, as defined below (see Note 5). As of September 30, 2022 and December 31, 2021, there were no amounts outstanding under any Working Capital Loans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. On September 29, 2022, the Company issued a Convertible Promissory Note (as described in Note 6) to the Sponsor, pursuant to which, the Company may borrow up to $1,500,000 from the Sponsor for working capital purpose<div style="display:inline;">s</div>. On October 12, 2022, the Company had <div style="display:inline;">drew</div> down $700,000 under the Convertible Promissory Note. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The C<div style="letter-spacing: 0px; top: 0px;;display:inline;">ompa</div>ny has until June 11, 2023 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by such date. If a Business Combination is not consummated by the required date, the Company will commence an automatic winding up, dissolution and liquidation. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the management has determined that the liquidity condition and <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">mandatory</div></div> liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 11, 2023. The management plans to continue efforts to close a Business Combination within the prescribed time frame. </div> 20000000 10 200000000 6000000 1 6000000 11587941 4000000 7000000 587941 200000000 10 10.06 100000 0.0001 10 70097 341314 25000 300000 0 0 1500000 700000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2—Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> and pursuant to the rules and regulations of the Security and Exchange Commission (“SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company Status </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the fun audited condensed financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant estimates included in these financial statements is the determination of the fair value of the warrant liability and Forward Purchase Agreement (“FPA”) liability. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have cash equivalents as of September 30, 2022 and December 31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments Held in Trust Account </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, the </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> assets held in the Trust Account were held in a money market fund. The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, investments in money market funds that invest in U.S. government securities, cash, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Interest earned on these securities is included in interest earned on Investments Held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2022 and December 31, 2021, the Company had $201,200,243 and $200,007,275 held in the Trust Account, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation limit of $250,000. As of September 30, 2022 and December 31, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with IPO </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC340-10-S99-1</div></div></div> and SEC Staff Accounting Bulletin (“SAB”) Topic 5A “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged to ordinary shares subject to possible redemption or the statement of operations based on the relative value of the Public and Private Warrants to the proceeds received from the Units and Private Placement Warrants sold upon the completion of the IPO. Accordingly, offering costs totaling $11,587,941 (consisting of $4,000,000 of underwriting fees, $7,000,000 of deferred underwriting fees and $587,941 of other offering costs), of which $507,417 was allocated to the Public Warrants and Private Warrants and was charged to operations in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">825-10</div> and $11,080,524 was charged to ordinary shares subject to possible redemption. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability and Forward Purchase Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for the 16,000,000 warrants issued in connection with the IPO (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) and Forward Purchase Agreement (“FPA”) in accordance with the guidance contained in FASB ASC 815 “Derivatives and Hedging” whereby under that provision the warrants and FPA do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company will classify warrants and FPA as liabilities at their fair value. These liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each reporting period. With such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the changes in fair value are recognized in the Statement of Operations in the period of change. Derivative warrant liabilities and FPA are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, excluding the warrant liability and FPA liability, which qualify as financial instruments under FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A Ordinary Shares Subject to Possible Redemption </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2022 and December 31, 2021, 20,000,000 and 20,000,000 Class A ordinary shares, respectively, subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity (deficit) section of the Company’s balance sheet. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Proceeds allocated to Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,511,409</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Class A ordinary shares issuance costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,080,524</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,591,933</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of September 30, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,200,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Per Ordinary Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 16,000,000 potential </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">ordinary</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three and nine months ended </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September 30, 2022 and 2021, </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares: </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,431,344</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,274,011</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">803,726</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">231,071</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,302,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,249,469</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,143,878</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,502,389</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,205,128</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.57</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.57</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">must be more-likely-than-not to be</div> sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt—Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“ASU2020-06”)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> amends the diluted earnings per share guidance, including the requirement to use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for all convertible instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU 2020-06</div> would have on its financial position, results of operations or cash flows. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> and pursuant to the rules and regulations of the Security and Exchange Commission (“SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company Status </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the fun audited condensed financial statements and the reported amounts of expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant estimates included in these financial statements is the determination of the fair value of the warrant liability and Forward Purchase Agreement (“FPA”) liability. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have cash equivalents as of September 30, 2022 and December 31, 2021. </div></div> 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments Held in Trust Account </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, the </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> assets held in the Trust Account were held in a money market fund. The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, investments in money market funds that invest in U.S. government securities, cash, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Interest earned on these securities is included in interest earned on Investments Held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2022 and December 31, 2021, the Company had $201,200,243 and $200,007,275 held in the Trust Account, respectively. </div></div> P185D 201200243 200007275 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation limit of $250,000. As of September 30, 2022 and December 31, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div> 250000 250000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with IPO </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC340-10-S99-1</div></div></div> and SEC Staff Accounting Bulletin (“SAB”) Topic 5A “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Public Offering. Offering costs are charged to ordinary shares subject to possible redemption or the statement of operations based on the relative value of the Public and Private Warrants to the proceeds received from the Units and Private Placement Warrants sold upon the completion of the IPO. Accordingly, offering costs totaling $11,587,941 (consisting of $4,000,000 of underwriting fees, $7,000,000 of deferred underwriting fees and $587,941 of other offering costs), of which $507,417 was allocated to the Public Warrants and Private Warrants and was charged to operations in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">825-10</div> and $11,080,524 was charged to ordinary shares subject to possible redemption. </div> 11587941 4000000 7000000 587941 507417 11080524 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability and Forward Purchase Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for the 16,000,000 warrants issued in connection with the IPO (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) and Forward Purchase Agreement (“FPA”) in accordance with the guidance contained in FASB ASC 815 “Derivatives and Hedging” whereby under that provision the warrants and FPA do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company will classify warrants and FPA as liabilities at their fair value. These liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each reporting period. With such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the changes in fair value are recognized in the Statement of Operations in the period of change. Derivative warrant liabilities and FPA are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div> 16000000 10000000 6000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, excluding the warrant liability and FPA liability, which qualify as financial instruments under FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A Ordinary Shares Subject to Possible Redemption </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2022 and December 31, 2021, 20,000,000 and 20,000,000 Class A ordinary shares, respectively, subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity (deficit) section of the Company’s balance sheet. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Proceeds allocated to Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,511,409</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Class A ordinary shares issuance costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,080,524</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,591,933</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of September 30, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,200,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 20000000 20000000 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Proceeds allocated to Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,511,409</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Class A ordinary shares issuance costs</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,080,524</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,591,933</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of December 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Accretion of carrying value to redemption value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shares subject to possible redemption as of September 30, 2022</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,200,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 200000000 8511409 11080524 19591933 200000000 1200243 201200243 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Per Ordinary Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 16,000,000 potential </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">ordinary</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three and nine months ended </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September 30, 2022 and 2021, </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares: </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,431,344</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,274,011</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">803,726</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">231,071</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,302,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,249,469</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,143,878</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,502,389</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,205,128</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.57</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.57</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> 16000000 The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of ordinary shares: <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,431,344</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,274,011</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">803,726</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">231,071</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 54%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,302,500</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,249,469</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,143,878</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,502,389</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares outstanding</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,205,128</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,750,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.57</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.57</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.26</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> </table> 4431344 1274011 803726 231071 20000000 20000000 5750000 5750000 20000000 20000000 5750000 5750000 0.22 0.22 0.22 0.22 0.04 0.04 0.04 0.04 11302500 3249469 -2143878 -1502389 20000000 20000000 5750000 5750000 8205128 8205128 5750000 5750000 0.57 0.57 0.57 0.57 -0.26 -0.26 -0.26 -0.26 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">must be more-likely-than-not to be</div> sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt—Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“ASU2020-06”)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> amends the diluted earnings per share guidance, including the requirement to use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for all convertible instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective on January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU 2020-06</div> would have on its financial position, results of operations or cash flows. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3—Initial Public Offering </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On June 11, 2021, the Company consummated its IPO of 20,000,000 Units (the “Units”), at a price of $10.00 per unit, generating gross proceeds to the Company of $200,000,000. Each Unit consists of one Class A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from the closing of the IPO, and will expire five years after the completion of the initial Business Combination or earlier upon redemption or liquidation (see Note 8). </div> 20000000 10 200000000 P30D P12M <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4—Private Placement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Simultaneously with the closing of the IPO and the sale of the Units, the Company consummated the private placement (the “Private Placement”) of an aggregate 6,000,000 Private Placement Warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $6,000,000. If the Company does not complete an initial Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">will be non-redeemable by the</div> Company and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">If the Private Placement Warrants are held by <div style="letter-spacing: 0px; top: 0px;;display:inline;">hold</div>ers other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units being sold in the IPO. </div> 6000000 1 6000000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5—Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December 31, 2020, the Company issued to the Sponsor 5,750,000 Founder Shares for $25,000 for certain expenses paid on behalf of the Company, or approximately $0.004 per share. On April 30, 2021, the Company effected a share capitalization, pursuant to which the Company’s initial shareholders held an aggregate of 6,500,000 Class B ordinary shares. The accompanying unaudited condensed financial statements have been retroactively adjusted to reflect the stock dividend in the share capitalization. On April 30, 2021, the Company entered into forward purchase agreements (see Note 6) with anchor investors, in connection with entering into the forward purchase agreements, the Sponsor transferred to the anchor investors an aggregate of 375,000 Class B ordinary shares for no cash. On April 30, 2021, the Sponsor transferred 25,000 Class B ordinary shares each to three independent director nominees. Up to 750,000 Founder Shares were subject to forfeiture by the Sponsor depending on the extent to which the underwriters’ over-allotment option is exercised. On July 23, 2021, the Sponsor surrendered 750,000 Founder Shares, with no return of capital or payment by the Sponsor, after the expiration of the unexercised underwriters’ over-allotment option. As a result of the foregoing, as of September 30, 2022 and December 31, 2021, the Sponsor owned 5,750,000 Class B ordinary shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor, officers and directors have agreed not to transfer, assign or sell any of their Founder Shares until earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s public shareholders having the right to exchange their ordinary shares for cash, securities or other property <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(the “Lock-up”).</div> Any permitted transferees would be subject to the same restrictions and other agreements of our Sponsor, officers and directors with respect to any Founder Shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory Note—Related Party </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Sponsor has agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the IPO. These loans were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured and were due at the earlier of September 30, 2021 or the closing of the IPO. The loan was to be repaid upon completion of the IPO out of the $1,000,000 of offering proceeds that has been allocated to the payment of offering expenses. The Company had drawn down $140,068 under the promissory note which was repaid as of June 11, 2021. The note was terminated as of June 11, 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Loans </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender. Such warrants would be identical to the Private Placement Warrants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September 29, 2022, the Company issued an unsecured, interest-free promissory note to the Sponsor pursuant to which the Company may borrow up to $1,500,000 from the Sponsor for costs and expenses reasonably related to the Company’s working capital needs prior to the consummation of the Business Combination (the “Convertible Promissory Note”). All unpaid principal under the Convertible Promissory Note will become due and payable in full on the date on which the Company consummates the Business Combination, unless earlier accelerated upon the occurrence of an event of default. The Sponsor will have the option, at any time on or prior to the maturity date, to convert any amounts outstanding under the Convertible Promissory Note, up to $1,500,000 in the aggregate, into warrants to purchase the Company’s Class A ordinary shares, at a conversion price of $1.00 per warrant, with each warrant entitling the holder to purchase one Company’s Class A ordinary share at a price of $11.50 per share, subject to the same adjustments applicable to the private placement warrants sold concurrently with the Company’s initial public offering. As of September 30, 2022, there were no outstanding amount under the Convertible Promissory Note. On October 12, 2022, the Company had drawn down $700,000 under the Convertible Promissory </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note. The Convertible Promissory Note will be valued using the fair value method at each reporting period. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative Service Fee </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Commencing on the Effective Date, the Company paid an affiliate of the Sponsor $10,000 per month for office space, utilities, administrative services and remote support services. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company accrued $30,000 and $90,000 for the administrative service fee for the three and nine months ended September 30, 2022, respectively. <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The Company accrued $30,000 and $</div>37,667<div style="letter-spacing: 0px; top: 0px;;display:inline;"> for the three months ended September 30, 2021 and for the period from June 8, 2021 (the Effective Date) through September 30, 2021. As of September 30, 2022 and December 31, 2021, there were $30,000 and $0 administrative service fee unpaid, which is included in due to related party on the accompanying condensed balance sheets. </div> </div></div> 5750000 25000 0.004 6500000 375000 0 25000 3 750000 750000 5750000 5750000 12 P20D P30D P150D 300000 1000000 140068 1500000 1 1500000 1500000 1 11.5 0 700000 10000 30000 90000 30000 37667 30000 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>—Recurring Fair Value Measurements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability and FPA Liability </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of September 30, 2022 and December 31, 2021, the fair value of Company’s Warrant liability was $2,414,882 and $10,423,429, respectively, and the fair value of FPA liability was $3,209,928 and $2,785,941, respectively. Under the guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> the Public and Private Warrants and the FPA do not meet the criteria for equity treatment. As such, the Public and Private Warrants and the FPA must be recorded on the balance sheet at fair value. This valuation is subject tore-measurement each balance sheet date. With each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the valuations will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recurring Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents fair value information as of September 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company’s Warrant liability is based on a valuation models utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair values of the Private Warrant liability and FPA liability are classified within Level 3 of the fair value hierarchy. The investments held in Trust Account includes money market funds. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its level 1 investments. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of September 30, 2022, that were accounted for at fair value on a recurring basis: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 1)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 2)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 3)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,200,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 1pt 0pt 0pt; text-align: right;">1,500,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">914,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FPA liability</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,209,928</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,500,000</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,124,810</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of December 31, 2021, that were accounted for at fair value on a recurring basis: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 1)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 2)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 3)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,007,275</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 65%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,500,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,923,429</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FPA liability</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,785,941</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 65%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,500,000</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,709,370</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 65%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Measurement of the Warrants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company established the initial fair value for the Warrants on June 11, 2021, the date of the consummation of the Company’s IPO. The Company used a Monte Carlo simulation model to value the Warrants. The Company allocated the proceeds received from (i) the sale of Units (which is inclusive of one Class A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one Public Warrant), (ii) the sale of Private Warrants, and (iii) the issuance of Class B ordinary shares, first to the Warrants based on their fair values as determined at initial measurement, with the remaining proceeds allocated to Class A ordinary shares subject to possible redemption (temporary equity), and Class B ordinary shares (permanent equity) based on their relative fair values at the initial measurement date. The estimated fair value of the Public Warrants was transferred from a Level 3 measurement to a Level 1 measurement in August 2021 after detachment of the Public Warrants from the Units and were separately listed and traded. For the period ended September 30, 2022, the Public Warrants were reclassified from Level 1 to Level 2 due to the valuation based on quoted prices (unadjusted) with less volume and transaction frequency than active markets. As of September 30, 2022 and December 31, 2021, the Private Warrants were valued using a Monte Carlo simulation model. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key inputs for the valuation of Private Warrants are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%;"/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">Input</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Free Rate</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">4.04</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">% </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.29</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">% </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Price</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">9.82</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">9.72</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Est. Term Remaining (Yrs)</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5.55</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5.35</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of changes in fair value of the Company’s derivative warrant liabilities classified as Level 3 for the nine months ended September 30, 2022 and 2021: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Public<br/>Warrants</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Private<br/>Warrants</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Warrants<br/>Liability</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at December 31, 2021</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,923,429</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,923,429</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,713,773</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,713,773</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at March 31, 2022</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">1,209,656</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">1,209,656</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(751,093</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(751,093</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at June 30, 2022</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">458,563</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">458,563</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">456,319</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">456,319</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at September 30, 2022</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">914,882</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">914,882</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Public<br/>Warrants</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Private<br/>Warrants</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Warrants<br/>Liability</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at December 31, 2020</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial value of warrant liabilities at IPO<div style="display:inline;"> (<div style="display:inline;">June 11, 202<div style="display:inline;">1</div></div>)</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,511,409</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,201,555</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,712,964</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">1,212,798</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">672,323</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">1,885,121</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair value at June 30, 2021</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">9,724,207</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">5,873,878</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">15,598,085</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,123,207</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(673,904</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,797,111</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)</td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer of Public warrants from Level 3 to Level 1</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(8,601,000</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(8,601,000</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at September 30, 2021</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5,199,974</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5,199,974</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FPA </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To arrive at the conclusion of Fair Value of the Forward Purchase Agreements, the Company analyzed the agreements and other documentation. The Company utilized the underlying shares and warrant values determined above and the following inputs in order to project the net asset or liability value of the FPA: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%;"/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">Input</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Price</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">9.82</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">9.72</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Price</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.150</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.65</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Est. Term to Business Combination (Yrs)</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.55</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.33</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of Business Combination</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">85</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">85</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase price of FPA unit</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">10.00</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">10.00</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Discount rate</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3.93</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.04</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of changes in fair value of the Company’s FPA liability classified as Level 3 for the nine months ended September 30, 2022 and 2021: </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">FPA liability</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at December 31, 2021</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,785,941</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127,629</td> <td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at <div style="display:inline;">March 31</div>, 2022</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,658,312</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">141,728</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at June 30, 2022</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,800,040</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">409,888</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at September 30, 2022</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,209,928</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">FPA Liability</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at December 31, 2020</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Initial value of FPA liability at IPO<div style="display:inline;"> (<div style="display:inline;">June <div style="display:inline;">11</div>, 2021</div>)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,322,741</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77,703</td> <td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at June 30, 2021</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,245,038</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">561,983</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at September 30, 2021</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2,807,021</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="clear:both;max-height:0pt;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Transfers between levels of the fair value hierarchy are recognized at the end of the reporting period. There are no transfers to or from Level 3 for the <div style="letter-spacing: 0px; top: 0px;;display:inline;">three and </div>nine months ended September 30, 2022. </div></div> 2414882 10423429 3209928 2785941 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of September 30, 2022, that were accounted for at fair value on a recurring basis: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 1)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 2)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 3)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">201,200,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 1pt 0pt 0pt; text-align: right;">1,500,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">914,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FPA liability</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,209,928</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,500,000</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,124,810</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth by level within the fair value hierarchy the Company’s assets and liabilities as of December 31, 2021, that were accounted for at fair value on a recurring basis: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 1)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 2)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">(Level 3)</td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,007,275</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 65%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,500,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Warrants</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,923,429</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FPA liability</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,785,941</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 65%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,500,000</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,709,370</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 65%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 201200243 1500000 914882 3209928 1500000 4124810 200007275 6500000 0 3923429 2785941 6500000 6709370 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key inputs for the valuation of Private Warrants are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%;"/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">Input</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Free Rate</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">4.04</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">% </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1.29</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">% </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Price</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">9.82</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">9.72</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Est. Term Remaining (Yrs)</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5.55</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5.35</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> </table> 4.04 1.29 9.82 9.72 5.55 5.35 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of changes in fair value of the Company’s derivative warrant liabilities classified as Level 3 for the nine months ended September 30, 2022 and 2021: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Public<br/>Warrants</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Private<br/>Warrants</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Warrants<br/>Liability</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 65%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at December 31, 2021</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,923,429</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,923,429</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,713,773</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,713,773</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at March 31, 2022</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">1,209,656</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">1,209,656</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(751,093</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(751,093</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair Value at June 30, 2022</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">458,563</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">458,563</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">456,319</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">456,319</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at September 30, 2022</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">914,882</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">914,882</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Public<br/>Warrants</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Private<br/>Warrants</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Warrants<br/>Liability</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at December 31, 2020</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 0px;"> <td style="width: 63%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial value of warrant liabilities at IPO<div style="display:inline;"> (<div style="display:inline;">June 11, 202<div style="display:inline;">1</div></div>)</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,511,409</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,201,555</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,712,964</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">1,212,798</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">672,323</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">1,885,121</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair value at June 30, 2021</div><br/></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">9,724,207</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">5,873,878</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">15,598,085</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,123,207</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(673,904</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,797,111</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)</td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer of Public warrants from Level 3 to Level 1</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(8,601,000</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(8,601,000</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at September 30, 2021</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5,199,974</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5,199,974</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> 3923429 3923429 -2713773 -2713773 0 1209656 1209656 0 -751093 -751093 0 458563 458563 0 456319 456319 914882 914882 0 0 0 8511409 5201555 13712964 1212798 672323 1885121 9724207 5873878 15598085 -1123207 -673904 -1797111 -8601000 0 -8601000 0 5199974 5199974 The Company utilized the underlying shares and warrant values determined above and the following inputs in order to project the net asset or liability value of the FPA: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%;"/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">Input</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Price</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">9.82</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">9.72</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Price</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.150</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.65</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Est. Term to Business Combination (Yrs)</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.55</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.33</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Probability of Business Combination</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">85</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">85</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase price of FPA unit</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">10.00</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">10.00</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Discount rate</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">3.93</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">0.04</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> </tr> </table> 9.82 9.72 0.15 0.65 0.55 0.33 85 85 10 10 3.93 0.04 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of changes in fair value of the Company’s FPA liability classified as Level 3 for the nine months ended September 30, 2022 and 2021: </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">FPA liability</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at December 31, 2021</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,785,941</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127,629</td> <td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at <div style="display:inline;">March 31</div>, 2022</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,658,312</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">141,728</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at June 30, 2022</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,800,040</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">409,888</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(255, 255, 255); line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair Value at September 30, 2022</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,209,928</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgb(255, 255, 255);"> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">FPA Liability</div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at December 31, 2020</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Initial value of FPA liability at IPO<div style="display:inline;"> (<div style="display:inline;">June <div style="display:inline;">11</div>, 2021</div>)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,322,741</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77,703</td> <td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at June 30, 2021</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,245,038</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">561,983</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);;text-align:right;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"> <div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Fair value at September 30, 2021</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">2,807,021</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="clear:both;max-height:0pt;"/> 2785941 -127629 2658312 141728 2800040 409888 3209928 0 2322741 -77703 2245038 561983 2807021 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7—Commitments &amp; Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of the COVID-19 pandemic on</div> the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of this financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the IPO. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</div> period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriters Agreement</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The underwriters <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">had a 45-day option to</div> purchase up to an additional 3,000,000 units to cover over-allotments, if any. The over-allotment option expired unexercised on July 23, 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The underwriters were paid a cash underwriting discount of two percent (2%) of the gross proceeds of the IPO, or $4,000,000. Additionally, the underwriters are entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the IPO upon the completion of the Company’s initial Business Combination. On July 7, 2022, a waiver letter was signed by the Company and BofA Securities, Inc. (“BofA”), pursuant to which BofA announced it waived its entitlement to the payment of any deferred underwriting discount to be paid under the terms of the underwriting agreement. The Company recognized $7,000,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;">gain recognized on extinguishment of deferred underwriting commissions in the operations in connection with such waiver. </div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward Purchase Agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April 30, 2021, the Company entered into forward purchase agreements with the Sponsor, Snow Lake Capital (HK) Limited and Valliance Fund (the “anchor investors”), pursuant to which the anchor investors agreed to subscribe for an aggregate of 3,000,000 Class A ordinary shares plus 750,000 redeemable warrants for a purchase price of $10.00 multiplied by the number of Class A ordinary shares, or $30,000,000 in the aggregate, in a private placement to close concurrently with the closing of the initial business combination. The Company issued 750,000 additional Class B ordinary shares to the Sponsor, which represent the adjustment to the ratio applicable to the conversion of the Class B ordinary shares that the Sponsor would have been entitled to at the closing of the initial business combination as a result of the issuance of 3,000,000 additional Class A ordinary shares under the forward purchase agreements. As a result, the issuance of the Class A ordinary shares at the closing of the initial business combination will not trigger a further adjustment to this ratio. Further, prior to the IPO, the Sponsor transferred to the anchor investors an aggregate of 375,000 Founder Shares for no cash consideration. Subject to certain exceptions to forfeiture and transfer provisions, the Founder Shares transferred in connection with these agreements are subject to similar contractual conditions and restrictions as the Founder Shares issued to the Sponsor in connection with the IPO. The forward purchase warrants will have the same terms as the public warrants. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The forward purchase agreements provide that the anchor investors are entitled to registration rights with respect to the forward purchase securities and Class A ordinary shares underlying the forward purchase warrants and Founder Shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proceeds from the sale of the forward purchase securities may be used as part of the consideration to the sellers in the initial Business Combination, expenses in connection with the initial Business Combination or for working capital in the post Business Combination company. These purchases will be required to be made regardless of whether any Class A ordinary shares are redeemed by the public shareholders and are intended to provide the Company with a minimum funding level for the initial Business Combination. The anchor investors will not have the ability to approve the initial Business Combination prior to the signing of a material definitive agreement and, if the Company seeks shareholder approval, have agreed to vote their Founder Shares and any public shares held by them in favor of the initial Business Combination. The forward purchase securities will be issued only in connection with the closing of the initial Business Combination. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combination Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September 29, 2022, the Company entered into a Business Combination Agreement with YishengBio Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands (to be renamed as YS Biopharma Co., Ltd, herein referred to as “YS Biopharma”), Oceanview Bioscience Acquisition Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub I”) and Hudson Biomedical Group Co., Ltd., an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of YS Biopharma (“Merger Sub II,” and together with Merger Sub I, “Merger Subs”). Capitalized terms in this Item 1.01 not otherwise defined shall have the meanings ascribed to them in the Business Combination Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination Agreement provides for (i) the merger of Merger Sub I with and into Summit (the “First Merger”), with Summit surviving the First Merger as the surviving entity (the “Surviving Entity”) and becoming a wholly-owned subsidiary of YS Biopharma, and (ii) the merger of the Surviving Entity with and into Merger Sub II (the “Second Merger,” and together with the First Merger, the “Mergers,” together with other transactions contemplated by the Business Combination Agreement, the “Transactions”), with Merger Sub II surviving the Second Merger as the surviving company (the “Surviving Company”) and remaining as the wholly-owned subsidiary of YS Biopharma. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to, and in accordance with the terms and conditions set forth in the Business Combination Agreement, immediately prior to the effective time of the First Merger (the “First Merger Effective Time”), (i) each preferred share of YS Biopharma with par value of US$0.000005 will be converted into one ordinary share of YS Biopharma with par value of US$0.000005; (ii) after the conversion of all preferred shares into ordinary shares, each four of the ordinary shares of YS Biopharma with par value of US$0.000005 will be consolidated into one ordinary share of YS Biopharma with par value of US$0.00002, and each four of the options to acquire ordinary shares of YS Biopharma will be consolidated into one option to acquire ordinary share of YS Biopharma, subject to rounding up to the nearest whole number of shares; and (iii) the second amended and restated memorandum and articles of association of YS Biopharma shall be adopted and become effective. Items (i) through (iii) are herein referred to as the “YS Biopharma Capital Restructuring.” </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, YS Biopharma and Summit entered into a Shareholder Support Agreement and Deed with certain YS Biopharma shareholders and certain Summit shareholders with respect to the Transactions and post-Closing rights and obligations of shareholders of YS Biopharma. </div></div> P30D P45D 3000000 -0.02 4000000 0.035 7000000 3000000 750000 10 30000000 750000 3000000 375000 0 0.000005 one 0.000005 0.000005 0.00002 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8—Warrant Liability </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2022 and December 31, 2021, 16,000,000 warrants (the 10,000,000 Public Warrants and the 6,000,000 Private Placement Warrants) are outstanding. Each warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. The warrants will become exercisable on the later of 12 months from the closing of the IPO or 30 days after the completion of its initial Business Combination, and will expire five years after the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days with in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a 30-trading day</div> period ending three trading days before the Company sends the notice of redemption to the warrant holders. </div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of the Class A ordinary shares; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of our Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant) for any 20 trading days with in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the 30-trading day</div> period ending three trading days before the Company sends the notice of redemption to the warrant holders; and </div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if the closing price of the Class A ordinary shares for any 20 trading days with in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a 30-trading day</div> period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above. </div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and in the case of any such issuance to the Company’s Sponsors or its affiliate, without taking into account any Founder Shares held by the Company’s Sponsor or such affiliates, as applicable, prior to such issuance (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the completion of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> 16000000 10000000 6000000 11.5 P12M P30D 18 0.01 P30D 18 P20D P30D 10 0.1 P30D 10 P20D P30D 9.2 0.60 P20D 9.2 1.15 18 1.80 10 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9—Shareholders’ Deficit </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2022 and December 31, 2021, there were no preference shares issued or outstanding. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A Ordinary Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is authorized to issue 500,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2022 and December 31, 2021, there were 20,000,000 Class A ordinary shares issued and outstanding, including the 20,000,000 shares presented in ordinary shares subject to redemption.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class B Ordinary Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is authorized to issue 50,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of September 30, 2022 and December 31, 2021, there were 5,750,000 Class B ordinary shares issued and outstanding. Of the 6,500,000 Class B ordinary shares, an aggregate of up to 750,000 shares were subject to forfeiture to the Company for no consideration to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding ordinary shares after the IPO. On July 23, 2021, the Sponsor surrendered 750,000 Founder Shares, with no return of capital or payment by the Sponsor, after the expiration of the unexercised underwriters’ over-allotment option. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class A ordinary shareholders and Class B ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law. Prior to the initial Business Combination, only holders of the Founder Shares will have the right to vote on the election of directors. Holders of the public shares will not be entitled to vote on the appointment of directors during such time. In addition, prior to the completion of an initial Business Combination, holders of a majority of the Founder Shares may remove a member of the board of directors for any reason. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have redemption rights or be entitled to liquidating distributions from the Trust Account if the Company does not consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on an as-converted basis, 20%</div> of the sum of (i) the total number of ordinary shares issued and outstanding upon the completion of the IPO, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued or to be issued to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, its affiliates or any member of our management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one.</div></div> </div> 5000000 0.0001 0 0 0 0 500000000 0.0001 20000000 20000000 20000000 20000000 20000000 20000000 20000000 20000000 50000000 0.0001 5750000 6500000 750000 0.20 750000 0.20 one-to-one <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10—Subsequent Events </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued. Based on this review, other than the events described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</div><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October 12, 2022, the Company had drawn down $700,000 under the Convertible Promissory Note. The Convertible Promissory Note will be valued using the fair value method at each reporting period. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> 700000 EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 247 189 1 false 49 0 false 9 false false R1.htm 1001 - Document - Cover Page Sheet http://www.smihu.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Balance Sheets Sheet http://www.smihu.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.smihu.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Unaudited Condensed Statements of Operations Sheet http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations Unaudited Condensed Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Unaudited Condensed Statements of Changes in Shareholders' Deficit Sheet http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit Unaudited Condensed Statements of Changes in Shareholders' Deficit Statements 5 false false R6.htm 1006 - Statement - Unaudited Condensed Statements of Cash Flows Sheet http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows Unaudited Condensed Statements of Cash Flows Statements 6 false false R7.htm 1007 - Disclosure - Organization, Business Operation, Liquidity and Capital Resources Sheet http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResources Organization, Business Operation, Liquidity and Capital Resources Notes 7 false false R8.htm 1008 - Disclosure - Significant Accounting Policies Sheet http://www.smihu.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 1009 - Disclosure - Initial Public Offering Sheet http://www.smihu.com/role/InitialPublicOffering Initial Public Offering Notes 9 false false R10.htm 1010 - Disclosure - Private Placement Sheet http://www.smihu.com/role/PrivatePlacement Private Placement Notes 10 false false R11.htm 1011 - Disclosure - Related Party Transactions Sheet http://www.smihu.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 1012 - Disclosure - Recurring Fair Value Measurements Sheet http://www.smihu.com/role/RecurringFairValueMeasurements Recurring Fair Value Measurements Notes 12 false false R13.htm 1013 - Disclosure - Commitments & Contingencies Sheet http://www.smihu.com/role/CommitmentsContingencies Commitments & Contingencies Notes 13 false false R14.htm 1014 - Disclosure - Warrant Liability Sheet http://www.smihu.com/role/WarrantLiability Warrant Liability Notes 14 false false R15.htm 1015 - Disclosure - Shareholders' Deficit Sheet http://www.smihu.com/role/ShareholdersDeficit Shareholders' Deficit Notes 15 false false R16.htm 1016 - Disclosure - Subsequent Events Sheet http://www.smihu.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 1017 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.smihu.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.smihu.com/role/SignificantAccountingPolicies 17 false false R18.htm 1018 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.smihu.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.smihu.com/role/SignificantAccountingPolicies 18 false false R19.htm 1019 - Disclosure - Recurring Fair Value Measurements (Tables) Sheet http://www.smihu.com/role/RecurringFairValueMeasurementsTables Recurring Fair Value Measurements (Tables) Tables http://www.smihu.com/role/RecurringFairValueMeasurements 19 false false R20.htm 1020 - Disclosure - Organization, Business Operation, Liquidity and Capital Resources - Additional information (Detail) Sheet http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail Organization, Business Operation, Liquidity and Capital Resources - Additional information (Detail) Details 20 false false R21.htm 1021 - Disclosure - Significant Accounting Policies - Additional information (Detail) Sheet http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail Significant Accounting Policies - Additional information (Detail) Details 21 false false R22.htm 1022 - Disclosure - Significant Accounting Policies - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) Sheet http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail Significant Accounting Policies - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail) Details 22 false false R23.htm 1023 - Disclosure - Significant Accounting Policies - Summary of Class A ordinary shares subject to possible redemption (Detail) Sheet http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail Significant Accounting Policies - Summary of Class A ordinary shares subject to possible redemption (Detail) Details 23 false false R24.htm 1024 - Disclosure - Initial Public Offering - Additional Information (Detail) Sheet http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail Initial Public Offering - Additional Information (Detail) Details 24 false false R25.htm 1025 - Disclosure - Private Placement - Additional Information (Detail) Sheet http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail Private Placement - Additional Information (Detail) Details 25 false false R26.htm 1026 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 26 false false R27.htm 1027 - Disclosure - Recurring Fair Value Measurements - Summary of Fair Value Hierarchy the Company's Assets and Liabilities (Detail) Sheet http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail Recurring Fair Value Measurements - Summary of Fair Value Hierarchy the Company's Assets and Liabilities (Detail) Details 27 false false R28.htm 1028 - Disclosure - Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants (Detail) Sheet http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants (Detail) Details 28 false false R29.htm 1029 - Disclosure - Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants of FPA (Detail) Sheet http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants of FPA (Detail) Details 29 false false R30.htm 1030 - Disclosure - Recurring Fair Value Measurements - Summary of reconciliation of changes in fair value of derivative warrant liabilities (Detail) Sheet http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail Recurring Fair Value Measurements - Summary of reconciliation of changes in fair value of derivative warrant liabilities (Detail) Details 30 false false R31.htm 1031 - Disclosure - Recurring Fair Value Measurements - Additional information (Detail) Sheet http://www.smihu.com/role/RecurringFairValueMeasurementsAdditionalInformationDetail Recurring Fair Value Measurements - Additional information (Detail) Details 31 false false R32.htm 1032 - Disclosure - Commitments & Contingencies - Additional Information (Detail) Sheet http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail Commitments & Contingencies - Additional Information (Detail) Details 32 false false R33.htm 1033 - Disclosure - Warrant Liability - Additional Information (Detail) Sheet http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail Warrant Liability - Additional Information (Detail) Details 33 false false R34.htm 1034 - Disclosure - Shareholders' Deficit - Additional Information (Detail) Sheet http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail Shareholders' Deficit - Additional Information (Detail) Details 34 false false R35.htm 1035 - Disclosure - Subsequent Events - Additional information (Detail) Sheet http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail Subsequent Events - Additional information (Detail) Details 35 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressPostalZipCode - d412062d10q.htm 7 d412062d10q.htm d412062dex311.htm d412062dex312.htm d412062dex321.htm d412062dex322.htm smihu-20220930.xsd smihu-20220930_cal.xml smihu-20220930_def.xml smihu-20220930_lab.xml smihu-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d412062d10q.htm": { "axisCustom": 1, "axisStandard": 18, "contextCount": 247, "dts": { "calculationLink": { "local": [ "smihu-20220930_cal.xml" ] }, "definitionLink": { "local": [ "smihu-20220930_def.xml" ] }, "inline": { "local": [ "d412062d10q.htm" ] }, "labelLink": { "local": [ "smihu-20220930_lab.xml" ] }, "presentationLink": { "local": [ "smihu-20220930_pre.xml" ] }, "schema": { "local": [ "smihu-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 338, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 48, "keyStandard": 141, "memberCustom": 24, "memberStandard": 22, "nsprefix": "smihu", "nsuri": "http://www.smihu.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.smihu.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:PrivatePlacementWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Private Placement", "role": "http://www.smihu.com/role/PrivatePlacement", "shortName": "Private Placement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:PrivatePlacementWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Related Party Transactions", "role": "http://www.smihu.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Recurring Fair Value Measurements", "role": "http://www.smihu.com/role/RecurringFairValueMeasurements", "shortName": "Recurring Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Commitments & Contingencies", "role": "http://www.smihu.com/role/CommitmentsContingencies", "shortName": "Commitments & Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:DisclosureOfWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Warrant Liability", "role": "http://www.smihu.com/role/WarrantLiability", "shortName": "Warrant Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:DisclosureOfWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Shareholders' Deficit", "role": "http://www.smihu.com/role/ShareholdersDeficit", "shortName": "Shareholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Subsequent Events", "role": "http://www.smihu.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "smihu:NetIncomeLossPerOrdinarySharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.smihu.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "smihu:NetIncomeLossPerOrdinarySharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Recurring Fair Value Measurements (Tables)", "role": "http://www.smihu.com/role/RecurringFairValueMeasurementsTables", "shortName": "Recurring Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Balance Sheets", "role": "http://www.smihu.com/role/CondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Organization, Business Operation, Liquidity and Capital Resources - Additional information (Detail)", "role": "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "shortName": "Organization, Business Operation, Liquidity and Capital Resources - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "lang": null, "name": "smihu:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Significant Accounting Policies - Additional information (Detail)", "role": "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Significant Accounting Policies - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Significant Accounting Policies - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail)", "role": "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "shortName": "Significant Accounting Policies - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P07_01_2022To09_30_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis", "decimals": "INF", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Significant Accounting Policies - Summary of Class A ordinary shares subject to possible redemption (Detail)", "role": "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "shortName": "Significant Accounting Policies - Summary of Class A ordinary shares subject to possible redemption (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "smihu:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Initial Public Offering - Additional Information (Detail)", "role": "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "shortName": "Initial Public Offering - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "div", "smihu:WarrantLiabilityAndForwardPurchaseAgreementPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "INF", "first": true, "lang": null, "name": "smihu:ClassOfWarrantsAndRightsIssuedDuringThePeriod", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Private Placement - Additional Information (Detail)", "role": "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "shortName": "Private Placement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "smihu:OfferingProceedsAllocatedToPaymentOfOfferingExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "smihu:OfferingProceedsAllocatedToPaymentOfOfferingExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Recurring Fair Value Measurements - Summary of Fair Value Hierarchy the Company's Assets and Liabilities (Detail)", "role": "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "shortName": "Recurring Fair Value Measurements - Summary of Fair Value Hierarchy the Company's Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "0", "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PublicAndPrivateWarrantsMemberusgaapFairValueByLiabilityClassAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants (Detail)", "role": "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "shortName": "Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PublicAndPrivateWarrantsMemberusgaapFairValueByLiabilityClassAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022_FpaLiabilityMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants of FPA (Detail)", "role": "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail", "shortName": "Recurring Fair Value Measurements - Summary of Valuation of Public and Private Warrants of FPA (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022_FpaLiabilityMemberusgaapFairValueByLiabilityClassAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "div", "smihu:OrganizationBusinessOperationLiquidityAndCapitalResourcesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityRedemptionPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022_CommonClassAMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn06_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FpaLiabilityMemberusgaapFairValueByLiabilityClassAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Recurring Fair Value Measurements - Summary of reconciliation of changes in fair value of derivative warrant liabilities (Detail)", "role": "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail", "shortName": "Recurring Fair Value Measurements - Summary of reconciliation of changes in fair value of derivative warrant liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FpaLiabilityMemberusgaapFairValueByLiabilityClassAxis", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Recurring Fair Value Measurements - Additional information (Detail)", "role": "http://www.smihu.com/role/RecurringFairValueMeasurementsAdditionalInformationDetail", "shortName": "Recurring Fair Value Measurements - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:OverAllotmentOptionVestingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Commitments & Contingencies - Additional Information (Detail)", "role": "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "shortName": "Commitments & Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:OverAllotmentOptionVestingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "smihu:DisclosureOfWarrantLiabilityTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Warrant Liability - Additional Information (Detail)", "role": "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail", "shortName": "Warrant Liability - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "smihu:DisclosureOfWarrantLiabilityTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Shareholders' Deficit - Additional Information (Detail)", "role": "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "shortName": "Shareholders' Deficit - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn09_30_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P10_12_2022To10_12_2022_ConvertiblePromissoryNoteMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Subsequent Events - Additional information (Detail)", "role": "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail", "shortName": "Subsequent Events - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Unaudited Condensed Statements of Operations", "role": "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations", "shortName": "Unaudited Condensed Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Unaudited Condensed Statements of Changes in Shareholders' Deficit", "role": "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit", "shortName": "Unaudited Condensed Statements of Changes in Shareholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P07_01_2022To09_30_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Unaudited Condensed Statements of Cash Flows", "role": "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows", "shortName": "Unaudited Condensed Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": "0", "lang": null, "name": "smihu:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:OrganizationBusinessOperationLiquidityAndCapitalResourcesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1007 - Disclosure - Organization, Business Operation, Liquidity and Capital Resources", "role": "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResources", "shortName": "Organization, Business Operation, Liquidity and Capital Resources", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:OrganizationBusinessOperationLiquidityAndCapitalResourcesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Significant Accounting Policies", "role": "http://www.smihu.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:InitialPublicOfferingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Initial Public Offering", "role": "http://www.smihu.com/role/InitialPublicOffering", "shortName": "Initial Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d412062d10q.htm", "contextRef": "P01_01_2022To09_30_2022", "decimals": null, "first": true, "lang": "en-US", "name": "smihu:InitialPublicOfferingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "smihu_AccruedOfferingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued offering costs and expenses.", "label": "Accrued Offering Costs And Expenses", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedOfferingCostsAndExpenses", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "smihu_AdministrativeServiceFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Administrative Service Fee [Member]", "terseLabel": "Administrative Service Fee" } } }, "localname": "AdministrativeServiceFeeMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_AnchorInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Anchor Investors [Member]", "terseLabel": "Anchor investors" } } }, "localname": "AnchorInvestorsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_CashHeldInTrustAccountPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash held in trust account.", "label": "Cash Held In Trust Account [Policy Text Block]", "terseLabel": "Investments Held in Trust Account" } } }, "localname": "CashHeldInTrustAccountPolicyTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "smihu_ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class A ordinary shares subject to possible redemption.", "label": "Class A Ordinary Shares Subject To Possible Redemption [Policy Text Block]", "terseLabel": "Class\u00a0A Ordinary Shares Subject to Possible Redemption" } } }, "localname": "ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "smihu_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, exercise price adjustment percentage higher of market value.", "label": "Class Of Warrant Or Right, Exercise Price Adjustment Percentage Higher Of Market Value", "terseLabel": "Class of warrant or right, exercise price adjustment percentage higher of market value" } } }, "localname": "ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "smihu_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right redemption threshold consecutive trading days.", "label": "Class Of Warrant Or Right Redemption Threshold Consecutive Trading Days", "terseLabel": "Class of warrant or right redemption threshold consecutive trading days" } } }, "localname": "ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right threshold period for exercise from date of closing public offering.", "label": "Class Of Warrant Or Right Threshold Period For Exercise From Date Of Closing Public Offering", "terseLabel": "Class of warrant or right, threshold period for exercise from date of closing public offering" } } }, "localname": "ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_ClassOfWarrantsAndRightsIssuedDuringThePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants and rights issued during the period.", "label": "Class Of Warrants And Rights Issued During The Period", "terseLabel": "Class of warrants and rights issued during the period", "verboseLabel": "Class of warrants and rights issued during the period" } } }, "localname": "ClassOfWarrantsAndRightsIssuedDuringThePeriod", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "smihu_ClassOfWarrantsAndRightsIssuedPricePerWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants and rights issued price per warrant.", "label": "Class Of Warrants And Rights Issued Price Per Warrant", "terseLabel": "Class of warrants and rights issued, price per warrant", "verboseLabel": "Class of warrants and rights issued, price per warrant" } } }, "localname": "ClassOfWarrantsAndRightsIssuedPricePerWarrant", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "smihu_ClassOfWarrantsRedemptionPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants redemption price per unit.", "label": "Class Of Warrants Redemption Price Per Unit", "terseLabel": "Class of warrants redemption price per unit" } } }, "localname": "ClassOfWarrantsRedemptionPricePerUnit", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "smihu_CommonClassAClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Class A and Class B [Member].", "label": "Common Class A Class B [Member]", "terseLabel": "Common Class A and Class B" } } }, "localname": "CommonClassAClassBMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_CommonStockSharesIssuedSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares issued subject to forfeiture.", "label": "Common Stock Shares Issued Subject To Forfeiture", "terseLabel": "Common stock shares issued subject to forfeiture" } } }, "localname": "CommonStockSharesIssuedSubjectToForfeiture", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "smihu_CommonStockSharesSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares subject to forfeiture.", "label": "Common Stock Shares Subject To Forfeiture", "terseLabel": "Common stock shares subject to forfeiture" } } }, "localname": "CommonStockSharesSubjectToForfeiture", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "smihu_ConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible promissory note.", "label": "Convertible Promissory Note [Member]", "terseLabel": "Convertible promissory note" } } }, "localname": "ConvertiblePromissoryNoteMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_DeferredOfferingCostsPaidBySponsorUnderPromissoryNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs paid by sponsor under promissory note.", "label": "Deferred Offering Costs Paid By Sponsor Under Promissory Note", "verboseLabel": "Deferred offering costs paid by Sponsor under promissory note" } } }, "localname": "DeferredOfferingCostsPaidBySponsorUnderPromissoryNote", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "smihu_DeferredUnderwritingCommissionsChargedToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commissions charged to additional paid in capital.", "label": "Deferred Underwriting Commissions Charged To Additional Paid In Capital", "verboseLabel": "Deferred underwriting commissions charged to additional paid in capital" } } }, "localname": "DeferredUnderwritingCommissionsChargedToAdditionalPaidInCapital", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "smihu_DeferredUnderwritingCommissionsNoncurrent": { "auth_ref": [], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commissions noncurrent.", "label": "Deferred Underwriting Commissions Noncurrent", "terseLabel": "Deferred underwriting commissions", "verboseLabel": "Deferred underwriting commissions noncurrent" } } }, "localname": "DeferredUnderwritingCommissionsNoncurrent", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "smihu_DeferredUnderwritingFeePercentInGrossProceedsOfTheIpo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fee percent on gross proceeds of the IPO.", "label": "Deferred Underwriting Fee Percent In Gross Proceeds Of The IPO", "terseLabel": "Deferred underwriting fee percent on gross proceeds of the IPO" } } }, "localname": "DeferredUnderwritingFeePercentInGrossProceedsOfTheIpo", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "smihu_DerivativeFinancialInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative financial instruments.", "label": "Derivative Financial Instruments [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeFinancialInstrumentsPolicyTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "smihu_DerivativeWarrantLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative warrant liabilities.", "label": "Derivative Warrant Liabilities [Member]" } } }, "localname": "DerivativeWarrantLiabilitiesMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "smihu_DisclosureOfWarrantLiabilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Warrant Liability [Line Items]" } } }, "localname": "DisclosureOfWarrantLiabilityLineItems", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_DisclosureOfWarrantLiabilityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Warrant Liability [Table]" } } }, "localname": "DisclosureOfWarrantLiabilityTable", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_DisclosureOfWarrantLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of warrant liability.", "label": "Disclosure Of Warrant Liability [Text Block]", "terseLabel": "Warrant Liability" } } }, "localname": "DisclosureOfWarrantLiabilityTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiability" ], "xbrltype": "textBlockItemType" }, "smihu_DissolutionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Dissolution expense.", "label": "Dissolution Expense", "verboseLabel": "Dissolution expense" } } }, "localname": "DissolutionExpense", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "smihu_EmergingGrowthCompanyStatusPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging growth company status.", "label": "Emerging Growth Company Status [Policy Text Block]", "terseLabel": "Emerging Growth Company Status" } } }, "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "smihu_FairValueAdjustmentOfFpaLiability": { "auth_ref": [], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value adjustment of FPA liability.", "label": "Fair Value Adjustment Of FPA Liability", "negatedLabel": "Change in fair value of FPA", "terseLabel": "Change in fair value of FPA liability" } } }, "localname": "FairValueAdjustmentOfFpaLiability", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "smihu_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Founder Shares [Member]", "terseLabel": "Founder shares" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_FpaLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FPA Liability [Member]", "terseLabel": "FPA liability" } } }, "localname": "FpaLiabilityMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsAdditionalInformationDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "smihu_InitialPublicOfferingDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Disclosure Text Block", "label": "Initial Public Offering Disclosure [Text Block]", "terseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingDisclosureTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "smihu_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount": { "auth_ref": [], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest earned on marketable securities held in Trust Account.", "label": "Interest Earned On Marketable Securities Held In Trust Account", "negatedLabel": "Interest earned on investments held in Trust Account" } } }, "localname": "InterestEarnedOnMarketableSecuritiesHeldInTrustAccount", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "smihu_MeasurementInputEstimatedTermToBusinessCombinationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Measurement Input Estimated Term To Business Combinations [Member]", "terseLabel": "Est. Term to Business Combination (Yrs)" } } }, "localname": "MeasurementInputEstimatedTermToBusinessCombinationsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "domainItemType" }, "smihu_MeasurementInputProbabilityOfBusinessCombinationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Measurement Input Probability Of Business Combinations [Member]", "terseLabel": "Probability of Business Combination" } } }, "localname": "MeasurementInputProbabilityOfBusinessCombinationsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "domainItemType" }, "smihu_MeasurementOfPurchasePriceOfFpaUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Measurement Of Purchase Price Of FPA Unit [Member]", "terseLabel": "Purchase price of FPA unit" } } }, "localname": "MeasurementOfPurchasePriceOfFpaUnitMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "domainItemType" }, "smihu_MergerAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger.", "label": "Merger [Axis]" } } }, "localname": "MergerAxis", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_MergerDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger.", "label": "Merger [Domain]" } } }, "localname": "MergerDomain", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_MinimumLockInPeriodRequiredForWarrantExerciseFromTheDateOfBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum lock in period required for warrant exercise from the date of business combination.", "label": "Minimum Lock In Period Required For Warrant Exercise From The Date Of Business Combination", "terseLabel": "Minimum lock in period required for warrant exercise from the date of business combination" } } }, "localname": "MinimumLockInPeriodRequiredForWarrantExerciseFromTheDateOfBusinessCombination", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_MinimumPercentageGrossProceedsRequiredFromIssuanceOfEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage gross proceeds required from issuance of equity.", "label": "Minimum Percentage Gross Proceeds Required From Issuance Of Equity", "terseLabel": "Minimum percentage gross proceeds required from issuance of equity" } } }, "localname": "MinimumPercentageGrossProceedsRequiredFromIssuanceOfEquity", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "smihu_NetIncomeLossPerOrdinarySharePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Income (Loss)Per Ordinary Share [Policy Text Block].", "label": "Net Income (Loss) Per Ordinary Share [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Ordinary Share" } } }, "localname": "NetIncomeLossPerOrdinarySharePolicyTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "smihu_NoncurrentLiabilitiesFromForwardPurchaseAgreements": { "auth_ref": [], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent liabilities from forward purchase agreements.", "label": "Noncurrent Liabilities From Forward Purchase Agreements", "terseLabel": "FPA liability" } } }, "localname": "NoncurrentLiabilitiesFromForwardPurchaseAgreements", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "smihu_NumberOfConsecutiveTradingDaysForDeterminingSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of consecutive trading days for determining share price.", "label": "Number Of Consecutive Trading Days For Determining Share Price", "terseLabel": "Number of consecutive trading days for determining share price" } } }, "localname": "NumberOfConsecutiveTradingDaysForDeterminingSharePrice", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of consecutive trading days for determining the share price.", "label": "Number Of Consecutive Trading Days For Determining The Share Price", "terseLabel": "Number of consecutive trading days for determining the share price" } } }, "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_NumberOfDaysOfNoticeToBeGivenForRedemptionOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of days of notice to be given for redemption of warrants.", "label": "Number Of Days Of Notice To Be Given For Redemption Of Warrants", "terseLabel": "Number of days of notice to be given for redemption of warrants" } } }, "localname": "NumberOfDaysOfNoticeToBeGivenForRedemptionOfWarrants", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_NumberOfIndependentDirectorNominees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of independent director nominees.", "label": "Number Of Independent Director Nominees", "terseLabel": "Number of independent director nominees" } } }, "localname": "NumberOfIndependentDirectorNominees", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "smihu_NumberOfTradingDaysForDeterminingTheSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading days for determining the share price.", "label": "Number Of Trading Days For Determining The Share Price", "terseLabel": "Number of trading days for determining the share price" } } }, "localname": "NumberOfTradingDaysForDeterminingTheSharePrice", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering costs associated with the initial public offering.", "label": "Offering Costs Associated With The Initial Public Offering [Policy Text Block]", "terseLabel": "Offering Costs Associated with IPO" } } }, "localname": "OfferingCostsAssociatedWithTheInitialPublicOfferingPolicyTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "smihu_OfferingProceedsAllocatedToPaymentOfOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering proceeds allocated to payment of offering expenses.", "label": "Offering Proceeds Allocated To Payment Of Offering Expenses", "terseLabel": "Offering proceeds allocated to payment of offering expenses" } } }, "localname": "OfferingProceedsAllocatedToPaymentOfOfferingExpenses", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "smihu_OrganizationBusinessOperationLiquidityAndCapitalResourcesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, business operation, liquidity and capital resources.", "label": "Organization, Business Operation, Liquidity And Capital Resources [Text Block]", "terseLabel": "Organization, Business Operation, Liquidity and Capital Resources" } } }, "localname": "OrganizationBusinessOperationLiquidityAndCapitalResourcesTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResources" ], "xbrltype": "textBlockItemType" }, "smihu_OrganizationconsolidationandpresentationoffinancialstatementstableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization Consolidation And Presentation Of Financial Statements Table.", "label": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table]" } } }, "localname": "OrganizationconsolidationandpresentationoffinancialstatementstableTable", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_OtherOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other offering costs.", "label": "Other Offering Costs", "terseLabel": "Other offering costs", "verboseLabel": "Other offering costs" } } }, "localname": "OtherOfferingCosts", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "smihu_OverAllotmentOptionVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Over allotment Option Vesting Period.", "label": "Over Allotment Option Vesting Period", "terseLabel": "Overallotment option vesting period" } } }, "localname": "OverAllotmentOptionVestingPeriod", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_PercentageOfNumberOfSharesOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of number of shares of common stock outstanding.", "label": "Percentage Of Number Of Shares Of Common Stock Outstanding", "terseLabel": "Percentage of number of shares of common stock outstanding" } } }, "localname": "PercentageOfNumberOfSharesOfCommonStockOutstanding", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "smihu_PrivatePlacementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Line Items", "label": "Private Placement [Line Items]" } } }, "localname": "PrivatePlacementLineItems", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_PrivatePlacementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Table", "label": "Private Placement [Table]" } } }, "localname": "PrivatePlacementTable", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_PrivatePlacementWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Warrants", "label": "Private Placement Warrants [Abstract]" } } }, "localname": "PrivatePlacementWarrantsAbstract", "nsuri": "http://www.smihu.com/20220930", "xbrltype": "stringItemType" }, "smihu_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement Warrants [Member]", "terseLabel": "Private Placement Warrants" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_PrivatePlacementWarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Warrants Text Block", "label": "Private Placement Warrants [Text Block]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementWarrantsTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "smihu_PrivateWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Warrants [Member]", "terseLabel": "Private Warrants" } } }, "localname": "PrivateWarrantsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "smihu_ProceedsFromSponsorToCoverCertainOfferingCostsPerShareValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proceeds from sponsor to cover certain offering costs per share value", "label": "Proceeds from sponsor to cover certain offering costs per share value", "terseLabel": "Proceeds from sponsor to cover certain offering costs per share value" } } }, "localname": "ProceedsFromSponsorToCoverCertainOfferingCostsPerShareValue", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "smihu_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note [Member]", "terseLabel": "Promissory Note" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_PublicAndPrivateWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public And Private Warrants [Member]", "terseLabel": "Public and Private Warrants" } } }, "localname": "PublicAndPrivateWarrantsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "smihu_PublicWarrantsAndPrivateWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public Warrants And Private Warrants [Member]", "terseLabel": "Public Warrants And Private Warrants" } } }, "localname": "PublicWarrantsAndPrivateWarrantsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public Warrants [Member]", "terseLabel": "Public Warrants", "verboseLabel": "Public Warrants" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_RedeemableWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants [Member]", "terseLabel": "Redeemable Warrants" } } }, "localname": "RedeemableWarrantsMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_RestrictedInvestmentsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted investments term.", "label": "Restricted Investments Term", "terseLabel": "Restricted Investments Term" } } }, "localname": "RestrictedInvestmentsTerm", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]", "terseLabel": "Share Price Equal or Exceeds Eighteen Rupees Per Dollar" } } }, "localname": "SharePriceEqualOrExceedsEighteenRupeesPerDollarMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_SharePriceEqualOrExceedsTenRupeesPerDollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Price Equal Or Exceeds Ten Rupees Per Dollar [Member]", "terseLabel": "Share Price Equal or Exceeds Ten Rupees Per Dollar" } } }, "localname": "SharePriceEqualOrExceedsTenRupeesPerDollarMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Price Equal Or Less Nine Point Two Rupees Per Dollar [Member]", "terseLabel": "Share Price Equal or Less Nine Point Two Rupees Per Dollar" } } }, "localname": "SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_ShareRedemptionTriggerPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share redemption trigger price.", "label": "Share Redemption Trigger Price", "terseLabel": "Share redemption trigger price" } } }, "localname": "ShareRedemptionTriggerPrice", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "smihu_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sponsor [Member]", "terseLabel": "Sponsor" } } }, "localname": "SponsorMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_StockHoldersEquityNoteLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Holders Equity Note Line Items", "label": "Stock Holders Equity Note [Line Items]" } } }, "localname": "StockHoldersEquityNoteLineItems", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_StockHoldersEquityNoteTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock holders Equity Note Table", "label": "Stock holders Equity Note [Table]" } } }, "localname": "StockHoldersEquityNoteTable", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_StockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issuance costs.", "label": "Stock Issuance Costs", "terseLabel": "Stock issuance costs" } } }, "localname": "StockIssuanceCosts", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "smihu_TransactionCostsAllocableToWarrants": { "auth_ref": [], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transaction costs allocable to warrants.", "label": "Transaction Costs Allocable To Warrants", "negatedLabel": "Transaction costs allocable to warrants", "verboseLabel": "Transaction costs allocable to warrants" } } }, "localname": "TransactionCostsAllocableToWarrants", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "smihu_TriggeringEventAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Triggering Event [Axis]" } } }, "localname": "TriggeringEventAxis", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_TriggeringEventDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Triggering Event [Domain]" } } }, "localname": "TriggeringEventDomain", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_UnderwritingDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting discount.", "label": "Underwriting Discount", "terseLabel": "Underwriting discount" } } }, "localname": "UnderwritingDiscount", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "smihu_UnderwritingDiscountAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Underwriting Discount [Axis]" } } }, "localname": "UnderwritingDiscountAxis", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "smihu_UnderwritingDiscountDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Underwriting Discount [Domain]" } } }, "localname": "UnderwritingDiscountDomain", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_UsGovernmentSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "US Government Securities [Member]", "terseLabel": "US Government Securities [Member]" } } }, "localname": "UsGovernmentSecuritiesMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Waiting period after which the share trading days are considered.", "label": "Waiting Period After Which The Share Trading Days Are Considered", "terseLabel": "Waiting period after which the share trading days are considered" } } }, "localname": "WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "smihu_WarrantLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Liability [Abstract]" } } }, "localname": "WarrantLiabilityAbstract", "nsuri": "http://www.smihu.com/20220930", "xbrltype": "stringItemType" }, "smihu_WarrantLiabilityAndForwardPurchaseAgreementPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liability and forward purchase agreement.", "label": "Warrant Liability And Forward Purchase Agreement [Policy Text Block]", "terseLabel": "Warrant Liability and Forward Purchase Agreement" } } }, "localname": "WarrantLiabilityAndForwardPurchaseAgreementPolicyTextBlock", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "smihu_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Working capital (deficit).", "label": "Working Capital Deficit", "terseLabel": "Working capital (deficit)" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "smihu_WorkingCapitalLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Working Capital Loan [Member]", "terseLabel": "Working Capital Loan" } } }, "localname": "WorkingCapitalLoanMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "smihu_WorkingCapitalLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital loans.", "label": "Working Capital Loans", "verboseLabel": "Working capital loans" } } }, "localname": "WorkingCapitalLoans", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "smihu_YsBiopharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "YS Biopharma.", "label": "YS Biopharma [Member]" } } }, "localname": "YsBiopharmaMember", "nsuri": "http://www.smihu.com/20220930", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r61", "r132", "r137", "r143", "r215", "r216", "r217", "r218", "r262", "r320" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r61", "r132", "r137", "r143", "r215", "r216", "r217", "r218", "r262", "r320" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r123", "r125", "r126", "r127", "r147", "r162", "r196", "r198", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r305", "r306", "r321", "r322" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r123", "r125", "r126", "r127", "r147", "r162", "r196", "r198", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r305", "r306", "r321", "r322" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r116", "r123", "r125", "r126", "r127", "r147", "r162", "r186", "r196", "r198", "r200", "r201", "r202", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r305", "r306", "r321", "r322" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r116", "r123", "r125", "r126", "r127", "r147", "r162", "r186", "r196", "r198", "r200", "r201", "r202", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r305", "r306", "r321", "r322" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r71", "r197" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r71", "r76", "r121", "r197" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r71", "r76", "r121", "r197", "r268" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r110", "r258" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r63", "r64", "r65", "r204", "r205", "r206", "r224" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r176", "r183" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedTerseLabel": "Less: Class A ordinary shares issuance costs", "terseLabel": "Offering costs charged to the shareholders' equity" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r7", "r59", "r102", "r104", "r108", "r112", "r132", "r133", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r215", "r217", "r240", "r263", "r265", "r293", "r299" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r16", "r59", "r112", "r132", "r133", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r215", "r217", "r240", "r263", "r265" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets Held-in-trust", "terseLabel": "Asset held in trust account" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Investments held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalUnitsMember": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares.", "label": "Capital Units [Member]", "terseLabel": "Capital Units" } } }, "localname": "CapitalUnitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r6", "r265", "r312", "r313" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r43", "r49", "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of the period", "periodStartLabel": "Cash, beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r43", "r241" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash Equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activity" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r8", "r9", "r10", "r57", "r59", "r79", "r80", "r81", "r83", "r85", "r90", "r91", "r92", "r112", "r132", "r137", "r138", "r139", "r143", "r144", "r160", "r161", "r165", "r169", "r176", "r240", "r328" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/CoverPage", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r184", "r199" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Class of warrant or right, exercise price of warrants or rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Class of warrant or right, outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r295", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r117", "r118", "r119", "r128", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments & Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/CoverPage", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/CoverPage", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Common Stock, Conversion Basis", "terseLabel": "Common stock, Conversion basis", "verboseLabel": "Common stock conversion basis" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r63", "r64", "r224" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Ordinary Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r176" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r265" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r95", "r298" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r51", "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Common stock shares issued with effect of conversion" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r51", "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Debt conversion, converted instrument, amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Working capital loans convertible into warrants" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r146", "r150" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Warrants issued price per warrant" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r145", "r151", "r152", "r249", "r250", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r26", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r24", "r25", "r26", "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Warrant Liability", "verboseLabel": "Warrant liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsAdditionalInformationDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "Warrant liability" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r17", "r60", "r135", "r137", "r138", "r142", "r143", "r144", "r256" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related party", "verboseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r34", "r68", "r69", "r70", "r71", "r72", "r77", "r79", "r83", "r84", "r85", "r87", "r88", "r225", "r226", "r297", "r304" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic net income (loss) per share", "terseLabel": "Basic net income (loss) per ordinary share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r34", "r68", "r69", "r70", "r71", "r72", "r79", "r83", "r84", "r85", "r87", "r88", "r225", "r226", "r297", "r304" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Diluted net income (loss) per ordinary share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r30", "r31", "r32", "r63", "r64", "r65", "r67", "r73", "r75", "r89", "r113", "r176", "r183", "r204", "r205", "r206", "r213", "r214", "r224", "r242", "r243", "r244", "r245", "r246", "r247", "r252", "r307", "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r47", "r155" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability", "verboseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r227", "r228", "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Valuation of Public and Private Warrants" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r148", "r151", "r152", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r228", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r235", "r237" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsAdditionalInformationDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r227", "r228", "r230", "r231", "r238" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Recurring Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r148", "r187", "r188", "r193", "r195", "r228", "r270" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r148", "r151", "r152", "r187", "r188", "r193", "r195", "r228", "r271" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r148", "r151", "r152", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r228", "r272" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsAdditionalInformationDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r232", "r237" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r232", "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "verboseLabel": "Summary of reconciliation of changes in fair value of derivative warrant liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "verboseLabel": "Initial value at IPO date" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r148", "r151", "r152", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r195", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r235", "r238" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net", "terseLabel": "Transfer of Public warrants from Level\u00a03 to Level\u00a01" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r47", "r153", "r154" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain recognized on extinguishment of deferred underwriting commissions", "terseLabel": "Gain recognized on the debt forgiveness", "verboseLabel": "Gain recognized on extinguishment of deferred underwriting commissions" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r35" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r29", "r207", "r208", "r209", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r46" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued offering costs and expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r46" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "verboseLabel": "Due to related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r46" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r36", "r101" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest earned on investments held in Trust Account" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r59", "r105", "r112", "r132", "r133", "r134", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r216", "r217", "r218", "r240", "r263", "r264" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r14", "r59", "r112", "r240", "r265", "r294", "r301" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r4", "r20", "r59", "r112", "r132", "r133", "r134", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r216", "r217", "r218", "r240", "r263", "r264", "r265" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r21", "r131" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r120", "r122", "r123", "r124", "r125", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Est. Term Remaining (Yrs)", "verboseLabel": "Warrant Price" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk Free Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Stock Price" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r43" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r43" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r43", "r45", "r48" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r27", "r28", "r32", "r33", "r48", "r59", "r66", "r68", "r69", "r70", "r71", "r74", "r75", "r82", "r102", "r103", "r106", "r107", "r109", "r112", "r132", "r133", "r134", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r226", "r240", "r296", "r303" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Allocation of net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r102", "r103", "r106", "r107", "r109" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r37" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Cash underwriting discount of the IPO paid to underwriters", "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Payments for Underwriting Expense", "terseLabel": "Payments for underwriting expense", "verboseLabel": "Payments for underwriting expense" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r42" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "auth_ref": [ "r38" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.", "label": "Payments to Acquire Restricted Investments", "negatedLabel": "Investment of cash in Trust Account" } } }, "localname": "PaymentsToAcquireRestrictedInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r9", "r160" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r9", "r160" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r9", "r265" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r2", "r15", "r114", "r115" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible debt", "verboseLabel": "Proceeds from convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r39" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Proceeds from issuance initial public offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "presentationGuidance": "Gross proceeds", "terseLabel": "Proceeds from issuance initial public offering", "verboseLabel": "Proceeds received from initial public offering, net of underwriters' discount" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r39" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from private placement", "verboseLabel": "Proceeds from issuance of private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "negatedLabel": "Less: Proceeds allocated to Public Warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromUnsecuredNotesPayable": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral).", "label": "Proceeds from Unsecured Notes Payable", "terseLabel": "Proceeds from unsecured notes payable" } } }, "localname": "ProceedsFromUnsecuredNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r194", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r194", "r255", "r256", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses from transactions with related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r194", "r255", "r259", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/PrivatePlacementAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r253", "r254", "r256", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r41" ], "calculation": { "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayment of note payable from related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r315", "r316", "r317", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "verboseLabel": "Investments held in Trust Account" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfFairValueHierarchyTheCompanySAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r11", "r183", "r265", "r300", "r310", "r311" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r63", "r64", "r65", "r67", "r73", "r75", "r113", "r204", "r205", "r206", "r213", "r214", "r224", "r307", "r309" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of basic and diluted net income (loss) per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r227", "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value Hierarchy the Company's Assets and Liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r257", "r259" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r8", "r9", "r10", "r57", "r90", "r91", "r156", "r158", "r159", "r160", "r161", "r162", "r163", "r165", "r169", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued, price per share", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balances at end, Shares", "periodStartLabel": "Balances at beginning, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r55", "r62" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r8", "r9", "r10", "r57", "r59", "r79", "r80", "r81", "r83", "r85", "r90", "r91", "r92", "r112", "r132", "r137", "r138", "r139", "r143", "r144", "r160", "r161", "r165", "r169", "r176", "r240", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/CoverPage", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations", "http://www.smihu.com/role/WarrantLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r23", "r30", "r31", "r32", "r63", "r64", "r65", "r67", "r73", "r75", "r89", "r113", "r176", "r183", "r204", "r205", "r206", "r213", "r214", "r224", "r242", "r243", "r244", "r245", "r246", "r247", "r252", "r307", "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsAdditionalInformationDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsTables", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r63", "r64", "r65", "r89", "r280" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsAdditionalInformationDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsTables", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfCashFlows", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Class\u00a0B ordinary share issued to initial shareholders, shares", "verboseLabel": "Stock issued during period, shares, issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r10", "r176", "r183" ], "lang": { "en-us": { "role": { "definitionGuidance": "Stock issued during period, shares, new issues", "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Stock shares issued during the period shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Number of shares forfeited during the period", "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited", "negatedLabel": "Forfeiture of founder shares, Shares", "terseLabel": "Number of shares forfeited during the period" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "verboseLabel": "Stock issued during period, value, issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, Forfeited", "negatedLabel": "Forfeiture of founder shares" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r12", "r13", "r59", "r111", "r112", "r240", "r265" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances at end", "periodStartLabel": "Balances at beginning", "totalLabel": "Total shareholders' Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' Deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r58", "r161", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r175", "r183", "r185", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/ShareholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r248", "r267" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r248", "r267" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r248", "r267" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r248", "r267" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r266", "r269" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionOfInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity during the period due to unpaid interest.", "label": "Temporary Equity, Accretion of Interest", "negatedLabel": "Accretion of carrying value to redemption value-interest" } } }, "localname": "TemporaryEquityAccretionOfInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "negatedLabel": "Accretion of Class A ordinary shares to redemption value", "terseLabel": "Add: Accretion of carrying value to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r5", "r157" ], "lang": { "en-us": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r132", "r137", "r138", "r139", "r143", "r144" ], "calculation": { "http://www.smihu.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Class A ordinary shares subject to possible redemption, $0.0001 par value; 20,000,000 shares issued and outstanding at redemption value of $10.06 and $10.00 per share, as of September 30, 2022 and December 31, 2021, respectively", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Class A ordinary shares subject to possible redemption" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheets", "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfClassAOrdinarySharesSubjectToPossibleRedemptionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r5", "r157" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary Equity, Par or Stated Value Per Share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r5", "r157" ], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Temporary Equity, Redemption Price Per Share" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/OrganizationBusinessOperationLiquidityAndCapitalResourcesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Temporary Equity, Shares Issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "definitionGuidance": "Temporary equity, shares outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Temporary Equity, Shares Outstanding", "verboseLabel": "Temporary equity, shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CondensedBalanceSheetsParenthetical", "http://www.smihu.com/role/ShareholdersDeficitAdditionalInformationDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r5", "r157" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "verboseLabel": "Summary of Class A ordinary shares subject to possible redemption" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r93", "r94", "r96", "r97", "r98", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/CoverPage", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfReconciliationOfChangesInFairValueOfDerivativeWarrantLiabilitiesDetail", "http://www.smihu.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants and rights outstanding, measurement input", "verboseLabel": "Warrants and rights outstanding, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsDetail", "http://www.smihu.com/role/RecurringFairValueMeasurementsSummaryOfValuationOfPublicAndPrivateWarrantsOfFpaDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r78", "r85" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Diluted weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r77", "r85" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.smihu.com/role/SignificantAccountingPoliciesSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail", "http://www.smihu.com/role/UnauditedCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r323": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r324": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r325": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r326": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r327": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r328": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r329": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r330": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" } }, "version": "2.1" } ZIP 54 0001193125-22-284524-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-284524-xbrl.zip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

/SWOV^6!Z&L!&+ 2!M24.FI5]*=:4!VA19%D65PO\9BX.(5Q: MW%,[^8[Q2L\E):AK6_C_!_/PC$9*%E_;-C=ERAHE=SNY,@O&!GBTNCSR8(1> M)O3D&$(^!.$B22+O/J6@PEUXXU3TZ&V%T#-^,<,FC-Z[%;T7 ]TGS:7@+*_W M5@[!,FJO47M?Q3:-VKMW\FQUM; F5-XF4T[7,O;12+QM2;P! MB (W3(D2]UGDM6:?):B:U=L5NHLMTIWZ-Y9LMGLV!!:=3J)YZK=51.. Q>0YYC0J?OB;S['G% M*\]]%:.+0&UP9E2D8,:N=L'[X@4=ZZ,3XGV+-0#:K_.-W/MP:\SP0'"#$\=[KD5P@8 GA M1NF$SXH>SB)-1!?L*[[]_4OY ];0(KNZZS.'LAH]*ZE%P]\M$7M._R]'=XF M.0K?#N6ILJTPHA(34:B3-7Y&O5SVS2XK(HE1*;2>&599"03B!82$'_ 'D\0U MP0D;Q-EDYWMJQ49$%^!(%S&@@07XC-:_Q)T[D=/C(WQ02W*2:&[[T(W ]\[:L7Q,RA# VXI.,E#O?,#Y]E)1B')J_G\%3W M:MQL@/O"\EHZ'^ JX1A@@G_+Y@)#XM5,0)*NJCV/#)A4541"C";IY,7B3].: M9DW3VQDM935\;E$;W(K&*/O8\[;7-4UOZYO>RA<%J>]/"_$9/7$S,.Y.@]P% M>MYR.V[NBP=O-E+*==[?@5*NXY,?EBW0RMTVSV?SZ.SS*J&#LY5BW-)3*) ^ M8YR=XTFR3)"T_D'3CP,T!L0-_O=-[^C-K&<+1.=_ZH&0S!N6OT3R.6.;5UG5K/<(2UXE;_M>*6[JS>6P?XWO,K!?S[M,/52[ M)?EO,@1NA/7NO#GCTX6D-3KXVQYOW EO<[ M@"T]NW]Z9'=[/8,MF\&6GH8M2S1!V2ZVG'4']FG_Q.#*EG%E%SA+'Z10]W3- M?,5XE-JM?G[(RBB,3VGWWF5@;V#_&M]E8&]\2D:H5PGU/V@=S#UT 'QP'K*T M62MK;H=[J9''+*[;2_A<!I< T!1_*+]I? M(-5,P]P[.WM/"7*#YOCN$N3. .G8/CTV]+@#]-@&5VKKZ7'W@60$Y,X3Y,[P M_FT2Y,X :5L"LLI[8'J+EO3<;$N;Z5>R38,7!B\,7AB\,'AA\&(7IC*80,C& M*E_;$0O9?(I3L1&HL";;[,G__?;#5SBWK[3>]=B0I>U1]QXFW0XV9]IW[\WN MTMAF$PIW@\9V#2:&QEI!8VUPN+>-QO8&)MU.MZRNQM!82VALUWCV)FALUV"R M!1K[N3 *2C,GASYS(GK6(]JCWY7QR<,!5?."A%G9G]?4K>S!SQ_1@),!067Z MA/]D'1_5]PD?K*_C]FX^NF_ZA"_TH)J&@J9/^&\X?XBW">=P,KW"MX>.K[GK MM.D5OHNG9GJ%KQ>W3,=;TZ]XMT_/] K?Y=,SM+?+IV=ZA9N,B14R)HJC,TW' MB-U[EX&]@?UK?)>!_4,M1U;>^U*V%^R%W3/'G3[]G%I8;?):-PDNNQ"@]^!W3\ZMX].S@VV MS($M;QM EY:D45>B2PP;_M\WA[/ZN=B]HX%]=GK6/-X<&,19#'%:PF?F0YP> MB*:^/3A; \,Y,#ZGW5%035/QG7Z7@;V!_6M\EX&]\3H9H5XEU$U3\;6V:&R3 M@ZJU+1KW!TBF9^K.$^3.M /=)D'N#)!,4_$=H<TH<==H,>=8?W;I,>= 9+I*6YZP9I>L*9'L,$+@Q<&+PQ>&+PP/<5?91QD MH0K9=D1$6MLNLDW^_+:TB]P[F'0[QZ?[[\3971K;M?:CFZ"Q78.)H;$U9>\N M2&1M\+O/BU#SY?0V2&W[!YQNIW^R ;)[A5GS3=%="QEY>^AN9X&S#;K[N="" M'-^&\/:"U,G>G_O&$H=(/1C :,R?(:\*N7.^WX2^-WRY@X-[[P.,YU)6WE@, M@#9!"SU*66/&L&Z@YWJCZQ;ZH@W(MF2H<_A: &!X?+[Q67E+^/D]+#J83BJA M='%[:9T>=:VA[T3>R(-G8H-E9S@,4T22!\1Q(),AX*3C!*^+/SD6DI@3O/R_OY[U>Z?O8FOD!4XP]!P?MB%H,2;/Q"0"[(B\>WB& M(Y]"7"1YA%\>X93HLC%SXC2B^^"6<,CBF-94\MS<4XKWAB-X#2S9FH2Q>(_S MC046/(I]G[ A.DF2T+IGXGO:#%X?L22-@H[%FT^',8-K C;R8!O\^@P"=O$5 M^O&5D>_"^#).XX03_#WC_QV'$3OTO6_,?SE,'IW@, C%%4DHKQ3(%,/-<(BP MT12X(&S;H0(87.C]"RX 1[STVP8HPO98G/ 39X'CXX-M'<$(H> J;XPN*2\$*,*VAWZ( M1T?W)9$3<(!VK&;I8A'VL1F& M'%#LWT,0&X'$=/SFTGF!A5E7L0\PA+.\"@CJ$3^Z9R]YE)>,&)PB$%)&UX#3 M#ZE/KXSM/+V#:(05);"Q)X\OA%[&J;X#'X*8_2>EE5?<&;&1S^G-R]U9$^ 'NVX!2[-J';)T4% MVEIO,9''B=S8>A_"?ZRW2 O][KM/%[?OZ6/OW0%PCS@%Y"Z][?>)"QBN[KNX M_5W=UKBPPKT<=D_$ ;K [M/B'3[[_"C8$%A /052XE]#3N/K.L)<1[K[6UZ M#\\'VFE\;4>GW<-^5_0AH5=_ ")] I;WQ+A^\@_FPD$]B!7#.A/4V6-D6A\! MJDG&AJZ?X2NR+]:YXK/>\>&16G'CC]J'0CO4 M&+<7Q,"!B*!0B_A];<@E%L=\CW09H;\*X0ELVF5^S(5!!&+) Q$4LXD3J@/3R)D (7 MT;%&*6P ]@%$B<3AHF45A?%$//'>B3U0-DDJ MP-F N:X(2<3.*&QE^"AW3/@R40FY0OHY13%O!X-Q 3&HSQ3H%$@)#AIL N# M%YMC<>,0)/F*R\N#\ID ].AP0*+RF;%.:3S: )\X]>$W('Q@&YQGQ0A!8DTC M/WR.]]\@^K5$Q[\'=L^>F. \<,XAJ0T1J7;^BU" ;.L^3>CZ%Y9DJ)LS/BAIC77Q>/ MOX/WR+A) 9P7\76P%3!6 MAD?Z\S<'[';* (D:&+[+MAY '4=!!W3S +I!S%V^S"5?JXZ^L^%Y(^[\!.HZ M0A45NU(&V39T7;J77K];C:P=ZZ,S?"24)=+W8J%8! !3;70.J!>@]L(BA4J, M^ESC6E&(J9*./Q+L4"PC8BYC8YHN^^Q$D8->/UKT\V.8?<<-"5_85A@F0/=< M:$W2:/CHQ&SVCO)$V>MUCKN9#6!;<7K_)WD0P8IQ_TSC)/,_BB4(5^$](^4N M"\S-<+,HP%Y9#6YH M\'C(!3$P$RDLP)]\[S]HEM*?;V/&+-(ZS@XRQ7$>MS,_@QOR1+ ;W^$:KSB, M>"7-T!+Z*7,O -+XJ%N&#GY8\-?C\T&O.^B?&?6Q2GT\$NJC.!I+G&0./L>.S^3WI/]4ZYGX_43L\HESXE[&:^")PB=G$NN8*_)SSG/GR+JLH1Y?PI1R.5(%;(.LX MC/2+OS"4$NZ-$R4O=QC@Y/N(W[_HOS2MSIY4:[/3""CW6']"ZC)U5'.IO?.< ME%2#Q<\[=U)-:,R5"G/E0=C<6Z@3BU*.YC5&RI3GZU$1M+MX($W33<>Z&N48 MGO)2"2T =>AZ^8]<-@N%JZ]O1#8$?E]#G+HV\AQ&R2/HQC'75VON:ERGQV7D M,U, 2H>93B]^$]Y:V),0:1)L*$X*JK1#CD[<#G<.6W%H^2'FJ)#R_T)!AT>& MKF:>!"%P!;4FM,PSMS%ED(#BR%B-QU0;PCQ/#5B)VJ ]8?7BNVF]KECR)O(# MQ;A.:P6%8($];D8UZO6LO.*3_T]%0245XA6WP<:Y:L-[!H2.U8;^,Q@[N$/Q MS$=5RBA'IG:[/[RS9$G? %>LM6_L'0]L2_YS\.[-CY48U1MT^F=X=VZIG9/3 MDM6*K]_I.JM%2BLLU+' 6@)6]M*@ MAO?J;&N5@EVTF_F!,S _>0P$4P#GYH7SR9;[G&M&L%H580LH+JF9K#$@F0.2 M*YYBZ>)6[K.)I;,D=L8B^"?X>N9FX5'8+%$L)8?K/4-+),8$4?$]F",96R_) M>>8_U&5C5:D4#05/9IO( V,B5YK(Q\)$%H=DT2E9^C$M9"LO#\UJNWDG@/D) M6Q #C^"1AJWX%[:T\^O ^L"&9$)P16O 8V+=O*]"),Z)4(/DH"N$Q/CWG\+H MED5/8'D5_;:]_M/[AR7 U5/P,/DYR &T$X.N;\EWHG MC>X,$+"X"R\Q+_J2OUJM3@,IR9 M$_&H3 T,TT'GS[#^@M9U)9>U M'"XO3CO-8O_@M$+.U.$^":%E/,H:B]DI&,\IQ2GF#"!^!GC%+'CS2Q!. Q:= MG/5D6D8+FT=OH;WQ9\Q=9-TFSEZE0M6B-L,4%. \=1J2;+A[!0 "#0P[D7WP M(N" 8?0;3AEC\\)8WL6A%4?)'>:ZT(.1V:>.3S!MPU%D&UN"#K#&ETT?A)?! M#Z0;!X45B!=UK-\GLPYB2F6YY=D\=R&@^XAY6,&QKD8[;3B456+#\YIMSUBA MJF5)C11DBW$8?I@B6Q]_ *"SHO9*SWZ.0$V*8J'"4LWEH>/[8<(K6KEG$0L0 M1':02PSSGZDOXDG]01F_C"F5VV4K\DO9O8*Y>'2@QI%F)1!JNM_'Z=?^0%*V M^MPF-CCG08M:C" 4)?!4@,252S0@)\X+'4[^S&TM#8J"DJIVB9^U.L#YS[UC M7? 6 5@-(9^$09R'$ [*1J\Q?'G+)HGNX.$"M"]*^TI\/P5<"9^#F5BRJ$&T M?]RDN1YH"\)2>0N6,2YW'Y8+=+:?8:2NP]];4S5TI[.&<#0"=3.*16=2+M^% M]4OVGTN)$VCF"4T7J1O;[2##B9GO6R+W&RC7BXJ""6MZ?)%*&1.G>'LAVN-@ M4C!F:2Z?I(E+?OM>/ ZDG^AR(&W2NGMMZ^UW<:,WRJ73J72<,C=.31)SC+63 M@$2\>PE/D)^GO( 2JIKF5*U+F>I7YDQQ#\E;)\X\*VBY\J_A4%')CGG3BS)G M2HPU>6'TX 3Z%X5K5&(D-F4Y$+E8+W59N=)ZT/*[0;GXP!*,V08\5['R^!I3 M7U<\QJI4\_Y4JCD2-RF%E&TNDI\(1$WG),T!\_+T^OT!_W2F_Z$ OQ !<)7H MNX,<$98VI"Y V.#% 29: \(_'"]1FO(%\M4_4*F7T-+ >1$QA+-'FOB. ;!W M/(W A3*)>MX/]/_VY4"EO5G4?P,=HT7_O4H81&U7R_JW+7CM \I"SI. X8O. M-)%(^H@]D-J.\ \)[B]Z'O *8I&E42%H)KQB,1\N<)Y4]3M&LJDM@7PQE[YE M/D#T9<$Z@:)X"ZELC9,(:YB3-5 Y9B?+5I*4HOP94.(PGL6I6:@NVKX-0SWL[WHSG%L7XIC6:J.61-P=,FLKH(UI/78&97<[_> M3)";*!Q[,<#WA>(/I2DAV\AHT!1<()I8ZK$)IJHZN=)P*R7WU0P]#5OC7*G. M#I^ ,BZH=U6]UI9!!X$S!P]L46![4!5MX^WUTEAH:8XU"2-=7U?1[JPJA8)P M,2/8"T]5X_P&\YIE7SN!9?=@6I O(B5M OU-5"B&[W=3JCFD!8LJKTIW1<\* MHXIZ&QY>))QZ=K+6@Q3HIZJQ:7N&2KI3Y3*IC?'+$+X,TUSX?CC$\[X+;[BC MYWHDK_DHX#YG)EQ#:-*K+EU!!BS+[;."812 2)$45W7D?B1OE^XK_5Z)4/DF M(H\.0XL%[O6+%4Y@52]87 = ;!.IB=3ET&?:9.-R(N"RPBH0CFQZT=B6:TI'>!;KEX$+2H."Y:,Q6K)>RK.IWSMO M*I3M6Y6+YY^D;(HTEOD[M<^5T M)JQ%QF@-$U*,7IX!;Y49)[+225BC$4B\,'#N?92COFYS%)6'HG *2* HPHC M>8MJGZ#19:ETU!4%[1"L$K\)5Q? P@.@D9X/;PR&WL3Q->.@YAFY]C=DWF)S M=^?%X9Q7-'KD K[.VRD;0\25NT*#FNI_I>7L#(>@440$5+)ZB6L-><\^SMZQ MU^B3L.Q<-G)27W3OD<=&JZ>88\;R>*\N6%4"G,'BC5=RYS#&YJ_8E!4W9..W M0MS07;R]..E%JD7J7*"TYW<*9>+G4O8(S<04E_I%D931)9F8KX!&12:TR@:V M"YJ WBAJT9BKZ.>FM03>D$J1G=NB+HIH$R9C&%5]PN8_ M_L64R-)^%K*U%9UUUO1$_!HW?OKMH?.5,0";M-6$].W2R$W6OBWFG8B')*&D M W"J$9'B$E1;#&>1M8)5C9"J:FU$#$VZ$BEGK3HKC;1![-=!#NIZWI&RNU # MLDJ!GK,)60I5_1ZF(3J''K],JU\>4>O]O(23V^O M^[77%V(X^[RM$_IZJY*7/J*>5.Q1J?TD7]B8Y#ZMDMLSSU'8CYI9UQ;W+<>P MN_E49NL)JR)!=U5]R$>.%_%O9:]W$#0DR2)&OBR,:5"*1;%3M.EBT_HN-GW3 MQ::^BXU\40 F(Y_ Z5'U!X?HC"8W&1BWUO%FWM8S@]K6,\O'OA9 ^3:&OBY< MS+ #PXB/1Q'U:-8GQO8X C:%YM-PN]I-?Z]K_FC%B<-![WQ*$.%!H*V!#4 )K<> M#^M9E"EB6VF"'E$^N#"/L;&HH"076,3&*.KC=(*"6_V&D9W2_(Q938'+[(U< M7J".!*1@#!DU>71>A'81BTEU8,&,6#&OP1D.(]1%EL,.X'!H7?^=&K;[%X&; M/^ ED:=[6IH-VA;D&50@#YY^J\!8GE3;%C">5WG8!=*7$QFBL+J$"D@)[@'0 MCFS=S>/_E4:W2+ZDW@J=:95!Y\G+#.[<#E//65$YVEC[L TJ*QJ4+D*8Q4C 54] \8<$(OPB"TZ8^O7;(R]Z70Y M%U!%:,WZ[#GWE,Q"?._3S87VS38<#+5!H9FM"C17,7G$\I:AW+.O=HBYV3,C MTW(VK02,-Y77GP\L-=?/T#[J'=EG9_TI%LWW/H>DFG?U:Q LO:Y]U!_ _\ZG MEI^W,VQ5#YP_/D3&-1_5UT\31^&[KH,J\?'^1?W. \N-:J%VOWMNG_>G:Q#6 M>,!;WG/?/CT[ML^/>C.PHF/]KB)>:@@T*!D7MY?KFAPNQ[!3IB:/5N,)R*3- MK#NY0%=$4#>DA.LQJ"\\&XW:M7@.J?5B2G42,4?,2 /VAFFZ]D+O&&/6-*6\ M#S'UWY4Z54YYPJ!81C_HQP+M##\[LC-0E@ 0L<-Q)C%Y+"W_,,SAZEA_J)R1 MQB&>7X(.>;7FK+FZWN0QVZ.M#5_B5;>869>Q$ 370P 22+5_+ H$U5\R/T"X MLSZM8=>5N6:UK]V*2I0ZM$:A[U/RKY50(&X"/(S@H"&B%W".2$U2EM1OJJIK MLF:I.+Q;, X_$P6\S'46=:*)CEQ&U#_*'FX8M@ -4YUO:'*0-7N>/2 M7*+AHVPVH_&:A T? ^\_J;A)%?=BC."_G(I=T3N"\:J%/..:WN6TYN;1Q!LY M.#U[]SATF1^+=^%6QMET[#]3]X$^4#8NV(R\W^HD342-2GB/MBZ=(UZ2!MH7 M@'C?6")JU"GC]BGTTS&_4B_ &D64'S+$2A8,.7&OC;B]8]UZP)-& %-LX,>> M/,'J9.ITS,#L3#R>],L/@-8WI)H"T>$+FQ5D4[;+F!\'8_:W*CXJ"!H-HE+_ MU[[!]BZH /!A]*(/R6<&XED@I^HU5H(7? F\!:WHX!SA)1#X;[*/S&L#EOUL! -HV(PS3"6W)X.ZVOXN0-'X%C]?1M M%RL[ZKP6M\-'YJ;8SE(I8Q=$UA>!J^EW@N&ZUX'BQ^^18BD78$TSS'>]\*2, M61/#'.%$,.S1Q\].&S56RNW*F' %ZZWE]?8*G/FG&<5" D[]%7(A]$>LGN-D M_>5_?N8@'S+?GV U:_! M@+^+1[,K0@]VX=>())+[JGJE7\CLDXI2^>=)5-5 MCGXHY$8MAE#\!8?P4-^9Q/"U_*1^R@'@#=]45 (U[6>WD$]SK66_N51,Z6?+.]5W_<(&0V;/QT9B4[;G6O>\, MOXD<&GZ;RO!ZJ\GNWD&#F]DCN/0-7$KA,F@>+JO0.^?9E00/ D=7CXX.9; %D7#$O,I<&<4B)J&M.5,RG5=(;4RH35 &U+ M?XL9BJ3\%()U\V)*-7;/P+"E-L@%LWF7@?VVWV5@OYYWK5&D&&'12"NC&>Z@ M3MIA\%UX1]!9T;0O__V >':H!'_GKVZ;!"X,7 M!B\,7BR%%\9[O%Z'0!O3S[0QN<LQO$#?>WUK[8V%-N(\F5R2END*\AWY8YJ)IS-1D:W95-&QK=+6=>8R+VR.[UC^RSWMZ+ M6.,8W$$+^)5LT^"%P0N#%P8O5G ,PK_8Q#J_P:'/G(AV_XB;^Z[6R*51LS,P M3%]UU5>]>@Z8::MNVJKG?V]_[_,U/GJ5H(9IJV[:JINVZFN$RVMMJV[E./?. M!C1WH,6ZE4D3T_YCB^\RQ]"*=YECV/-F.$:RM* ?>Q-DUI;<]"5Z'.O3EO:1/J2.G=O_T>/L-10S2U2'='J4\&+QJ$5ZU,TR_NW6&+8BAYU6H+9#+OL20 M7LDV#8H8%#$H8E#DM57B[(FKH8U5.4W5XQA_7SO>98ZA%>\RQV"\W[L@DG:I M+?P^N8?F+=UHNX-[ZWVV3]K39]O@9_M\X3O>]>\ 7N&ORU0#'<;?PT6 M[H=FN.TF\@/[O#^PC_KG>]U&WFAM&VXI;YA-"U6V7>[5;?2U5ZZO[3+R&A3< M"V5MNSWG^_;IV;%]?M3;^Y[S)BW6)+29G$>#(@9%6@&[5[)-$XLR:;%K:E:_ M/FW>--7=5E/=MGM[-I)AM5=-=0TE&TINH^O+M+ WY&K(=6?P-"IWM\_^IP%;RE1:WP<8Y M%_(] U417L>9E[QP/;DO\LQ0F7XKTDX?//+';71#T?6 M)>KU5!/@E T"*$&5 L'+OOF=8P\01;\>7=!JC1%?#>_"G_-1TU?<*D$CPPM2 MA\P2S_W?-W?PN%OF,]*WOQZ?#WK=H^Z 6R-P(7,ODL)%%Y,)"UQUZ=?>FQ+0 MKL_]OB-^=./7Y4\:ARWP M5B9OJK\8QS?#X=.(C8UB<(A M8VZ,,SD8V-JN-8K"L?76.^![P&MBAY,HFJ^Q]1;,QN&CY<4 D*&?QG 3_A@& M\ I,>5&<(.QSN'#OX(&%-'L% M,"9#&YJDXC+8Z1BVX>*$%(E;XXP>;!K=0H^$+QRX(GC(CDL[Q; .[K$5I_=_ M DO"ZR9A''NDX#"7C2>$-V\3^!1&> /[3^HE+P<<&'4[MMY.8.U.@%0K;BKN M-F(^^6[RVTYRA*1MEJB#XRF0G3>FG>EC8SB-%!H'6,\ R 0^QB,611)W'4OO M\Y]["\ @]VLO]ZL76!?I S;A1:JUG!&<$)Z3,WS4&51Q$?12_('3!P*/QN#$ M;.)$L!'_!53(&#>$/\%R7>9VK$^"=0 DO="U0%; !;=LDNC#=;K$0/IV^>;Q M)4"V>%#>R)/;SVT/-JP/@[!<9 T<3Q&PG'6HHT.N#I\FH*CA(:>!X_Z9XLH/ M."[Z+(ZMI] '74[N)8B%\VXD?5XX""BP\%LX?6"RWQARH N:'52Q/WI8]5PA M-D6O?.^$&B[P1:2,>L;844I73ATMN!R5-X\W_K\(7,WU*$25>QTH3R!<\%L8 MJ&E&[W&8T;\D6._8\#'P "8QZ3BH'+P'FOU6<&%V>U^[Y+[LWX7:8$Y^V/"" MY2M"6#QT)DQ%!)H1G>T0,O4OXO442*18#M,P JK(!5*=W_G1/'I-A1&6 MDH:*XA=ZTT\\QZQ\4-#F0B#3 O'G^PB,<)0!2T9UZ@]A+0\RYSBEO*AC[*WQ M&+==13EOYN*N9B)N1H'YXL7?K$\18]87T%&632F<\RR:+,%;Z)4;>=GBQ4A2 M(P1-^PO>$%^#$IF /4*!?F4;DB0L23[0-/;BU7BL>*I7R(S J,7#U;7WXO5W M+Q.F=0=:2?7/9QQ,X#5ZRD%_[I2#HT[WJ.GRHGG1YH>%\:9]^+C?R*]EWNPC M\OVRAJ7]\3&MVDC[^:3];1(.OZ%#8MBTJ"\>Q 9$??&5 MJQ83S_>>-DGY6W2(TVENA[W]?OOAZX1%7VD=.I^[^NW3W)SNO'/6WQ2G*\?2 M=6&_P?LU"?@]P?O35N"]L>/W0;)_C)..=<>BL?5%Q6O?_CN*#XQ)OTM638VP M__A]PG"$'Q[R=MC>OYN M=(3Z+ 1*._@]".]C%CWA>[@'AL%!#^$ND8RP4/9!5GLE#C"W@NUF(%0E[[W+ M:20\9MQH &ASZ0P\+0'U!Q[DGT3A$^ATL>5@OH]VK)C;,'QT@@>&V7@E"5/% MI$)7':SUS$]6M7:$H[6T7"(GSJ=1R;P*4&N8-89=/L;U24N4U(-Y,CD7 MS;%8^W$WF[&QN;R-LZ.-YFV4G<,RF1R\TJXZV^)X?8D<:WSTT;ZGB#17!K-R M9'SUI50M:!_S&[BF1FD*Q7$,+3B)%BWE52$%U]H-5ABLT':L, '1XG.Q$W@+ M#F/^Y@%& =F\ K*Q_G>[XZ'^E!EJ3E)1^;!$ ?2.-X8N:[ORAY<\3ODVXKQS M(\Z[0A2'HF=MIF/,:QLK:'!MB[CV2F;$&#QL-QX*!-Q;_-MR5'YWM)DM>TK!C#_[YO#V0-@>@/[]'2P=VJ80=E&47:=BMK6 M4?6@9<.*-D<\^S)HXY5LT^"%P0N#%P8O5IT_],H3^A>>7HR^@7_)4,NOJ!I9 M(L0B.VQ@6'-MV?EER)@!X7L14M^K8* CRT*CAE;(9&UJ[95HQN]9\$3_MB1C MV# HIC>J]R3E%LD:\+T=[N:6NX'F\#J/O._,/?POB\(WTBLT9;Q8*PFJ5I#F MLFQE1Y;9!A"_7NZW**];'3K[R_VV'?3MV?WNN7UR?%([?::]"&G8GV%_AOWM M*OO;6J[!JV%[S7@8\ET.2E)^!Z<\Z7=CKH?O):Z'[YMQ/=0D*#3JWOF@E@YR'JD!5E/5*FS<4\TW]VFQ2QHU]?? M.AZSY]O;DB+?UD25-?/0UN16G1[W[.YY6;K*3O/2$L1L7/H?K"9U#(,V#-HP MZ)8RZ.UG$AK&O ;&O./9)5MT\>2S2W#THR7['YGD$A-?,,DE:XDO&.]-V_#1 M1%<-]S/1U9WE?MM.+CDZ/K./3[:CU;>-J^S(,ML 8L/\#/-KM4_#,#V36&(2 M2UZA5WK/M[=7[H>5?>ZGI3WTC6NBY3YWDUC2:AZSY]O;*S6^[2QT^_Z-$WO0 M*^M79SBHX:"&@QH.VG(.ND4GR>OFG+.:D&YW]O>N-A3)IVVH 5:%W(W]F-6Y MKMG$JTXMW)C+N-TF^>8[DK9C<*>A@1VG@6W;5.>](_MLS/S+^<8(MXMT=47F:2R/H:R MA ]ZM>7\K9$UE 8Q6I?1OO1PX&XK0^0-9:VO 2$7'\%D*,I0U&X$W U)&9+: MV%/-\<.5K30=F/N M]D9K)J[B.&65([9[6F/,WJZ:.U-I7V?V,:#>4;>L4&+C"IG!R7;@Y+8S=(_M M?K=G'Q\?&Z0T2+GMQ-C>P#[M]>WSDZ/U8N,Z>NFVH=W-%OWKFVIWLQS06U.* M.]>F9A?LFNV92N/:2N/]UJ1[=A_$Q.GY60OZLC7?8GX>)%YKX\K=VM+NW??8CPY[=N#?AM:8NX6G]K#+>TN(WI].S:L=X?](O;9V;'=Z_?VC>EN MM4'QZ^A#G,] U*TH,P;-.PS=UWEQS;9Z<#^-]V?-4[P'UV=^4M/0C#-PW?W&%? MQ[%]?'YF=\_*,I)V 1--V^#6)+%L,(NY)O]EC_H4;_!E99EW;UOJ=C[5W,[G MNVCYQP#E_WUS.-,-W>L/*EP &T&_ T-$AHC::P?.1T4G8 Z>=QO/<)V;AO:H M*;*AI"U0TCHM@WGET.GYJ=WKE85#-RF'MEQ9V+HHYVYJ[G> S?&(15AZR%4M M68$86Z,H'%N$^J)E"SQ(_[O7L(K?4)_450S>#;YL%9[Z&TL^,)+IWA.[B&.6 M*,XCV*U[7>"DL_BN1(08GOU*-?PS^Z3;L[O=[J8X:Q'[&M-.#"6]2D)J??^5 M=F*>(2(CCMJDX;=+#M7W93%#4K;/ MR@"CB?$H)@]A(^.+A1\Q5X&Q'[D!9D+E+OH%6^C-,%-<#8VTU^57DN#=.S^W MST^W%M$W]&'HHX6)O*VB"^/":[5)V;HIDP8:QAFRFV=EH&$P=S?/RD"C$4?> MSV5SCH<^B5(D9F6&S3!9?A>.($+Y83 M./[+?YE+7SKJ(OC>M0!Q6014/DSQ.S+0.M;/.>2LLOLHI2.^"%QI,'DL+DGL M@ M^"X,H9_3A_3RA@PT? ^\_*8OOD$#O@&#>^^'P6U43J[Z6W-'_^FGB:"DE MD'*W NPVG !M\QG9)1]/3X?]+I'W6,X' V<:0(/E. $ M7L0B_P4V9L6/3L0X5.6X#BIYB\%4!$P8PS&[EG,?X@D'_.Y1Z/OA,][LD46+ MM7+$@#&G=A*%?\)"Z,* )9:#\(:?U1"0EVP^".'#S<5/TWPE1SKPH]@N0=_R MW.HMKSX3?NU3W$DZK'E^^^G)1N>W+S>M_73&L*->=WTCB#]%M2?V\34/NL&U!:]K!'0%MC.#)""#KZ%[PAO@8E- 'M%(Y,"^N0!*P+ MS2RIBG\MON,656C" ?T9Q:ON7B:L(BSS=<*BK_04/4#3G[^C7^>LWX;83//X M;C!]%4Q70UQ[^X/IIZW ]#9GVCEYWR(I9D:0SQ#D@M+6(,K+CV/MXKS\M>MA M=&7OVGVQ_O'[A T3YMZQ:-PHNQO,S>ZZG=[QABJGZM!TG21@D+^5DGYMR#^_ MK.]V3AJ?9;HL?AIK?1^$_,)_&\&T<8X3DW@MX:.'MOZ/X8/\L M^2VW5]HQN1\GP( $[[L+)9YH:!(OPQ'_O2P7;'ZB\ZNR[?<9]YL7^RW#_4'9 M=#IC[1MK?S5%X"8*[V4V0C@J507VUP>PX1?NOD*@8: 8R+76"@0!*8;VY('3=/Z_ GD8] MFY3_UR.)$!08NA[!$Y%E;8/S,[T K]1:_^#% M0]A08D5.PHQIO'OF0..FL<2(+X 036C^\[.%0>=\0[Y!8P?O/N(W;@=O#_%! M'&ZH$5E@3H^CKSA;K:^>O)A,6.#*&LK!U]Z;7^:LI:TOH2WOC5YH MC;[YTMEJ2MMQ4K[+E>;R"M-)%#YY+M;W6E$.\(BP0YIT&>='7>O,/M45HVC^ M2;*B54J_^!.P@JNJ\G[1@N RHF^T.JW9\N+-%1F?G&VTR+CL')8I.SX[KB\[ M/M[WTN#F6IZL7!&Y^E*J%K2/=:TY'MRB,]"74M^?;[?)ZX M!#]EBH.36%.EU,OUQF[4_[>ZS[^]749UMT9#74:75+$;:C7:MT_/CNWSH\8' M@K8JG7]WR'M+ILPE629YPV3)^'O#O*21Q^S2"&+=$!\(;M/?'6XSYQSB_JE] MTC]OGNG,F"^\P:;%BZ/NLI2S;X-8]GR;C<>X=S?G+#_I15_T%$Q_149F#81N M:VM-GTQNV%[T[]]!63=#LSXY/K,'O;:USWBEJ335&J[)J-EH8L'6%.LC3;$^ MR2)<>\%L>D<]^[1_UL+J_7G838YBB:ISNG0R)\LK<;@.3KG+=2UG;C$KD L"9L00,Z [K%0+=W M9-KF[FG[8F:KT@IC:^^CK;UOZN_ [H,"?+ZI")&9*&^F&[=$"]\[:&QPNG'I M+.-E9WR:XD!3'+B;54BF.- 4!U84!WXVQ8&F.+!E-NI4<: EZ@*[VZ[E>05U M@=W=-!A'WG?F'OZ712$>^5F_UW\W92DVZ8=HJ*K&E!7.R1BN !D\Q\\ZCN2[ MBP"SN+JYKJV_X&!_6WL-Y9[47M'3ZS?$YV7'_^Q*H>%&H[U7<9RRRIK"GI;Z MO#\5S(-^WS[=X0KFUZBIF#IG4^>\TSQIOCKGTU/[M-MXVU13YKR,)[G5U'TN&NYF^L,;^Y M%3D;K1Z[N?6?G[5M8.<:"W[+\JI-3O-VBWY7.9.V)$RV ML7IUCF(B [[%P&<*@/>9B$TL:"F;=2J1>7'#=0>*_M:3T+S=>K^EDYKW1?_% M N)3FS"V=55][4IL;J@2=OUTOJPJM/MIO08BDTMP+F1&;R04.I6N6S+/)G*">,2BV+IGR3-C 3P3.'TL)]1H M,VL>I2RPG(C1I)N' -;BHD:!E[+ E7=%;!(":@(\9P[HV.>G,/S.D41W9-CUBK&]]T&8['7H)B M':?I7=*-#PP$.8MQJIT?HM1?;#!38<22)5;#W(ND,&Q*C)DZZ3:&:#FT/IL? MK<70+YKY-3L-?S/Y +^%";-.1<:;=DY"?#EC4 9R!Y;#A*J:AM7A>K+;8/WB MQ=]B&C/U>S $P>9X0;(H\!;CK]4 ^]4)P*[#4U540KR&(2=SX/B1MWACV%J^ M W&Y?;T@(,(1QR1X!_]P>?VOJP^'O7/^UP1 Q,;>D/\5!@(FM*+ 3>,D>B$H M/CHQ+IX[N^%GX+*P/)#47F)Y,;!8)PX#D'X #2.SX^U4-F8L.KXM1/2"1X^!_@ MZ=P8P77^")PZ9M2H&9FV8R5P( SA3@^VZ2WQ!/3W$3!) 7-8?Q FN <7SAT, M 0#PV NH6L91LL?%DZ+/GKZP.('O\6Q)JI3] #H-XV_P./Q@H0!4]T^ +I$Z MA]08B4CLCLL@?&N8)K#V[,6IPN87*1/60?V[SE6_L /38[="^H@2 MCP 8U"X$'GU"?9)%%LU'CVWK)O*>$+5N?*!SPA?2F7@)8.+G$!02XK4=Q8-O5A-"9RQWB;6>F ]>[Z/-\+CO<1'CA,":6AG M&O$SG:01K!?6 +\[^2MP,;0I#G]YA_, >A@M&VZ!-V 6%3Q_ HIA)!1 N7%B M3PD+7V@>U[ M#P\OAVC?T!>]=Z70??:21^1($V31Q1-0_ VY(>XS3N]C]I]4@+:,G2,7!DH6 M1X__3& @WCO&6>T!(O*9C_2-\!C4\LH46O\CAJBF84R DU$)N/$$N MGU@96(L;$_OBY(J/N,U.^&(H$(BX*]SJ3B0_6-9)6XS+^ M,RCMA^E$,#5NY-@HGP%%PB&L&:C?.^ D[W'D'CH911Z-)!!@* D6/V%!3&-AJ;#7Q1P5@$K #3C.!\C^]GP\*7@=/H0.K((G M=(QN4D6MOR/*/P,?0>9\(3G6MK235%]-XYSIT1'^#D>X/:J)^AHX_87OAZ03 M7T\0G_[%8K1[.87/Z96HHJ>CXR(]'<+WPNRAMPD[*91L- 4K ID>E]M.)EZ! MPNKC*;<)3ZDD=H!YZ]P;/4E,GG&@RZ!,."A"YVEW$I2$[R%WDD,J9I5 ME8 X]T@0X)[K 7>^=7RF/;(8+^&\>]D^,%WLN=J=[KE*+R'#>!C"0BW\Y]"1 MRP6)X!';X8PL_Z/%3Q 9&0H!>)+46EW4YOZ9^N*D^P,>89QM.^VA<[5([<_H M!)TX'I@%*-X?LU^1RH5F#1NE51S<&)^'?M"1_$ ^8DW#R* M ?4Q'<'Z"L$.^_.6/DS/O?GA0(K*AR@$^0A:XI Q-]:4>QLM@+_5T_>-\T(H M"S MFZ?5LZ(Y5*^N7>M\ZY2' 4 W!PW90^[(^0'\%4L3]OXE9^>@)OX^'%UH5HL- M1N*P8[T51B#^*LR_ SMG2G/3@>YV@B!$IY.+GCYZMTN6F\"'L6;N33A92/5P M!HYP\YO83V9AH>&DP)F[3YEV>456"_S,(%K,V(TQ99?%U\''[_C0U(L?212. M/K#[*3YU^A7^7R"8^MP8.9Y6R\%5PDP/:.1K0"&AJ.\5@5M^,D,,/L0QN5*% MT:<3&PF/M/132?4KN*VV#C7/[:/0/TQ_PU_QG,5BV\_:@R4V3;G&[W MAW>6#.\/<,5:TG?O&%0V^<_!NS<_5G?P&G3Z9WAW;JF=D].2U8JOW^E&HD56 M(BS4L1XC)/"_@@P&M8E\-D U&(5#J?_SC\ZDS\(Q/5(P$U9QDX&-^4BN@7])PXCV[H-PF?K M,SJ^I6__[3_^OP/KLS<&I=(E]>1?H&]Z#B@7UJ<4?8YXO]!-X-M'4,2]X(G% M21C%=7H*N5<+U_.UD;:*?NEAY(&R02%!L.,?X+<'X=-?P9+GWP,VW;+HR1M. M6_1',MT1- CU^>L%+?5*KE2W KXP'Y;EWCA1\D*Y,'Q1\?L7_1>RY1?V"\PV MXJ]^^]2$&5_K[YWX:;RS,/_"7,!WE =E3MX-0?[TN +ND5I=%H3C07!%L$#N M0\+Z&;IRJ;]:.M1O\"'JQUC\&O?*$G[5"93HS5]!N?Q*IUINZ,^<.-GME(%A MG/J)-_&]S"*".S&['$5X#6K.9?@+@P]C"HB)R+NN1YP4Z;CGP\;%?7J"JRZ' MM\WU<.Y64[VP&!1OM?$;!S&.0D43%2I"_YX?QHS227@;4?\EDQ_XFX@QZ"&- M>VDC#ZM"&B+&O'G>HIWF^RV;LUJCF_11#%[:_$OM<)$=L C_2<2-2 MJ%P7>3E9E7I,5'R?3PX@3:3VY3*X*UYO/6=)1O>8/IKS6B6+(AAF_S@R)4=> M+\A^MNYPJ?8BSE['LB*W;">G6).COQRW*H+#//!8K7IVK(OLE.RI,RK@T/1+ MED +E4*0@*WVP%#$CM((;HNF4!USX_"F#JBX=(6=I9HHC[..P3(;.>)(6Z[; M[I\..R?G%*D*?.VEMWS\3XJE/B 4PH#RG9M7?4^/R]$ZGT=!NM=&U(G=/HPY MM1$*YL)9/ /]@F!Y\TL03I\ 1;$ 9%@Z&0D=X3:]_U/D+\DD*/9]R";?1P%N P0S%%W'9(H32DQ?"5=D;*G5MBILJ>X$X&XE/2I0%;!4N>?'Z M27H/$EM=7RQ+V)-@:FGHM,[[(;+-,GUDFF5'LY,9B^EVI8)/SS($')DWN:KT M6<]ZUE8>LU[3R:HPGLJZCAU?*0]U)R#26U/,,P *F0 SE;?EN) \S9CY/@94 MA;%4%P"T]:RL4G*NNYOJF$@?YNFU0^&"$R^>A'%2?I](E"<^@0X#L>E89>1& M(M%.Q._&CDNIF0 A'Y\%NW]^9%P5FI5KS NWT&F1V>J"P6BYG2(-.L(-)[Q( M"EZ=49R>U :0<:PQSPX$E2R@Q%HJ(5,U7+-SY*9H5ZE[BC'*KL4)V3"P%#;[ M1')J'X9L928=P!!0%N]SV8@>\:0Q%]P]I;[H.XT9^Q;G$F#Y,AS?%A46ROOY M%/("$R\JR@Z9#ZZ#/+8>F2\/8\Q;53V%T?P)AG74(E%("*TP +N_ K,P 2UO[;BQ]9\/#>"^&J MCFU]3MP.IE)C_<1X@A$/P5HM7T1 [K.BBV 81I,P0H5<,WI]YUGE0EPZ+P ( MZRKVL3+ >LNY;\30H"#9\^];"]X]@0>.';4"X :P#\H(R$Q*N%@$6?1[L@#+ M]9 YP9,'P("$^_!FK?T@V M,:JZT$V$,> *=KT#K*(8F[1%QE+5J*>=UZ1FSN BJF(%-155KL%A3"<(V*$? ML%!W L&E;E,L'<[%4#]Y$:AY_)Z,O.DV<76<1D_>D[0/].NEP9==0=;+2^X% MM^K'C_1CCMBH-(8RM^;%]V+E27[O9. 67EB 08Y.\BO%OC6NN*"&@HI@X&(A M1TFQNCU_*Y$*]PH()PMWWHPGY&B1"FX]%N3>ISML"N>7WVG^&'-[G3Y'R=7* M#U++450G&;&QXY&Z*AXVYWF^%N+./$RVP$7+&8* <,D'K?!*.%("5_?SQ(QJ M_N"2N?@E6 )CE%V 45AJK9L460U:XHVSVBZ=IJN8@_51W8LPRG -V)#%G.$C MO$DJ$"0!IR05;1+,WVR\R^^W,V.IXI'D4+QQHNN(_(8NM6VZ$7[%^M&X_X[5 M$E2YPR7ZP'P/:S9=XA)@>E3X'X(Q W_-YTGK$P='L]*I"HYLTF' M\/MFH2-JK#5?1OE"P/@E#-A4:F;>0&_BD+4][=<)OR,YE:O&TR.7J",5:";F M*#"5=4#T-0I3)>2*;I(V'(.HN"RI*5K+ 2T2CIF+"-5RQ"$$13"W LK: ^8. MI]24>[7D:*;+<+B8G$;\+";C#,G+. T.>; M=.(X''JJ@#RW9VZ!W6-:13B1J93%0O0.&7*Q;DC AAX>^?K(G5KN&M!4A+Q+ M07B0OV!0*ATF%$GN2%7X=2AZEZ492^P[&Z9ZG<\L%2X'5SP\88T5O$ZWFGOW M-IU@#S/-7,3[/J"/E]8A(YM%1,D[T>55TOK3?R\+/ND&"#T XP:'E\(W*WLN M8*.U>]][$(4BDAZT_AAU1D%))S-3(-(>E.^=F *1^@(1^:(@]?VRD>2U]2,9 M&'^964NRCE*2NBX;66= E>RK6NFNU"MP'6T =[PDA;H GHDN@ +8V6COUQ2B MN2")4=$&4TB]H?Y33]:M+)'2?ITFH(N1FE>KF3>9%]D[J4Z,5 D9Y*E9XX:^ MWE#0=\%>-0T"H2:3G"]MNJ706L&Q6A.?Y@!3@QS579>X/A]FF^U8'YVLF9), M/(JUMF"40R%C]&@KU61J8(JLL_G:D4KJ:Z)VI- MA> =J!PQGAW/WOT41GJ# M*][=2FCFG("NP12,IA%_@;XYU)@88-6?12O M'I:U^LS@,-+H\)&)7#?B6TC9=2R._2=UL,]X1,G!F PX@\T1\R%V-H]/;Y$* MCB5$\]=L-1]Q(]? '&@7'_$*QH(OZ82Q&%C'A]#W'5$=0J1XQTL8L'W-$ZQF M(5_@ OSVK*Q6K_.:%-MK# 8FNJB8EA+Y+"3,+N7YD=P]FLEW35'DN>PDF)A, MP1">O3*73HT2\=,,QL$W?[*R&^:D(3<,CFH@T3IDOB]&11$FXM_BP5SU$M,< M:-0$O< 2;CQR([RSV35 M[-$B&V012+,46D!]@C<,IYSR=P4^"9"F&2,U(T8LFC%B:4-&!,H9ZC;4;:A[ M&]0]EQ5=9A[%F8I+*AZH<:B7->[@:;T6V>UTIR>MD6HO]"'#* VC-(QRUQDE MN3>R.JYZ9]EOE(5Q/4*_T/7HMQ!@S>["]^SO'C"B3V&4\*/9U3%B BJ20.9K+",:GAH0SS4&W'W,*]V M'-DY?[G2!F=V*3'^R2WX)[-XD/466P%1'(BYO*N:/K\K+/09*QVFE U2DE,W MQ-\*"QS)C@]$J\*7>21?>8P$1-\',<@,OJG$AMV3??UIV9?P;?,H#GD]O:#Y M61:S1UC($ZD\AKM'MDL MFR2ZJE!@-&>Z'':51136H;;L2Q[KU8A'+&6(K!B1T#I)YIO*3\J]2$/U<+?YJ0I;$SC9UI0I:&N@UU M&^I>2\ARE^*4+5#TNIU>A1])6JI[&-U8'.[K"VR(-CHN[\6953>*DEEA@"JS ME7?&4SHI'0UVD:5FAO?8?"'KLJ&]A=?Q#AFUV\ 73?G^7.'UX9U?J,B6&FD) MOP47%/?,#Y]M? \?U86_:&^AN>.R_$$4Y8X<6"\PCF\LX:7IL@1W#B^R$(VAG18(XPJO"TICO>FI">ZT0?1O+:X#Q[7SD9UU:F!;#^KD MLU*,TF*4%J.TK*"T+)F!(H56O[O9>/N@.Q\#$N93\NA%KK["?)=$,JFPT[B: M'+D2:\*P)IF*8 0&UM\HC61[62/VC!(O:PPOMT")"D7/K*R;$2"S+]:H%Y8& M%7- ]&!,82:(G:]%<^Y#[$9EPO)SA.4#-1F+.OZ__:XU$LN-N8OG'J&%5@5U MC3N$EWS#7H3YN+H<#!$Y'N<':30):X9.+-"8G]H&!'S!$ELCK4UI[H>13D9U M+D?2@+1*<:[;K,4:FE*V/L,2?X-]WH1>D-P]A]NV;\X[_0KSIA#8?YO-:Y_K M.'AW>3($^A#Q:=Q=M?H60& M+1801.E*>56P0":U0L:E9I!ZDYZ==&FLB)C+.3:D%@OJ%-@4FAY;K<&^E"NP MV ,U'>,PH7AFRQ+K+?$9.O)\CWL>6?B7%EDX0"67(A5&,J\NF45[H7)5/IH&M?ML+;__.%'+H)KV8WLO)KV"R&O)K^'!7 MH;ZS&E7-4%_;8VT;(;RE46%6J4#+ND]/Z9*OJAOU:5DW:O&OMJ2&>E&OWHIZ MHYVHZUI-MZB[=&XNO?"C_^N E(+>3N]O[H;U^[O)5IYD$$XQGB6^*&'O'K=$,0"I MM^_?VDC[G=6U<@&J:QF@NC5JU^IJES:6<#&=:PD/9(NTM&[-C)+:<.@2*EM# MHR.W!NJU:GC*A[@1M6H*V^?1J18&?Y,S8YK:CR9Y=VD_<^M,:]C4(NC=Z+;: M%KD367 8P8VV@%V^B]L8U:9QN] MWT';:"[3Z'W;3*-M0'I3IM$_Y*!O;.3'!SX2%N-PQR<,](UH@MSP4>1C8)BX MYJBV8VLMH[?L(/G8I\?+4$^Y MRQKD<;T'QW#\PG]O$R3 ISP[0B#:"!=#(S MM:\M8I^6(G2DO4C.] TNI$"2:$ B!A5$%(^NPNLZVXC![@%JHY%M%SLS]:.B:;D.GI]4QID%#F;I"U.S6MJ\EQ5%]PBLZ7&3299%!)- MC923EU'9V!!^FUMOI&)*K.X%%@BHA*3MCF\HU -2LS[T7GBG4EX MHW)X-BU0%%\Q7]0]YY,Z_I%_KMY#2#P696 M%/?*CA 1<^)64.-=OH=%F?F)O>-3>(A#_3M\JIK#;AZ\AKC6_?R6E]S1&=67 M0S(?E )$8.K@P-\0\S)Z@2.$?L5V^53I7, >-=<;2P&].(F\^Y1D039\_2[" MK@X7HOS9RXE2RPT9UWBRZL!9*'-@"=6'?#1 N(W@J%+!E,;I2[^WF^Y:$ 5^W(_\; M'PHD8R[_AOI*VKFF4T9I7%1I%'Q&H%C,6ZF^];2"9U[$G>'4?.8T1ZKR,FP M'#!C/P5FX-6]:9XP%A -]K9'$T1]48W8D=8(AO=0J&SK$:HTQXHWV85$QK)> M']PM+,9$Y2]-)JHO8'+YHZ58EVI $CO8N833E(=?S6;>J MB_@;VTA0*R"P["+)*^I[G 0NW5+3="=[=DX=SK6TH-W3T ,E=+%O),A'('YZ M7,*<<1F_^R.,J ?&I5# /X= DZ0^@'Z.\U<2SO^26;)Q?D$HV;=JVR()P5E# M%ZCF'UA7DZ)QU4L%YO?(KA>ON=R<%P=$#@-UZ1#^4RP/ZY362Q5+R&K+=$ Z M %W"JJE\,&Y=6<[^Q>NH+J?7E84YZ@ L?@(F9"<%%\,@$M(".A8ED!@'$E5\ M:G3#M_X#L_(92SA?5BXPU>U9=&\C0X(,WP?H#[ MT5(^"- MP9!#,+-Y+J;AS6NYSF(*=+NP,84]GW>=()U"5=E+2E6U%,I#[Z,>V.%I6GJ6U MJ8E'UC48RBC.>WT>--0;L#",JN=2ESN

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end